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Abstract 
Pancreatic Duodenum Homeobox (PDX-1) is a homeodomain transcription factor and a 
key regulator of β-cell development and differentiation. In mice and humans, mutations of 
the Pdx1 gene in β-cells have been linked to MODY and type 2 diabetes. Therefore, the 
regulation of PDX-1 transcriptional activity is very important.  
Phosphorylation is known to be a pivotal regulatory mechanism for several transcription 
factors. Therefore in this study, I focused on the regulation of phosphorylation on PDX-1 in 
intact β-cells and investigated the potential signalling pathways involved in its regulation.  
Firstly I showed that PDX-1 is phosphorylated under physiological conditions in pancreatic 
β-cell line. Additionally, recombinant PDX-1 is efficiently phosphorylated in vitro at Thr-
152 in the homeodomain by the nutrient-regulated protein kinase, PASK. To explore the 
physiological relevance of this site I made dephospho- (T152A) and phosphomimetic 
(T152E) mutants of PDX-1. In INSrαβ  cells, a less differentiated cell line derived from 
INS-1 cells, wild-type PDX-1 and PDX-1T152A were partially redistributed from the cytosol 
to the nucleus in response to elevated glucose concentrations (20 vs 3 mM). By contrast, 
PDX-1T152D and PDX-1T152E displayed enhanced nuclear immunoreactivity at low glucose 
concentrations, and underwent nuclear export as glucose concentrations were raised. PDX-
1 binding to an oligonucleotide based on the consensus A3 binding site of the preproinsulin 
gene promoter was completely abolished by mutation of Thr-152 to an acidic amino acid. 
Furthermore, the PDX-1 phosphomimetic mutants failed to suppress preproglucagon gene 
expression in INSrαβ cells, an action fully preserved in the T152A mutant. However, 
metabolic labelling of INS-1(832/13) cells with 32Pi, as well as mass spectroscopic analysis, 
and the use of a phospho Thr-152-specific antibody, failed to reveal any clear evidence for 
phosphorylation at this site under a variety of in vivo conditions, including in cells over-
expressing PASK. Thus, Thr-152 is not a major site of phosphorylation of PDX-1 in intact 
β-cells. However, a novel phosphorylation site, Ser-269, at the C-terminus of PDX-1 was 
identified by mass spectrometry. To explore the potential upstream regulatory kinase and 
the signalling pathway involved, I generated dephospho-(S269A) and phosphomimetic 
(S269E) mutant PDX-1 and a phospho-Ser-269-specific antibody. Candidate kinases were 
also identified using recombinant wild-type and mutant PDX-1 in in vitro phosphorylation 
experiments.  
In this thesis I demonstrate that PDX-1 is phosphorylated under physiological conditions in 
β-cell lines. I have shown that Thr152 is not a major phosphorylation site of PDX-1 in 
intact cells and we also defined the novel in vivo phosphorylation site of PDX-1. Moreover, 
we reported that PDX-1 is phosphorylated in vitro by a number of kinases including 
Aurora, Rsk1, PKCa, JNK. The work presented in the thesis provides evidence that PDX-1 
phosphorylation is important in its role as a transcription regulator in mature β-cells; 
moreover, it suggests several physiological signalling networks to investigate.  
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1.1 Diabetes  
1.1.1 What is Diabetes? 
Diabetes is now taking its place as one of the main threats to human health in the 
21st century1. Diabetes is a chronic, potentially debilitating and often fatal disease, 
which is a condition primarily defined by abnormally high blood sugar levels 
(hyperglycaemia), giving rise to a risk of microvascular damage2. There are two 
main forms of diabetes1, 2. Type 1 diabetes, where insulin treatment was required 
for survival, is mainly due to autoimmune-mediated destruction of pancreatic β-cell 
islets, resulting in absolute insulin deficiency3. It is the most common chronic 
disease of children. Type 2 diabetes is characterized by insulin resistance and/or 
abnormal insulin secretion, where pancreatic insulin production continues, but may 
be insufficient for control of blood sugar levels3. The diabetes epidemic relates 
particularly to type 2 diabetes, accounting for more than 90% diabetes cases, and is 
taking place both in developed and developing nations1, 4. Chronic elevation of 
blood glucose will eventually lead to tissue damage, with consequent and often 
serious disease, including the kidneys, eyes, peripheral nerves and vascular tree, 
sometimes even fatal. Indeed, diabetic complications are those aspects of the 
disease that are most feared linked to human suffering and disability, and the huge 
socio-economic costs through premature morbidity and mortality1, 5, 6. 
 
1.1.2 Diabetes affects everyone, at all ages.  
Ageing, unhealthy diet, obesity and a sedentary lifestyle are some of the key factors 
that have conspired to create the current worldwide epidemic of type 2 diabetes. 
This is projected to occur because traditional lifestyles and dietary patterns, that 
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have sustained people over generations, are disappearing, and families are often 
forced to move into urban areas where diabetes is primarily concentrated7, 8. 
 
Ageing is an important factor for type 2 diabetes. This type typically occurs in 
people over the age of 40 and the 40-59 age group currently has the greatest number 
of persons with diabetes. Moreover, type 2 diabetes is now also affecting children 
and adolescents at an increasingly younge age and to a greater extent, especially in 
those with a family history of diabetes9, 10. Children as young as eight years of age 
are now affected. Type 2 diabetes has been reported in children from Japan, the 
United States, Pacific Islands, Hong Kong, Australia and the United Kingdom1, 10-13. 
What is worse, though it is now becoming a global public health issue with 
potentially serious health outcomes, compared to that for adults, little information is 
available on type 2 diabetes incidence and prevalence in the young. What cannot be 
ignored, however is that, type 1 diabetes usually accounts for only a minority of the 
total burden of diabetes, but it is the predominant form of the disease in younger 
age groups in most developed countries. It is estimated that about 65,000 children 
aged under 15 years develop type 1 diabetes every year worldwide with an 
estimated overall annual increase of around 3% in the world14-17. The reason for this 
increase in the prevalence of type 1 diabetes remains largely obscure 18.   
 
1.1.3 Diabetes mellitus is a current and growing heath 
problem.  
The greatest challenge to our health systems all over the world in the 21st century 
might be how to develop effective responses to the growing burden of chronic 
diseases. Diabetes mellitus which will be referred to as Diabetes, one of the most 
important chronic diseases, has not been paid so much attention until recent 
decades, although been recognized since antiquity19.  
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Whilst absent 15 years ago, Diabetes treatment programmes have become common 
across Europe, and include medical and paramedical personnel training for the 
establishment of well-organized diabetic clinics, diabetes education programmes for 
patients, and so on20. Pharmaceutical research and development (R&D) of 
antidiabetic agents has been holding top three of the most popular therapeutic areas 
in recent years and continually being promoted. In 2007, it showed an almost 15% 
rise in R&D over 200621. Consequentially, new antidiabetic drugs with novel 
targets are introduced sequentially, such as the first glucagon-like peptide 1 (GLP1) 
analogue exenatide (Byetta; Amylin/Eli Lilly) approved in 2005 by the FDA, and 
the dipeptidyl peptidase IV (DPP4) inhibitors Sitagliptin phosphate (Januvia, 
Merck) in 20067, 22. 
Vigorous scientific research continues to combat diabetes, and vastly expands 
understanding of the underpinnings leading to diabetes and its complications. The 
NIH (National Institutes of Health) of the United States, for example, spends $1.037 
billion on diabetes research23. Almost all westernized countries have now 
established diabetes associations, and over 200 of them existing in more than 160 
countries joined the IDF (International Diabetes Federation), a worldwide alliance, 
coming together to enhance the lives of people with diabetes everywhere, raising 
global awareness of diabetes, promoting appropriate diabetes care and prevention16, 
17. 
 
Introduced in 1991 by the World Health Organization (WHO) and IDF, 14 
November (Frederick Banting’s birthday) was selected as World Diabetes Day in 
memory of Frederick Banting who, along with Charles Best, first conceived the 
idea which led to the discovery of insulin in 1922. It is celebrated worldwide every 
year, and had been made an official United Nations World Health Day24. 
One may be curious as to why diabetes is provoking so much concern from so many 
countries, health organizations, pharmaceutical companies and researchers 
currently. 
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In fact, diabetes is fast becoming the epidemic of the 21st century, creating serious 
problems not only for health and medicine but also for the global economy and 
society. There is an urgency to increase diabetes awareness worldwide8.  
 
In 1985, there were an estimated 30 million people with diabetes worldwide. Today 
there are more than 246 million people with diabetes, or 6.0% in the adult 
population. In just over 20 years, there has been an amazing eight-fold increase, 
with the total so expected to rise to 380 million by 2025: a further 7 million people 
will develop diabetes each year, or two people every 10 seconds8, 16, 17, 25. Nowadays, 
diabetes is forward distributed all over the world. For the adult (20-79) age group, 
the Western Pacific Region, with 67 million, and European Region, with 53 million, 
currently have the highest number of people with diabetes. However the prevalence 
rate of 4.2% for the Western Pacific Region is significantly lower than 8.3 % in the 
North American Region and 6.6% in the European Region, which will increase to 
9.6% and 7.8% respectively by 202517. The region with the highest prevalence of 
diabetes is Eastern Mediterranean and Middle East. 
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Figure was taken from Diabetes Atlas, third edition © International Diabetes 
Federation, 2006 17 
In 2007, the five countries with the largest numbers of people with diabetes were 
India (40.9 million), China (39.8 million), the United States (19.2 million), Russia 
(9.6 million) and Germany (7.4 million)16, 17, 25. There are currently over 2.5 million 
people with diabetes in the United Kingdom and more than half a million people 
who have the condition but don’t know it, as reported by Diabetes UK.  
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1.1.4 Impact on economy of the world 
 
Fig. 1.2 Annual health expenditure for diabetes (ID) vs persons with 
diabetes in the five countries with the largest numbers of people 
with diabetes and in the United Kingdom in 2007. ID, international 
dollars. Figure was taken from American Diabetes Association. 
Economic costs of diabetes in the U.S. In 2007. 5, 17 
The rapid increase in diabetes cases represents a considerable impact on the 
economy of the world. Its costs affect health services, national productivity, 
governments, insurance companies, as well as individuals and families5, 26. The 
annual direct healthcare costs of diabetes worldwide, for people in the 20-79 age 
group, is estimated to be at least 153 billion international dollars, for blood sugar 
control, treating long-term complications, and so on. The costs will be between 213 
billion and 396 billion international dollars in 2025, which would mean that the 
proportion of the world’s healthcare budget being spent on diabetes care will be 
between 7% and 13% in high prevalence countries16, 17. The largest costs of diabetes 
worldwide are its devastating effects on families and national economies. 
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People living with diabetes, and their families, feel the impact of diabetes most 
directly. People with diagnosed diabetes, on average, have medical expenditures 
that are about 2.3 times higher than what expenditures would be in the absence of 
diabetes5. In the poorest countries, people with diabetes and their families bear 
almost the entire cost of whatever medical care they can afford. Indirectly, diabetic 
retinopathy is the leading cause of vision loss in adults of working age in 
industrialized countries. The number of people in the United States with diagnosed 
diabetes now is the third in the world and the total cost of diabetes in 2007 is 
estimated at 174 billion international dollars, including 116 billion international 
dollars in excess medical expenditures and 58 billion in reduced national 
productivity. People with diagnosed diabetes incur average expenditures of 11,744 
international dollars per year, of which 6,649 is attributed to diabetes5. 
In addition to these quantified costs, diabetes imposes high intangible costs on 
society in terms of increased absenteeism, reduced quality of life, and the pain and 
suffering of people with diabetes, their families, and their friends5, 27. Diabetes 
increases the likelihood that chronic disability prevents working, or in some cases 
limits employment opportunities. WHO estimates that diabetes as well as diabetes, 
associated heart disease and stroke together will cost about 333.6 billion 
international dollars in lost national income in India and 555.7 billion in China over 
the next 10 years, based on lost productivity, resulting primarily from premature 
death. Accounting for disability might double or triple these figures16, 17, 26, 28. 
 
1.1.5 Diabetes complications  
It is estimated that the costs of diabetes complications, including visual impairment, 
kidney failure, heart disease, stroke and nerve damage, account for between 5% and 
10% of total healthcare spending in the world16, 17.  
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Diabetes is the main cause of partial vision loss and blindness in adults in 
developed countries. The prevalence of retinopathy is probably around 30% in type 
2 diabetes, accounting for 5% of all cases of blindness globally. It is estimated that 
more than 2.5 million people worldwide are affected by diabetic retinopathy16, 17, 28. 
Diabetes is the leading cause of kidney disease (nephropathy) and is responsible for 
huge dialysis costs. About one third of all people with diabetes develop kidney 
disease and 10% to 20% of people with diabetes die of renal failure16, 17, 28. 
Diabetic nerve disease or neuropathy affects at least half of all people with diabetes.  
 
Figure modified from the image (http://www.healthhype.com/wp-
content/themes/healthblog-CT/topic/images/diabetes_complications.jpg) 
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This results in a loss of sensation in the feet or hands, pain in the foot and problems 
with the functioning of different parts of the body, leading to ulcers and possibly 
amputation16, 17, 28.  
Diabetes is the fourth leading cause of global death by disease. Every 10 seconds a 
person dies from diabetes-related diseases 6, 29. Cardiovascular disease is the major 
cause of death in diabetes, accounting for some 50% of all diabetes fatalities, and 
much disability. Their risk of heart disease is 2-4 times higher than those who do 
not have diabetes. On average, people with type 2 diabetes will die 5-10 years 
before people without diabetes, mostly due to cardiovascular disease16, 17, 28. 
Additionally, people with diabetes are more prone to bacterial and fungal infections. 
 
1.1.6 No cure for diabetes  
Though still not fully defined, the mechanisms of the diabetic complications are 
likely to involve the toxic effects of high blood glucose levels, along with the 
impact of elevated blood pressure, abnormal lipid levels and both functional and 
structural abnormalities of small blood vessels. Diabetes has been treatable since 
insulin became medically available in 1920s30. However, there is no cure for 
diabetes today31. 
With appropriate medication, quality of care and good medical advice, diabetic 
patients should be able to lead an active and healthy life and reduce the risk of 
developing complications. Good diabetes control means keeping blood sugar levels 
as close to normal as possible, which can be achieved by a combination of 
controlled diet, physical exercise and medication. People with type 2 diabetes may 
require oral hypoglycaemic drugs to lower their blood sugar and some may need 
insulin injections at some point7, 31. Treatment for type 2 diabetes typically begins 
with oral antidiabetic agents and a reduction in glycated haemoglobin A1c 
(HbA1c)-a reflection of glucose levels over the preceding 3 months — to below 7% 
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represents an elusive but key goal of therapy7. Metformin, the sulphonylureas and 
the thiazolidinediones were the most widely prescribed classes of non-insulin 
antidiabetic medications, whereas incretin-based therapies 7and some others are also 
approved as well as 503 candidates in development in 200821. Metformin inhibits 
gluconeogenesis. Sulphonylureas sensitize pancreatic β-cells to produce insulin. 
Thiazolidinediones (TZDs) act by activating the peroxisome proliferator-activated 
receptor-γ (PPARγ), which promotes adipocyte differentiation and improves insulin 
sensitivity. TZDs were also reported to increase the level of adiponectin 32. 
Adiponectin was secreted by adipocytes and has been reported to increase fat 
oxidation and improve insulin sensitivity 33. Incretins are peptide hormones that 
stimulate insulin secretion, inhibit glucagon secretion and promote satiety after 
nutrient ingestion. Glucagon-like peptide 1 (GLP1) is the short-lived activity of 
native incretins which can be rapidly degraded by the dipeptidyl peptidase 4 (DPP4) 
enzyme. GLP1 analogues such as exenatide (Byetta; Amylin/Eli Lilly) and DPP4-
selective inhibitors such as Sitagliptin (Januvia; Merck) are also applied to treat 
hyperglycaemia7, 22, 31. However, with the controversy on some side effects of the 
marketed drugs (such as rosiglitazone, believed to slightly increase the risk of heart 
failure 34, 35) and insufficiency of even combination therapy, development of 
antidiabetic agents is limited7, 36, 37 and there is an urgent need to identify novel 
targets and develop new drugs to treat diabetes effectively. 
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1.2 INSULIN SECRETION AND BETA CELLS 
 
As is discussed in the ‘diabetes’ section, Type 1 diabetes is caused by the failure of 
the body to secrete insulin due to autoimmune destruction of the pancreatic islet 
β‑cells. Compared with type 1 diabetes, the cause of type 2 diabetes is more 
complicated, but provides more possibilities and pathways to study and potentially 
treat it. Type 2 diabetes is often associated with obesity and develops when chronic 
overnutrition conspires with genetic susceptibility to cause impaired insulin 
signaling (insulin resistance), as well as a relative insulin deficiency of non-
autoimmune aetiology 38.  
 
Insulin normally acts by regulating nutrient homeostasis through the stimulation of 
glucose uptake into peripheral tissues and by suppressing the release of stored lipids 
from adipose tissue. Therefore, any disorder of insulin secretion and action leads to 
multiple metabolic abnormalities in type 2 diabetes, including hyperglycaemia due 
to impaired insulin-stimulated glucose uptake and uncontrolled hepatic glucose 
production, and dyslipidaemia, which includes disrupted fatty acids homeostasis, 
triglycerides and lipoproteins metabolism. Chronic increases in circulating glucose 
and lipid levels can further worsen insulin secretion and action and cause other 
forms of tissue damage due to metabolic overload 38.  
 
1.2.1 Regulation of insulin secretion in normal β-cells in islet 
of Langerhans  
The endocrine pancreas plays a pivotal role in glucose homeostasis. The 
maintenance of plasma glucose within a narrow range of concentrations is critical 
and is a result of a balance between glucose storage and consumption. In higher 
animals the blood glucose level is controlled primarily by two antagonistic 
hormones, insulin and glucagon. Insulin stimulates glucose uptake and metabolism 
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in the peripheral tissue such as liver, muscle, and adipose tissue, whilst it also acts 
as an inhibitor of glucose release from the liver. In the fasting state, glucagon 
activates glycogenolysis and gluconeogenesis to maintain normoglycemia. In all the 
mammals, postprandial insulin secretion is regulated in a biphasic manner 
controlled by both nutritional and hormonal signals and the most important 
physiological regulator of insulin is glucose. Besides glucose, other secretagogues 
such as free fatty acids, amino acids or the incretin regulator glucagon-like peptide-
1 (GLP-1) also works as potentiators but a threshold stimulatory level of glucose in 
the bloodstream is required for potentiation38.  Insulin is synthesized and stored in 
the β-cells in pancreatic islet of Langerhans where it is secreted from the pancreatic 
islet β-cells primarily in response to elevated blood concentrations of glucose (Fig. 
1.4). Glucose stimulates insulin secretion by generating triggering and amplifying 
signals in β-cells39, 40. Glucose is transported into the β-cells by facilitated diffusion 
through glucose transporters including GLUT2 and/or GLUT1 41; increased 
extracellular glucose concentrations lead to elevated concentrations of glucose 
within the β-cell, which in turn leads to a rise in the ATP:ADP ratio and results in 
the closure of ATP-sensitive K+(KATP) channels. This shutdown of KATP channels 
leads to membrane depolarization, activation of the voltage-gated Ca2+ channels and 
an influx of extracellular calcium. The resulting increase in intracellular free Ca2+ is 
believed to trigger exocytosis of insulin-containing secretory granules 42. There has 
also been evidence that the increased level of glucose within β-cells also appears to 
stimulate insulin secretion independently of changes in KATP channel activity such 
that glucose can trigger insulin release under conditions of fixed high [Ca2+]c 43.  
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Fig. 1.4. KATP channels and insulin secretion in pancreatic β-cells. In 
pancreatic β-cells, glucose is shuttled in the cytosol by the glucose 
transporter GLUT2 and metabolized by glucokinase (GK) and 
mitochondria to produce ATP from ADP. Cytosolic ATP raises and ADP 
decreases.These changes cause closure of  KATP channels by the cumulative 
effects of increased inhibition of Kir6.2 by ATP and decreased activation 
of SUR1 by MgADP. The ensuing depolarization elicits opening of 
voltage-dependent Ca2+ channels, Ca2+ entry, and Ca2+-initiated insulin 
granules exocytosis (Modified from Dr. Michel Vivaudou webpage, Institut 
de Biologie Structurale Jean-Pierre Ebel. www.ibs.fr).  
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1.2.2 β-cells and pancreatic transcription factors  
The pancreatic β-cell is a highly specialized cell playing an irreplaceable role in 
regulating fuel metabolism in conjunction with the glucagon secreting α-cell and 
other cell secreted hormones to maintain the glucose homeostasis. The features of 
the β-cell are determined by a group of genes controlled by several pancreatic 
transcription factors which act as a network covering the whole life cycle of the β-
cell from the differentiation, development, and maintenance until death 44.  In brief, 
in early developmental stage, among these factors, pancreatic duodenum 
homeobox1 (PDX-1) 45-47 is crucial for defining the region of the primitive gut, 
which will later form the pancreas. Ngn3 48, 49 expression will open up the 
endocrine lineage, and will later be joined by several other transcription factors 
such as PDX-1 (the second wave of expression), Pax4 50, NeuroD1/β2 51, 52, and 
MafA 53. In mature β-cells, the most important roles that these transcription factors 
play are in regulating insulin gene expression, and controlling some b-cell specific 
gene expression in order to maintain the normal function of β-cells. These 
transcription factors include PDX-1 16, MafA 54, β2 55 and Nkx2.2 56. During the 
survival stage of β-cell life, a number of transcription factors are also recruited to 
defend against the autoimmune-mediated attack and the toxic metabolic milieu. 
PDX-1 16 helps maintain an adequate pool of healthy β-cell mass with its anti-
apoptotic and proliferative activities which is also the case the Pax4 57, 58, Ngn3 58 is 
involved in the regulation of progenitor cells. There are also other transcription 
factors which are also highly involved and important for β-cell survival and 
proliferation including forkhead box O1 (FoxO1), nuclear factor of activated T-cells 
(NFAT), activating signal cointegrator-2 (Asc-2) and cAMP response element 
binding (CREB) family members 59.  
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1.3 Pancreatic Duodenum Homeobox-1   
Various laboratories discovered and studied pancreatic duodenum homeobox-1 
(PDX-1) in independent experiments in the early 1990’s. The protein has been 
given different names in different studies: Somatostatin transactivating factor-1 
(STF-1) 60, Insulin promoter factor-1 (IPF-1) 61, islet/duodenum homeobox-1 (IDX-
1) 62, insulin upstream factor-1 (IUF1) 63, β cell-specific glucose-sensitive factor 
(GSF) 64. According to the Human Genome Database Nomenclature Committee 
(University College, London), IPF-1 is used as the human gene encoding this 
protein and pancreatic duodenal homeobox-1 (pdx-1) was designated as the name 
for mice gene by the international Committee on Standardized Genetics 
Nomenclature 46, 65. The PDX-1 protein in different species are highly homologous, 
eg, human PDX-1 shares 90% homology with hamster, 88% with rat, 87% with 
mouse.    
1.3.1 Distribution and structure of PDX-1  
The islets of Langerhans consist of four major types of cells (fig. 1.5). There are 
glucagon-expressing α-cells (15-20% of total islet cells), insulin-expressing β-cells 
(65-80%), somatostatin-producing δ-cells (3-10%) and pancreatic polypeptide-
producing (PP) cells (3-5%) 66.  
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Fig. 1.5.  Location of human β  cells in the islets of the pancreas. (a) The 
pancreas is located in the upper abdomen, close to the liver and behind the 
stomach. (b) The pancreas secretes digestive enzymes via its duct into the 
duodenum. (c) An islet is a collection of endocrine cells supplied by 
capillaries. A thin fibrous capsule separates them from the surrounding (d) 
exocrine cells, which produce and secrete zymogen. The endocrine cells 
include: (e) β cells, which synthesise proinsulin, which is cleaved into insulin 
(stored in granules) and C peptide; (f) α cells, which secrete glucagon; and 
(g) δ cells, which secrete somatostatin. The hormones are under homeostatic 
control and are secreted into the bloodstream. The β cells form the islet core 
and the non-β cells (α, δ and pancreatic polypeptide-producing cells) form 
the islet mantle. The islets are vascularised by arterioles entering the islet 
core and the arterioles branch into a dense capillary network. The β cells are 
destroyed as a result of the autoimmune processes of type 1 diabetes, and can 
be replaced by islet cell transplantation. Disease processes (including 
malignancy) that result in the loss of pancreatic tissue can affect both the 
endocrine and exocrine functions of the organ (Taken from Expert Reviews 
in Molecular Medicine © 2000 Cambridge University Press). 
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In the adult pancreas, PDX-1 immunoreactivity is restricted to pancreatic β-cells 
and somatostatin-expressing δ-cells of the islets of Langerhans 67, 68. During rat 
central nervous system development, PDX-1 was also found expressed in neural 
forebrain cells. This finding provided the evidence for an extrapancreatic 
developmental function of PDX-1 69. 
At the protein level, PDX-1 consists of 283 amino acids and has an estimated 
molecular weight of 31 kD 61. The transcription factor contains an N-terminal 
transactivation domain, a homeodomain in the middle and a COOH-terminal 
domain of uncertain function (Fig.1.6). The proline-enriched N-terminal trans-
activational domain possesses three evolutionarily conserved subunits termed 
subdomain A (amino acid 13-22), subdomain B (amino acids 32-38), and 
subdomain C (amino acids 60-73) 70 71. The stimulatory properties of rat PDX-1 are 
very similar to the Xenopus laevis homeoprotein, XIHbox8 72 71 , of which the N-
terminal regions share  50% identity 73.  
 
In PDX-1, an antenna-type pentapeptide (FPWMK) is present in the proline-rich 
region, close to the homeodomain. This pentapeptide motif mediates the PDX-1 
heterodimerization with the DNA-binding protein termed PBX1 and interacts with a 
regulatory element of the somatostatin (SST) promoter 74 75. 
 
In the central domain of the protein lies the antennapedia-like homeodomain, which 
is crucial for PDX-1 DNA-binding activity and protein-protein interactions. This 
homeodomain comprises three helices (amino acids 146-206) with proline-rich 
sequences flanked on both sides. In the third helix a seven amino acid-motif 
(RRMKWKK) conserved in human, mice and rats defines the nuclear localization 
signal (NLS) 76 77.  A recent study by Kawamori et al 78 also reported a nuclear 
export signal (NES) at position 82-94 of the mouse PDX-1 protein.  
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Fig. 1.6.  Structure of PDX-1. The homeodomain of PDX-1 is flanked by 
two proline-rich regions. The NH2-terminal activation domain comprises 
three sub-domains. A nuclear localisation signal (NLS) is present in helix 
three of the homeodomain and the pentapeptide motif that interacts with 
PBX1 located close to the homeodomain, whereas a nuclear export signal 
(NES) was proposed 78 at position 84-92 of mouse PDX-1 (Modified from 
McKinnon and Docherty, 2001).  
 
1.3.2 PDX-1 regulates pancreatic morphogenesis   
PDX-1 is of great importance in the development of the pancreas. The pancreas 
consists of three major types of cells: the digestive enzyme-producing exocrine 
acinar tissue; the endocrine cells which make up the islets of Langerhans and 
produce the nutrient homeostasis hormones, i.e. insulin, glucagon and somatostatin 
etc.; and the elaborately branched ductal tree 79.  
Pancreatic development starts early during embryogenesis 79. In general, the 
pancreas arises from the endoderm as a dorsal and a ventral bud, which will finally 
grow to form the adult pancreas. For the mouse pancreas, there are three transitions 
during the development. On embryonic day 8 (e8), the dorsal and ventral buds are 
formed by the endodermal epithelium of the foregut. This process will last until 
e9.5. The buds will then grow into branching ducts and undifferentiated epithelium 
on e12.5, which is the first developmental transition. After this stage, the second 
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transition occurs. Hence, single endocrine cells are found among the 
undifferentiated epithelium and the clusters developed from the buds start to 
differentiate into endocrine and exocrine cells by e14. On e15 the dorsal and ventral 
clusters start to rotate and fuse, eventually forming a pancreas. The process takes 
about four days, up to e19. In the newly formed pancreas, islets of Langerhans are 
formed from the organized endocrine cells, which is the beginning of the third 
transition. During the third transition, the maturation of endocrine cells and the full 
nutrient responsiveness will be completed and this process will continue for two to 
three weeks after birth.  
Different developmental stages involve the effects of a combination of specific 
transcription factors and signaling molecules. Considerable progress has been made 
in the understanding of the embryogenesis of pancreas, notably by identifying key 
genes controlling islet development. Most of these genes encode transcription 
factors such as Isl-1, PDX-1, BETA2/NeuroD1 Nkx2.2, Pax4 and Pax6 80 81, 82.  
PDX-1 is the major regulator for the determination of the endocrine and exocrine 
cell population. It is found in murine foregut endoderm on e8.5 and is detected in 
both ventral and dorsal buds on e9.5 47, 67. After the first transition, PDX-1 
continues to be expressed in the developing ductal tree during the second 
development transition. As the differentiation of the exocrine and endocrine cells 
occurs (e14-e15), PDX-1 expression starts to shift to the endocrine cells. On e13.5, 
PDX-1 still localizes with the exocrine cell-specific enzyme amylase. However, the 
expression is decreased dramatically by e16.5 and disappears in the adult murine 
exocrine pancreas. PDX-1 expression is predominantly restricted to the mature β-
cells thereafter. In adult pancreas, besides β-cell expression, PDX-1 is also detected 
in somatostatin-producing δ-cells where it primarily regulates the expression of 
insulin and somatostatin expression 79. PDX-1 is also reported to be expressed in a 
very few glucagon-producing α-cells 61, 62, 67, 83. 
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1.3.3 Animal models of PDX-1 dysfunction  
The role of PDX-1 in pancreas development and islet cell differentiation has been 
demonstrated using animal models.  
Mice with targeted disruption of the Pdx1 gene (Pdx1-/-) were born with pancreas 
agenesis and abnormalities within specific regions of the duodenum 45, 47, 
homozygous null Pdx1 mice die within days after birth 45. Interestingly, a few 
insulin-positive cells are detected during early pancreas development in mice 
without PDX-1 expression indicating the possible existence of PDX-1-negative 
insulin-expressing cells 84, 85. 
PDX-1 expression also increases during pancreatic regeneration. Thus, in islets 
isolated 3-7 days after pancreatectomy the level of PDX-1 protein was much higher 
than control islets, indicating a possible up regulation of PDX-1 in the dividing 
ductal cells during pancreas regeneration 86. These findings highlight the potential 
role of PDX-1 as therapeutic target in pancreatic disorders.  
 
1.3.4 PDX-1 and the regulation of gene expression  
PDX-1 regulates a number of islet genes including insulin 61, glucose transporter 2 
(GLUT-2) 87, glucokinase 88 and islet amyloid polypeptide 89-91 . Each of these is 
involved in maintaining β-cell identity and function. β-cell–specific inactivation of 
the mouse PDX-1 gene using the Cre-lox system results in reduced β-cell mass, loss 
of the β-cell phenotype, reduced insulin, and GLUT2 expression and eventually 
diabetes 92.  
The homeodomain of PDX-1 is very important for PDX-1 protein-protein 
interaction, by which PDX-1 interacts with other transcription factors to activate 
gene transcription in a tissue specific manner 46.   
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Serup et al 89 induced endogenous insulin mRNA expression by transfecting 
exogenous PDX-1 cDNA into transformed pancreatic a cells that contain islet-
enriched factors. This measure failed to do so in fibroblasts which lack the PDX-1 
interacting factors.  
In exocrine acinar cell lines, the endogenous PDX-1 interacts with two three-amino 
acid loop extension (TALE) class homeobox proteins PBX1b and MRG193. This 
trimeric complex then activates the elastase promoter 93. 
 
1.3.5 PDX-1 and insulin gene expression  
Tight regulation of insulin synthesis and secretion is at the centre of glucose 
homeostasis. However, the regulation of this process involves a cooperative 
network comprising multiple factors including nutrients, hormonal stimuli, several 
transcription factors and even electrical activity (Ca2+ channels, ATP-sensitive 
potassium (K-ATP) channels) and other intracellular signaling pathways 94, 95.  
 
In mice and rats there are two nonallelic insulin genes, insulin I and II. In human, 
and most of other animals, only carry one copy of the insulin gene exists. The 
human insulin gene is located on chromosome 11p 15.5 and consists of three exons 
and two introns 96.  
 
Insulin gene expression is regulated substantially at the transcriptional level, i.e. 
through changes in insulin gene promoter activity. The insulin gene and its 
promoter sequences have been well conserved during evolution. The activation of 
insulin gene transcription depends on the binding and interaction of multiple 
nuclear factors 95 i.e. transcription factors at the enhancer region, which is located 
between -340 and -91 of the insulin gene 97. The human insulin promoter consists of 
five A elements (A1 to A5) and two E boxes (E1, E2) and except for the A2 
element (GGAAAT), all the A boxes have the same core sequence TAAT which is 
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the motif for homeodomain protein recognition 98.  
 
By mutational analysis the rat insulin I promoter A3/A4 site, which corresponds to 
the A3 region in the human promoter, was found to be responsible for most of the 
insulin promoter activity 97, 99, 100. The rat insulin I gene also contains two regulatory 
regions lying at: -104 to -112 and -233 to -241 99. They are now termed E1 and E2 
boxes 98 and bind to the β-cell specific heterodimeric protein complex IEF1. This 
consists of two basic helix-loop-helix proteins, E47 and BETA2/Neuro D1.  
 
PDX-1 binds to the A3/A4 region of rat insulin I promoter and interacts with E47 
and NeuroD1 thus binds to the adjacent E2 site to activate insulin gene transcription 
101-103. A multi-protein complex including E47, NeuroD1 and the high-mobility 
group protein I (HMG1Y) is formed by protein-protein interactions during which 
PDX-1 homeodomain acts as a protein-protein interaction domain 102, 103. HMG1Y 
is an architectural protein that affects the conformation of DNA and is important in 
the assembly of nuclear pore complexes 103. This complex acts as an activation 
group on the E2A3/4 mini-enhancer and activate transcription probably through 
further interaction with other potential coactivators like the p300 coactivator, which 
interacts directly with the N-terminal PDX-1 and activates the rat I insulin gene 
transcription synergistically 104.  
 
Fig. 1.7. Scheme of insulin promoter and PDX-1 binding sites (Modified 
from McKinnon and Docherty, 2001).  
However important, the regulation of PDX-1 on insulin gene transcription is not the 
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only pathway regulating this process. In the rat insulin I gene, other homeodomain 
proteins can also activate the A/E mini-enhancer by binding to the A3/A4 boxes and 
co-operate with E47, such as Isl-I, Cdx-3, Lmx1.1, HNF1α, and HMGY 103, 105-107. 
It has been reported 103 that the overall function of PDX-1 in forming the activation 
complex on the mini-enhancer of insulin promoter can be substituted by other 
homeodomain factors in the β-cells 108. As mentioned above, in β-cells with Cre-
mediated deletion of PDX-1, insulin expression is still approved 92, likewise, 
Kajimoto et al provided another example that in β-cells with reduced PDX-1 via 
anti-sense RNA, the insulin expression level was sustained 109, these examples may 
reflect insulin transcription being regulated by other homeodomin factors 
substituting for PDX-1. Conversely, overexpression of PDX-1 was reported to 
repress the insulin promoter activity 64, 110. This was possibly due to the fact that the 
overexpressed PDX-1 binds to other factors and inhibits the availability of other 
potential factors to form the transcription complex 64, 110. 
 
1.3.6 PDX-1 and the regulation of other β-cell specific gene 
expression  
1.3.6.1 PDX-1 and somatostatin gene expression 
In mature pancreas, PDX-1 is expressed not only in β-cells but also in δ-cells where 
it regulates somatostatin gene transcription 62. The somatostatin promoter region 
contains four homeodomain binding elements with the common TAAT motif which 
are termed SMS-UE-B, SMS-TAAT1, SMS-TAAT2, SMS-TAAT3, which function 
as the mini-enhancer 60.  
PDX-1 binds to the SMS-UE-B (TSE-I) element, and cooperates with a 
heterodimeric protein complex containing two homeodomain factors, the 
Drosophila melanogaster extra-denticle PBX1 (the same homeodomain protein 
interacting with PDX-1 in acinar cells) and Prep1. The dimeric complex acts by 
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binding to the distal A-element of the somatostatin gene, upstream to the enhancer 
element 75. The trancription factor complex consisting of PDX-1, PBX1 and Prep1 
interacts and is stabilized through the interaction between PDX-1 and PBX1 
involving the FPWMK motif that locates upstream of the PDX-1 homeodomain as 
discussed before in this Introduction 74. 
1.3.6.2 Glucose-transporter 2 (GLUT-2) 
The membrane protein glucose transporter 2 (GLUT-2) works as a glucose 
diffusion facilitator through the plasma membranes in mammalian liver, small 
intestine, kidney, some limited areas of the brain and the pancreatic β-cells. In 
different tissues GLUT-2 gene is regulated under different factors 111. The GLUT-2 
expression has been shown to decrease in the β-cells in various diabetic animal 
models. Thus islet-derived insulin-secreting cells were shown to lose glucose 
responsiveness due to decreased levels of PDX-1 expression which further down 
regulates the intracellular level of GLUT-2 112. A repeated TAAT motif sequence 
was identified and was found conserved in both human and murine GLUT-2 
promoters 87. It has been proposed that PDX-1 binds this motif and mediate the 
transactivation of GLUT-2 gene transcription 87.  It has also been shown by Bonny 
et al that GLUT-2 gene transcription is also regulated by another islet-specific 
DNA-binding protein, GTIIa 112. 
 
1.3.6.3 Glucokinase 
The glycolytic enzyme glucokinase (GK) is mostly expressed in pancreatic b-cells 
and hepatocytes 113 and plays a major role in glucose-stimulated insulin secretion. 
GK is the glucose sensor and controls the entry of glucose into the glycolytic 
pathway by regulating the transfer of phosphate from ATP to glucose to generate 
glucose-6-phosphate. In the liver, glucokinase controls the process of glucose 
storage as glycogen. Defects in the GK gene were shown to be responsible for one 
of the maturity-onset diabetes of the young (MODY2) 114-116. The human GK gene 
promoter region has been identified to contain multiple cis-acting elements, 
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including two crucial motifs: the palindrome structure hPal-1 and the insulin gene 
cis motif A element-like hUPE3 88. PDX-1 transactivates the GK gene transcription 
by binding the hUPE3 motif 117. However, later evidence shows that by applying 
immunoblot in pdx1 (+/-) mice, the expression of PDX-1 and GLUT2 was found 
reduced 68% and 55% compared to wild-type mice whereas GK expression was 
relatively unchanged.118 
 
1.3.6.4 Islet amyloid polypeptide (IAPP) 
IAPP is firstly isolated from the amyloid deposits from type 2 diabetic pancreas, as 
well as from the extracellular component of human insulinomas 119. It is also known 
as amylin, a 37-amino acid peptide expressing in pancreatic β-cells and islet δ-cells. 
In β-cells it works by co-storing with insulin in the secretory granules and co-
releasing with insulin in response to various secretagogues. IAPP is proposed to 
play a critical role in regulation of plasma glucose level in mammals due to its 
inhibitory effect on insulin secretion in isolated islets and its ability to neutralize the 
insulin action in peripheral tissues 120, 121. There are three A box-like sequences in 
the regulatory area of IAPP gene promoter 89 90, 91 and it has been shown by Watada 
et al that all three A box-like elements could bind PDX-1 however only the AT1 or 
AT3 disruption shows an obvious reduction in IAPP gene promoter activity 122. 
Additionally, overexpression of the two K-ATP channel sub-units SUR1 and Kir6.2 
in the human β-cell line (NES2Y), which lacks PDX-1, and operational K-ATP 
channel shows that glucose induction of IAPP promoter activity requires PDX-1 
and calcium influx 123. 
 
1.3.7 Regulation of the Pdx1 (IPF1) gene  
The 6 kb human IPF1 gene consisting of two exons is mapped to chromosome 
13q12.1 124, 125 while the mouse Pdx1 gene is on chromosome 5 126 and the rat 
counterpart on chromosome 12 127. There are three consensus E-box motifs on the 
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Pdx1 promoter -190 to -95 region.  It has been shown that deletion of the E2 box at 
-177 did not affect the Pdx1 promoter activity. However, removal of the proximal 
E-box sequence at -104 completely abolishes PDX-1 expression in HIT-15 cells 124. 
It is also reported that this site binds to the ubiquitous bHLH/leucine zipper nuclear 
factor USF-1 124. Another E box at around -6 kb is identical to the insulin promoter 
E-box. Like the one in the insulin promoter, this E-box also binds the β-cell E-box 
transactivator-2 (BETA2/NeuroD1)/E47 heterodimer which in turn regulates PDX-
1 expression in β-cells 82. 
Moreover, the endodermal transcription factor hepatocyte nuclear factor 
3β (HNF3β; alternative name: Forkhead box A2 (FoxA2)) binds to several sites on 
the Pdx1 promoter 82, 128-130. As members of the HNF family are structurally related 
to histone H5 and can alter the nucleosomal structure, unfold the chromatin to 
provide access to promoter sequences for other transcription factors. Thus, this 
winged-helix family forkhead transcription factor may prime Pdx1 gene expression 
by cooperating with other factors like BETA2/E47. Interestingly, PDX-1 is also 
able to bind at an HNF3β sites with a TAAT sequence, which leads to the 
autoregulatory feedback mechanism of Pdx1 expression 128. HNF3β activity could 
be blocked by glucocorticoids, which in turn represses Pdx1 expression. This could 
explain that finding that, in vitro, islet cell maturation is inhibited by 
glucocorticoids 129, 131-133.  
It has also been demonstrated that there is an interaction between HNF1α, HNF3β 
and PDX-1 at a highly conserved region in both mice and human which lies at -2.5 
kb upstream of the 5’ flanking region of the Pdx1/IPF1 gene 128, 129.  
 
1.3.8 Nutrient and hormonal regulation of PDX-1  
While the role of PDX-1 in pancreas development has been extensively studied, the 
post-translational regulation of PDX-1 is not as well understood. Glucose and a 
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number of other nutrients and some hormones have been shown to regulate PDX-1 
at several levels, including protein content as well as nuclear localization.  
 
1.3.8.1 Regulation of PDX-1 by phosphorylation 
In a study to examine the role of IUF-1 (PDX-1) in glucose-stimulated insulin gene 
expression, Macfarlane et al 63 reported that, in isolated rat islets incubated at low 
glucose (3 mM) decreased the PDX-1 activity to ‘undetectable level’ in 6 h whereas 
at high glucose (20 mM) PDX-1 activity remained stable for 24 h. Moreover, the 
decrease in activity caused by low glucose was recoverable after 15 min at elevated 
glucose concentration. Interestingly, when islets were cultured for 4 h at low 
glucose concentrations together with phosphatase inhibitors, the decline of PDX-1 
activity was prevented. These findings pointed out the importance of glucose in 
regulating PDX-1 activity and suggested that the regulation by glucose may be 
phosphorylation-dependent 63. Potential kinases triggering this event were 
investigated. Moreover, neither cyclic AMP-dependent protein kinase A nor protein 
kinase C could be involved.   
Further study indicated that the glucose-stimulated PDX-1 DNA-binding activity 
(using oligonucleotides corresponding to regulatory region of the human insulin 
gene134) and PDX-1-activated gene transcription were inhibited by a specific 
inhibitor of stress-activated protein kinase 2 (SAPK2, or, p38 mitogen-acticated 
protein kinase, reactivating kinase, CSBP, and Mxi2), SB203580 135, which also 
inhibited the glucose triggered activation of MAPKAP-K2, an immediate 
downstream target of SAPK2. The protein kinase p38/SAPK2 is a member of the 
MAP kinase-related kinases stimulated by adverse stimuli such as heat, osmotic 
shock, ultraviolet light, DNA-damaging reagents and by proinflammatory cytokines 
made under stress condition 136.  PDX-1 DNA-binding activity and PDX-1-
dependent gene transcription are also stimulated by cellular stresses i.e. sodium 
arsenite and heat shock. Overexpression of p38/SAPK2 can also mimicked the 
glucose effect of stimulating PDX-1 DNA-binding activity and moreover, these 
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stimulations were also inhibited by SB 203580, which indicated that the 
p38/SAPK2 pathway is involved in regulating PDX-1 DNA-binding activity. 
Additionally, a role for phosphatidylinositide 3-kinase (PI 3-kinase) in glucose-
stimulated PDX-1 DNA-binding activity is also proposed as the glucose stimulation 
was found inhibited by PI 3-kinase inhibitor wortmannin/LY294002 or the 
overexpression of dominant-negative form of the PI 3-kinase. Finally, the inhibition 
of PI3K did not affect the activation of MAPKAP-K2, PDX-1 DNA-binding and 
PDX-1-dependent gene transcription induced by arsenite in MIN6 cells, based on 
which a novel pathway that glucose induces the activation of SAPK2 was proposed 
135.  
However, later studies by Rafiq et al 137 later, which examined preproinsulin 
promoter (using pINS (260-60).Luc plasmid 138 ) activity in MIN6 β-cells treated 
with SB 203580 or overexpression of the upstream kinase MKK6 (MAP kinase 
kinase-6) or wild-type p38/SAPK2, reported failed to provide any evidence of a role 
for p38/SAPK2 in the context of insulin gene expression. Moreover, no sign of an 
effect of elevated glucose concentration on subsequently extracted p38/SAPK2 
activity was observed.  On the other hand, this study conferred a role of PI 3-kinase 
in the activatory effect of glucose in the promoter activity. Thus, overexpression of 
a constitutively-active form of PI3K (p110.CAAX), mimicked the activatory effect 
by glucose. Furthermore, the PI3K inhibitor LY 294002 or overexpression of a 
dominant-negative form of the p85 subunit lacking the p110-binding domain, both 
blocked activation of the insulin promoter by glucose. Hence, the conclusion drawn 
by the later study was that PI3K is ‘necessary and sufficient’ for the glucose-
activated PPI gene transcription. Interestingly, work by da Silva Xavier et al 139 
suggested that PI-3K is involved in a positive mechanism, through which glucose 
acts to stimulate insulin release and rebinding to its receptor in β-cells. Similar 
conclusions were also revealed by Leibiger, and colleagues 140. However, the 
downstream signaling pathway does not seem to involve p38/SAPK2 and remains 
unknown.  
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It was proposed that glucose stimulates the phosphorylation of PDX-1 89, 141, 
although the phosphorylation sites have yet to be mapped and the kinases (a 
putative PDX-1 kinase) involved identified.   
In 2006, Boucher et al 142 demonstrated that a minor portion of PDX-1 may be 
phosphorylated on serine 61 and/ or serine 66 in β-cells, as detected with a 
phospho-specific antibody. Oxidative stress, which is associated with the diabetic 
state, (i) increases IPF1/PDX-1 Ser61 and/or Ser66 phosphorylation and (ii) 
increases the degradation rate and decreases the half-life of IPF-1/PDX-1 protein. In 
addition, they provide evidence that GSK3 activity participates in oxidative stress-
induced effects on β-cells.  GSK3 has been found in insulin target tissues of 
diabetic mice and human with an increased activity 143, 144 and inhibiting GSK3 
using specific inhibitors or lithium chloride has been shown to improve the glucose 
metabolism in insulin resistant Zucker rats 145, 146. In the Boucher et al142 study, the 
authors also found that oxidative stress increased PDX-1 phosphorylation on either 
site, and increased the degradation of the protein, such that the half-life of the 
protein was decreased, and the phopshorylation is also modulated by  GSK3-
dependent mechanisms142.  It has been reported that active canonical Wnt signaling 
decreases GSK3 activity 147 and β-cells are sensitive to the oxidative stress which 
increases with age. Thus a new mechanism to explain the declined levels of PDX-1 
and resultant β-cell dysfunction during diabetes progression was proposed whereby 
canonical Wnt signaling counteracts age-related increase in oxidative stress by 
inhibiting GSK3 activity to rescue PDX-1 from protein degradation and in turn 
maintain normal β-cell function 142. 
In another later study by Boucher et al 148, it was reported that the homeodomain-
interacting protein kinase (Hipk) 2, which was confirmed as expressed in both 
embryonic and adult pancreas, directly phosphorylates PDX-1 in the C-terminal 
domain. Moreover, active Hipk2 also increased PDX-1 transcriptional activity in 
these studies. Although the actual phosphoryaltion site needs to be identified, this 
mechanism was proposed to open up a new way through which PDX-1 
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transcriptional activity may be regulated to modulate pancreas development and/or 
β-cell function.  
 
 
1.3.8.2 PDX-1 subcellular localization:  effects of glucose, insulin and 
oxidative stress  
There appears to be a growing number of transcription factors that are controlled by 
a regulated nuclear translocation mechanism to control the expression of specific 
genes including signal transducers and activators of transcription, nuclear factors of 
IgkB cells, nuclear factors of activated T-cells (NFATs), p53, and steroid receptors 
149. In the PDX-1 Structure section (Page 19) I discussed the fact that there is a 
nuclear localization signal lying on the third helix of PDX-1 homeodomain 76, 77.  
It has indeed been demonstrated that glucose affects the intracellular distribution of 
PDX-1 in β-cells by different research groups 138, 141. Thus, it was first reported by 
Rafiq et al 138, using laser-scanning confocal microscopy, that Pdx1.c-myc, 
translocated from the nuclear periphery to nucleoplasm rapidly at elevated glucose 
concentration (3 mM to 30 mM). It was proposed that in cells exposed to 3 mM 
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glucose the endogenous PDX-1 might be tied to immobile anchors involving the 
microfilaments/microtubules beneath the nuclear membrane. However, it is noted 
that the PDX-1 fused to enhanced fluorescent protein (EGFP; 27 kDa) remained 
largely in the nucleoplasm at both 3 and 30 mM glucose and no sign of 
translocation was observed.  This observation may indicate that the EGFP protein 
150 blocked the interaction between PDX-1 and the binding site(s) located on or 
around the nuclear membrane. Nevertheless, in this study138, Rafiq et al speculated 
that the localization to the nuclear periphery might be a general phenomenon for 
glucose-sensitive transcription factors such as, for example, the transcription factor 
Sp1 151 which was found to interact with the nuclear pore protein p62 and is 
involved in the regulation by glucose of the fatty acid synthase promoter 152. 
Another example is the β-cell-specific c-Jun interacting protein (JIP) homologue 
IB1 153which regulates the glucose-sensitive GLUT-2 gene in β-cells. This 
transcription factor was also reported to be localized to the nuclear periphery 153.  
As discussed in the previous “phosphorylation of PDX-1” Section (page 33), 
phosphorylation seems likely to be involved in regulation of PDX-1 by glucose. 
Rafiq et al 137, 138 also proposed that a shift of PDX-1 from nuclear periphery to 
nucleoplasm at elevated [glucose] might be controlled by a phosphorylation event 
catalyzed by unknown kinase(s).  However achieved, the authors speculated that the 
translocation of PDX-1 is very likely to affect the trans-activational capacity of 
PDX-1 in native β-cells exposed to high extracellular glucose concentrations.  
In another study, Elrick and Docherty 154 also observed that PDX-1 shuttles 
between the nuclear periphery and the nucleoplasm in a phosphorylation-dependent 
manner in response to changes in extracellular glucose and insulin concentrations. 
Moreover, in this study, it was claimed that the translocation of PDX-1 from the 
nuclear periphery to the nucleoplasm stimulated by extracellular glucose or insulin 
is inhibited by the PI3-K inhibitor wortmannin and the p38/SAPK2 inhibitor 
SB203580 hence suggesting that the PI3K and p38/SAPK2 pathway is involved 154.  
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By contrast, Rafiq et al 137 reported that the movement of PDX-1 from the nuclear 
periphery to the nucleoplasm in response to glucose involved PI 3-kinase but not 
p38/SAPK2 137.  
However, in both of the above studies the regulatory role of phoshorylation in the 
glucose stimulated PDX-1 translocation was agreed and also the PI3K was involved 
in this process. This left to be addressed which protein kinase(s) may be involved.  
 
1.3.8.3 Role(s) of the N-terminal domain of PDX-1 
The principal physiological regulator of insulin transcription in islet β cells is 
glucose 155. As discussed above, glucose regulates PDX-1 DNA-binding activity, 
phosphorylation and nuclear translocation. Moreover, it has been reported that 
glucose also directly stimulates the transactivation capacity of the PDX-1 N-
terminal domain 155-157. 
Thus, Petersen et al 155 showed that glucose induces the transactivation capacity of 
PDX-1 by both affecting PDX-1 DNA-binding and also regulating the 
transactivation domain function. Another study by Shushan et al 156 explored the 
functional regions of the human PDX-1 protein by fusing it to the DNA-binding 
domain of the transcription factor Gal4. The N-terminal domain of the hPDX-1 
turned out to be important for transactivation in transfected βTC6 and HeLa cells, 
as well as in transfected rat islets. Moreover, two regions, which are critical for 
PDX-1 transactivation properties, were also mapped within the N-terminus. 
Additionally, study by Peshavaria et al 157 also confirmed the important role of 
PDX-1 N-terminus in its transactivation activity to mediate glucose-inducible 
insulin gene transcription in islet β-cells.  
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1.3.8.4 Role(s) of the C-terminal domain of PDX-1 
In contrast to the relatively well-studied functions of the N-terminus and the 
homeodomain of PDX-1, the role of the conserved C-terminus is less well defined. 
Mutations in the IPF-1 gene in human which affect the C-terminus of PDX-1 are 
associated with the development of type 2 diabetes 158-160, and other findings 
indicate that the C-terminal domain may serve as both a repressor and an activator 
of PDX-1 function. Thus, the C-terminus may inhibit the synergy between PDX-1 
and a second transcription factor, E47, on the preproinsulin promoter, whilst also 
containing a cryptic transactivation domain involved in regulating the somatostatin 
gene TAAT1 enhancer 70, 101. Stoffers and colleagues 160 have also identified a 
PDX-1 C-terminus interacting protein, termed PDX-1 C-terminal interacting factor 
(PCIF1) and suggested that PCIF1 may modulate PDX-1 function during pancreas 
development and/or differentiation.  
Importantly, a recent study reported that HIPK2 is co-localized with PDX-1 both 
the developing and adult pancreas. Moreover, HIPK2 was reportedly able to 
modulate positively the transcriptional activity of PDX-1, possibly by 
phosphorylation of the C-terminal domain 161.  
 
1.3.9 Other mechanisms involved in regulating PDX-1   
Besides glucose, several hormones such as the insulinotropic hormone glucagon-
like peptide-1 (GLP-1) and TGFβ have been reported to regulate PDX-1 at the level 
of DNA-binding activity, transactivation potential or expression of the Pdx1/IPF1 
gene 162-166. 
GLP-1 was found to be able to stimulate insulin secretion and effectively lower the 
blood glucose levels 166. This hormone normally works through a G-protein coupled 
receptor linked to protein kinase A (PKA) and was found to stimulate Gal4:PDX-1 
activity. Notably, the PDX-1 activation domain linked to the Gal4 DNA-binding 
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domain does not contain any phosphorylation site for PKA 167, which suggests the 
regulatory effect of GLP-1 on glucose-dependent activity of PDX-1. Moreover, 
GLP-1 also increases the β-cell mass in diabetic animal models 166, in a process 
which has been shown to be mediated by the transcription of PDX-1166. 
Finally, it has also been reported that increased fatty acid levels can down-regulate 
PDX-1 expression 168. Isolated rat pancreatic islets exposed to palmitic acid 
expressed nearly 70% decrease in PDX-1 mRNA and protein expression. This 
treatment also resulted in a decrease of the PDX-1 DNA-binding activity to the 
promoter region of insulin to 65% and GLUT-2 to 40%, respectively 168.  
1.3.10 PDX-1 and diabetes  
1.3.10.1 IPF-1 mutations in diabetes  
Several mutations in the Pdx1/IPF1 gene have been reported. These include 
frameshift and missense mutations 158, 169, 170 which lead to decreased binding 
activity of PDX-1 to the insulin promoter accompanied by reduced transcription of 
insulin in response to hyperglycemia in vitro. 
PDX-1 was reported firstly to be associated with Type 2 diabetes in studies 169 on a 
child patient born with pancreatic agenesis 169 who was also found to be 
homozygous for an inactivating cytosine deletion in the protein coding sequence of 
IPF1 (pro63fsdelc). This frameshift mutation generated a truncated protein that 
lacked a functional homeodomain necessary for DNA binding and nuclear 
localization. Members of the patient’s family who carried the heterozygous 
mutation of the same allele exhibited an autosomal dominant early onset form of the 
type 2 diabetes (MODY) 171, 172.  
Maturity-onset diabetes of the young (MODY) is characterized by autosomal 
dominant inheritance and defects in insulin secretion, resulting in an early onset of 
non-insulin dependent diabetes mellitus, usually before 25 years of age and 
frequently in childhood or adolescence 171, 172. There are six genes which are 
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associated with MODY: hepatocyte nuclear factor 4α (MODY1), GK (MODY2), 
HNF1α (MODY3), Pdx1/IPF1 (MODY4), HNF1β (MODY5), and BETA2 
(MODY6). All these genes are expressed in pancreatic β-cells, and mutation of any 
of these genes leads to β-cell dysfunction and diabetes mellitus.  
 
Macfarlane et al 173  identified three novel missense mutations (C18R, D76N and 
R197H) from patients with type 2 diabetes. These mutations were further 
demonstrated in a human β-cell line NES2Y to be able to decrease PDX-1 binding 
activity to the insulin promoter and in turn a declined insulin transcription in 
response to hyperglycemia. 
Hani et al 158 identified three novel IPF1 mutations; including two substitutions 
(Q59L and D76N) and an in-frame proline insertion (InsCCG243) in 192 French, 
non-MODY type 2 diabetic families. Functional transactivation assays were applied 
with these IPF1 mutant isoforms in a pancreatic β-cell line transfected with a 
transcriptional reporter. Transfection with IPF1 expression plasmids resulted in a 
significant inhibition of basal insulin promoter activity (stronger than with the 
InsCCG243 mutant) 158.  
In a study aiming to examine the putative role of mutations in the IPF1 gene in 
early-onset diabetes, Weng et al 159 reported two novel IPF1 variants (G212R and 
P239Q) and the previously found D76N, in 115 Scandinavian families with at least 
two members with onset of diabetes younger than 40 years. They concluded that 
although mutations in the IPF1 gene are rare in early- (3.5 %) and late- (2.7 %) 
onset Type 2 diabetes, they are functionally important and also occur in families 
with other MODY mutations 159.  
 
1.3.10.2 PDX-1 and diabetes treatment 
Transplantation of insulin-producing cells is still a potentially powerful tool for the 
treatment of type 1 and certain types of type 2 diabetes; however, donor supply 
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remains an obvious limitation. Meanwhile, progress based on regenerative 
medicine, aimed at converting adult cells into other cell types for tissue repair and 
regeneration through the molecular mechanisms of pancreatic islet engineering, 
could help to generate sufficient β-cells from embryonic stem cells and overcome 
this problem. Ferber et al 174 have reported that ectopic expression of PDX-1 in 
liver cells endowed the hepatic tissue with pancreatic β-cell characteristics and 
induced secretion of insulin from liver cells. This report indicated the capacity of 
PDX-1 to reprogram extrapancreatic tissue towards a β-cell phenotype. It thus 
became possible to study the self-neogenesis of islets in organs such as the liver, 
spleen, and pancreas through the introduction of PDX-1 and/or other related genes.  
 
Very recently an important study by Zhou et al 175 again renewed the progress of 
treating diabetes via β-cell regeneration. Aiming to identify a way of turning one 
cell type into another in a controlled manner (“transdifferentiation”), by re-
expressing key developmental regulators in vivo, Zhou et al 175 identified for the 
first time a specific combination of three transcription factors (Ngn3, PDX-1 and 
MafA) that reprograms differentiated pancreatic exocrine cells in adult mice into 
cells that closely resemble β-cells 175. Remarkably, not only were the newly-
induced β-cells indistinguishable from endogenous islet β-cells in size, shape and 
ultrastructure, they also expressed genes essential for β-cell function and could 
improve hyperglycaemia by remodeling local vasculature and secreting insulin. 
These exciting findings provide an example of cellular reprogramming using 
defined factors in an adult organ and may open up a new method for cell 
reprogramming without reversion to a pluripotent stem cell state. 
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1.4 Nutrient-responsive kinases  
1.4.1 The metabolic ‘master switch’: AMPK   
Imbalanced energy intake and energy expenditure underline various metabolic 
diseases such as obesity and type 2 diabetes. In general, systems that detect energy 
excess will shunt energy into storage and dissipate energy by increasing energy 
expenditure and consuming ATP. On the contrary, systems sensing energy deficits 
will increase fuel utilization in order to increase ATP production, decreasing 
carbohydrate oxidation in an effort to preserve glycogen stores.  
 
Energy and nutrient sensors ultimately decided how cells respond to fuel substrates 
such as glucose, and further activate appropriate pathways176, 177. Among the 
nutrient-responsive kinases, an important example is the 5' AMP-activated protein 
kinase, AMPK, a metabolic master switch 178 regulating a number of intracellular 
systems including glucose uptake, β-oxidation of fatty acids and the biogenesis of 
glucose transporter 4 (GLUT4) and mitochondria 179-182. AMPK is conserved from 
yeast to human and plays an important role in cellular energy homeostasis 178. This 
kinase senses changes in the ratio (AMP:ATP) by binding both species in a 
competitive manner 183. Hence, the kinase is activated by increases in the 
concentration of AMP, which leads to the phosphorylation and differential 
regulation of a series of downstream targets that control anabolic and catabolic 
pathways 183. AMPK is believed to be activated by phosphorylation on Thr-172 by 
at least two upstream signaling pathways 184. In one case an increase of cellular 
AMP: ATP ratio caused by metabolic stress leads to the phosphorylation of AMPK 
by LKB1; alternatively phosphorylation at Thr-172 may be triggered by an increase 
in cytosolic free Ca2+ mediated by CaMKKβ 184. An adenosine analogue 5-amino-4-
imidazolecarboxamide riboside (AICAR) was shown to be taken into cells via 
adenosine transporters 185 and further converted to 5-amino-4-
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imidazolecarboxamide ribotide (ZMP)186 which activates AMPK 187-190.  
 
AMPK is expressed in several tissues including liver, brain, skeletal muscle and 
pancreatic β-cells 178. AMPK is involved in regulating a number of downstream 
processes including the stimulation of hepatic and skeletal muscle fatty acid 
oxidation via phosphorylation and inactivation of acetyl-CoA carboxylase 191, 192, 
inhibition of cholesterol synthesis by phosphorylating and inactivating 3-hydroxy-
3-methylglutaryl-CoA reductase (HMGR)193, and modulation of insulin secretion 
by pancreatic β-cells 178.  
 
Salt et al 194 firstly showed that stimulation of AMPK with AICAR stimulated the 
basal insulin secretion while inhibited the glucose-stimulated insulin secretion. This 
was later also found in rodent β-cell lines as well as in rodent and human islets 195-
197 using either the activator 5’-aminoimidazole carboxamide-4-ribonucleotide 
(AICAR) or an adenovirus expressing a constitutively active form of AMPK. It was 
reported that increases in glucose concentration within physiological range resulted 
in an inhibition of AMPK activity in both MIN6 cells 195 and in islets 196. The 
findings that both glucose-dependent changes in AMP: ATP ratio 194, 195, 198 and the 
depolarization-stimulated free Ca2+ increase 199 regulate the AMPK activity and 
phosphorylation also indicated the involvement of the LKB1 and 
CaMKKβ pathway in the stimulation of AMPK 199. Metformin is one of the most 
commonly prescribed oral antidiabetic agents worldwide which usually causes 
weight loss and reduced appetite. In 2001 Zhou G et al 200 reported that the 
antidiabetic drug metformin stimulates peripheral AMPK and leads to reduced 
glucose production in the liver and reduced insulin resistance in the muscle.  
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1.4.2 The nutrient-sensing kinase: Per-Arnt-Sim Kinase 
 
The per-arnt-sim domain or PAS kinase (also termed PASKIN), is another Ser/Thr 
kinase, distantly related to AMPK (it is phylogenetically closer to LKB1) 201. It is 
one of a group of kinases containing PAS domains which regulate the function of 
many intracellular signaling pathways in response to both extrinsic and intrinsic 
simuli 202.  
PAS is an acronym from the names of the proteins in which imperfect repeat 
sequences were first recognized 203: the Drosophila period clock protein (PER), 
vertebrate aryl hydrocarbon receptor nuclear translocator (ARNT), and Drosophila 
single-minded protein (SIM)204.  The PAS domain is found in all kingdoms of life 
as a small regulatory module 202. PAS domain-regulated histidine kinases are very 
common in prokaryotes and control a wide range of fundamental physiological 
processes, e.g. Rhizobia nitrogen fixation, via the oxygen-sensing protein FixL 205-
207. The evolutionarily-conserved PAS kinase consists of two PAS domains and a 
canonical serine/threonine kinase domain 202. PASK is conserved with orthologs in 
humans, flies, and yeast 202. Evidence has been provided that phosphorylation of the 
activation loop within the catalytic domain of PASK is critical for kinase activity, 
analogous to the regulation of AMP kinase. Moreover, the enzymatic activity of 
PASK is reported to be subject to inhibition by the most N-terminal PAS domain, 
designated PAS-A. Finally, the PAS-A domain expressed separately is able to 
transinactivate its cognate kinase domain in vitro 202.  
As discussed by Rutter et al 208 in budding yeast gave evidence that PASK may be 
involved in the control of sugar metabolism and protein translation.  It was later 
shown by da Silva Xavier et al 209 that mammalian PASK was rapidly activated in 
clonal β-cells and rat islets in response to elevated glucose concentrations both by 
reversible phosphorylation at Thr-152 in the “T-loop”, and through enhanced 
expression of the PASK gene. 209.  
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Importantly, by both transcriptional and post-transcriptional mechanisms, PASK 
activity was necessary for mediating the direct (intracellular) effect of glucose to 
stimulate transcription of the preproinsulin and PDX-1 genes 209. Overexpression of 
wild-type PASK in pancreatic MIN6 β-cells resulted in marked increases in 
preproinsulin promoter activity at low glucose concentrations. Conversely, 
blockade of PASK function with a dominant negative form of the enzyme, with 
short interfering RNAs or by antibody microinjection into single cells blocked the 
induction of preproinsulin and pdx-1 and other genes by glucose 209.  Notably, da 
Silva Xavier et al also found that regulation by PASK or glucose of both the 
preproinsulin and PDX-1 promoters was completely abrogated by deletion of PDX-
1-binding sites 209. As a result, it was proposed that PDX-1 and possibly MafA 
could very like to be the targets of PASK action 209. 
More recently, in order to understand the in vivo role of PASK in pancreatic β-cell 
function and energy homeostasis, Hao et al 210 studied the role of PASK in the 
pathogenesis of metabolic disease in PASK-/- mice 211. It was demonstrated that 
islets from PASK−/− mice display defective glucose-stimulated insulin secretion 
although expression of preproinsulin was normal210. PASK is thus required for 
normal β-cell insulin secretion and mice with PASK deletion exhibited resistance to 
the metabolic effect of a high-fat diet, including obesity, insulin resistance, and 
hepatic triglyceride accumulation. It was proposed that metabolic rate and energy 
expenditure are increased in PASK−/− mice independently of the activity of AMPK, 
mammalian target of rapamycin (mTOR), or peroxisome proliferator-activated 
receptor γ coactivator 1 (PGC-1). Hao et al also observed increased oxidative 
metabolism and ATP generation in cultured cells with PASK knocked down by 
RNAi.  Taken together, it was hypothesized that PASK acts in a cell-autonomous 
manner to maintain cellular energy homeostasis and could be a potential therapeutic 
target for metabolic disease 212.  
 
The molecular mechanisms through which glucose regulates PASK activity, and by 
which activated PASK regulates β-cell function, remain undefined. However, the 
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finding that PASK−/− mice displayed improved insulin sensitivity after a high-fat 
diet indicated that lowered levels of PASK in peripheral tissues may be protective 
against insulin resistance 201.  Interestingly, in 2007 Borter et al 213 demonstrated 
that PASK/PASKIN expression is weak and insensitive to regulation by glucose in 
islets. However, unpublished studies in our laboratory involved screening the 
expression of PASK in islets from a variety of tissues, including human, and we 
demonstrated the clear presence of both PASK mRNA and protein, albeit at levels 
which are substantially lower than those in haemopoetic cells or testis, the main 
sites of PASK expression (GAR, G. daSilvaXavier, unpublished) 201.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  54 
1.5 Background for work  
There appears to be a growing number of transcription factors that function by a 
regulated nuclear translocation mechanism to control specific gene expression. 
These include signal transducers and activators of transcription (STATs), nuclear 
factors of IgkB cells (NF-κB), nuclear factors of activated T-cells (NFATs), p53, 
and steroid receptors 149. By using immunocytochemistry and laser-scanning 
confocal microscopy, previous work in our laboratory has investigated the 
mechanisms by which PDX-1 may be activated by glucose. PDX-1 is associated 
with the nuclear periphery and the nuclear membrane region in cells incubated at 
low glucose concentrations 137, 138. Elevated glucose concentrations stimulated the 
transcriptional activity of a preproinsulin promoter reporter construct monitored in a 
single living MIN6 β-cell and caused a concomitant translocation of PDX-1 from 
the nuclear periphery into the nucleoplasm. We have therefore proposed that this 
shift may contribute to the transactivational capacity of PDX-1 in native β-cells 
exposed to high extracellular glucose concentrations 138. 
It has been discussed previously in the Introduction (page 33) that phosphorylation 
of PDX-1 is important for the regulation of PDX-1 activity and that the regulation 
by glucose and potential kinases have been proposed to be involved in the upstream 
phosphorylation regulation of PDX-1. However, no direct evidence for PDX-1 
phosphorylation in living cells has been provided so far using a well-validated 
biophysical approach such as mass spectrometry. Whether a specific kinase or 
kinases regulate PDX-1, and whether this phosphorylation regulates glucose-
stimulated PDX-1 translocation, still remain unclear.  
As discussed above, PASK was shown to be an important mediator of the effects of 
glucose on insulin and PDX-1 gene expression209. Therefore, PASK became a 
promising new upstream kinase candidate for PDX-1 regulation.  However, given 
the complex regulating network surrounding PDX-1, there might also be other 
kinases involved. Hence, besides targeting potential kinase candidate, it is also an 
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interesting question to investigate the in vivo phosphorylation regions or residues on 
PDX-1 under physiological condition which could possibly provide more detailed 
information to help identify a kinase candidate.  
Consequently, the overall aim of this thesis is to firstly investigate the 
phosphorylation of PDX-1 under physiological condition and investigate the in vivo 
phosphorylation sites, further focus on proposed potential upstream kinase (i.e. 
PASK) and understand the contribution of phosphorylation effect on PDX-1 
function in pancreatic β-cells.  
 
 
 
 
 
 
 
 
 
 
 
  
  56 
 
 
 
 
 
2.  Chapter 2  
 
 
Materials and Methods 
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2.1 Materials  
2.1.1 Cell culture and reagents   
INSrαβ cells (kindly provided by Dr. Thomas Mandrup-Poulsen, Copenhagen) were 
maintained in RPMI-1640 medium containing 11.2 mM glucose, 10% FCS, 
streptomycin and penicillin, 50 µM β-mercaptoethanol, 100 µg/ml G-418 and 100 
µg/ml hygromycin-B in a humidified 5% CO2 incubator at 37 °C. INS-1(832/13) 
cells were grown in RPMI 1640 medium containing 10% heat-inactivated fetal 
bovine serum supplemented with 100 IU/ml penicillin and 100 IU/ml streptomycin, 
1 mM sodium pyruvate, 50 µM 2-mercaptoethanol, and 10 mM HEPES (pH 7.4). 
Human embryonic kidney (HEK) 293 cells 214 were grown in Dulbecco’s modified 
Eagle’s medium (Gibco Grand Island, NY, USA) containing 10% fetal bovine 
serum and penicillin and streptomycin. MIN6 cells were cultured in Dulbecco’s 
modified Eagle’s medium (Gibco Grand Island, NY, USA) containing 15% fetal 
bovine serum and penicillin and streptomycin together with 0.25 µM β-
mercaptoethanol.  
Mouse recombinant tissue necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and 
interleukin-1β (IL-1β) were from PreproTech EC (London, U.K.) and all chemical 
reagents are from Sigma unless specified. Anti-c-myc antibody was purchased from 
Roche, and rabbit polyclonal anti-PDX-1 antibody was generated as described 138.   
Bacterial culture media LB media and LB agar were purchased from Sigma.   
Glycogen synthase kinase 3 (GSK3) and homeodomain interacting protein kinase 2 
(HIPK2) were purchased from Upstate (Lake Placid, NY). CK1δ isoform was 
prepared as previously described 215. 
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2.1.2 Plasmids and generation of the anti-pT152-PDX-1 and 
anti-pS269-PDX-1 antibodies  
Plasmids pcDNA3.1-PDX-1-c-myc (wild-type, T152A, T152E and T152D) and 
HisMBPPDX-1-c-myc (wild-type) were generated by Dr. Huai-xiang Hao 
(University of Utah, USA).  
Plasmids based on pcDNA3.1 (Invitrogen) and encoding wild-type human PASK 
bearing C-terminal c-myc and his epitope tags (pPASK.WT) or inactive PASK 
mutated at the ATP-binding site (K1028R; pPASK.KD) were provided by Prof. 
Jared Rutter (University of Utah, USA). 
 
Polyclonal anti-phospho-PDX-1 antibodies against the region 
145EENKRTRpTAYTRAQ158 (anti-pT152-PDX-1), or 
259LPSGLSVpSPQPSSIAPLRPQ 
EPR284  (anti-pS269-PDX-1) of mouse PDX-1 were raised in rabbit by Pacific 
Immunology Inc, USA.   
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2.2 Methods  
2.2.1 Molecular Biology   
2.2.1.1 Site Directed mutagenesis (SDM)  
Complementary HPLC-purified oligonucleotide primers (approximately 30 
nucleotides in length), containing the desired mutation flanked by the unmodified 
nucleotide sequence, were generated by Invitrogen UK.  Primers were diluted to a 
concentration of 100 mM in distilled water prior to use. Amplification of the 
plasmid containing the cDNA of interest was performed by using QuikChange® 
XL Site-Directed Mutagenesis Kit (Stratagene) mainly following the 
manufacturer’s instruction with optimization. The Pfu polymerase extends the 
nucleotide chain by approximately 1000 nucleotides per minute. Extension times 
were calculated based on the size of the plasmid with 11/2 minutes allowed for each 
1000 nucleotides, ensuring the complete amplification of plasmid.  
Following amplification, reaction product 10 µl was migrated on agarose gel to 
check the size of the product. The rest of template DNA was degraded by the 
addition of 1 µl of the restriction enzyme DpnI, which specifically recognizes and 
digestes methylated template DNA, for 1 h at 37 °C. The reaction product (40 µl) 
was precipitated by adding 0.1 volume of 3 M NaAc pH 5.2, 2.5 volume of ice-cold 
100% ethanol and 1 ml of glycogen. The mixture was precipitated at -80°C for 1 h. 
DNA was collected by centrifugation at 4°C for 20 min. at 13,000 rpm and the 
pellet was air-dried and resuspended in 8 µl dH2O at 65°C for 10 min. Resuspended 
DNA 4 µl was introduced into XL10-Gold ultracompetent cells provided in the 
QuikChange® XL Site-Directed Mutagenesis Kit (Stratagene). The obtained mutant 
DNA plasmids were sent for sequencing to further confirm (see section 2.2.1.7).  
PDX-1 (S269A/E) site directed mutagenesis (SDM). pcDNA3.1-PDX-1-c-myc and 
HisMBPPDX-1-c-myc (S269A/E) mutation were made to prepare PDX-1 
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(S269A/E) mutant adenoviruses and recombinant protein in bacteria, respectively 
(for experiments described in Chapter 5).  
The SDM primers used were:  
PDX-1 S269A (Forward): 5'-ggccttagcgtggcgccacagccct-3' 
PDX-1 S269A (Reverse): 5’-agggctgtggcgccacgctaaggcc-3’ 
PDX-1 S269E (Forward): 5'-gggccttagcgtggagccacagccctcc-3'  
PDX-1 S269E (Reverse):  5’-ggagggctgtggctccacgctaaggccc-3’  
2.2.1.2 Restriction digests 
To enable the cloning of DNA fragments into plasmids, DNA was digested using 
specific endonucleases that identify unique restriction sites. Typically, restriction 
digests were performed using 0.5 µl of each restriction enzyme required in a 20 µl 
reaction mix containing a buffer suitable for the enzyme used. Reactions were 
allowed to proceed for 1 h (single enzyme digestion) or 2 h (double digestion) at 
37°C, before the digested DNA was visualized on an agarose gel.  
 
2.2.1.3 Ligation  
The ligation of cloned DNA into expression vectors was performed using an insert-
to-vector ratio of 3:1. Ligations were performed using a T4 DNA ligase (Invitrogen, 
UK) in its specific reaction buffer. Ligation reactions were typically performed for 
16°C for 16 h, before the product was transformed into competent cells (see section 
2.2.1.5).  
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2.2.1.4 Visualization of DNA on agarose gels 
Visualization and separation of DNA was typically performed with 0.8% agarose 
gels. Molten agarose was generated by dissolving 0.7% (w/v) agarose in 1 x Tris-
acetate-EDTA (TAE) buffer (diluted from 10 X stock (Sigma)) and heating in a 
microwave. Following cooling, 40 ng/ml ethidium bromide was added to the 
agarose and the gels poured using a gel mould with an appropriately sized comb. 
Gels were allowed to set and then submerged in 1 X TAE buffer in the gel tank. 
DNA samples in 6 X sample buffer along with appropriate DNA ladder (Promega, 
UK) were loaded into the wells of the gel and the gel run at 90 volts until adequate 
separation was achieved. DNA was visualized using Bio-Rad ChemiDoc XRS 
system with Quantity One software (Bio-Rad, Hertfordshire, UK). DNA 
concentrations were estimated by comparison to known DNA concentrations within 
the DNA ladder.  
 
2.2.1.5 Estimation of the DNA concentration by Nano-Drop.  
DNA concentration was determined by a Nano Drop Spectrophotometer (Labtech 
international). 0.5-1 µl plasmid DNA was added onto the Nano Drop probe and the 
absorbance measured at 260 and 280 nm. The concentration was calculated as the 
extinction coefficient for DNA at 260 nm and compared to a distilled H2O or Tris-
EDTA (pH8.0; TE) buffer control.   
2.2.1.6 Sequencing of DNA plasmids 
DNA sequencing reactions were performed by GATC Biotech AG (Konstanz, 
Germany) or MWG Biotech (London, UK). Sequencing primers were generated by 
Invitrogen, UK. Sequence alignments were performed using online sequence 
alignment software Basic Local Alignment Search Tool provided by NCBI. The 
plasmids used throughout the thesis are detailed in Table 2.1. 
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2.2.1.7 Transformation of Top 10 electrical competent E.coli 
Top 10 electrical competent Escherichia coli (Invitrogen, UK) cells were thawed on 
ice and mixed gently by flicking. The ligation product was transformed into 20 µl 
electrical competent cells in a 2.0 mm cuvette and mixed well without air bubbles. 
The mixture was electroporated at 2,500 V, 200 Ohms in an electroporator 
(Eppendorf). The transformation products were resuspended in 500 µl of LB-broth, 
and incubated at 37°C in shaking incubator for 1 h. After incubation, the bacteria 
were plated out onto 4 LB plates with selection antibiotics (Table 2.1), and were 
cultured at 37°C overnight (16-20 h). 
 
2.2.1.8 Transformation of XL-1 blue super-competent E.coli 
XL-1 blue super-competent cells (Stratagene, UK) were thawed on ice and mixed 
gently by flicking. 45 µl of cells were added to a pre-chilled rounded bottom falcon 
tube (BD science, UK), and 4 µl of ice-cold site-mutagenesis reaction product was 
mixed with the cells and incubated on ice for 30 min. Cells were heat shocked at 
42°C for 30 s. and immediately placed on ice for 2 min. LB media (500 µl) was 
added to the cells and incubated for 1 h at 37°C with shaking. Cells (25 µl and 100 
µl) were plated on to agar plates containing the relevant selection antibiotic (100 
µg/ml ampicillin or 50 µg/ml kanamycin) for each specific plasmid and colonies 
grown at 37°C for 16 h.   
2.2.1.9 RNA Isolation and Reverse-Transcription PCR  
INSrαβ cells216 were cultured in six-well dishes and treated with 500 ng/ml 
doxycyclin or various viruses at an multiplicity of infection (MOI) of 100 plaque-
forming units (pfu)/cell for 16-24 h. To isolate total mRNA, the monolayer was 
rapidly washed twice with PBS, pH 7.5, and scraped with a rubber spatula in to 
TRIZOL reagent (Invitrogen). Phenol extraction of the homogenate was performed 
as described by the manufacturer. Isopropyl alcohol precipitation of RNA was 
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performed at 20 °C overnight. The RNA was then washed with 75% ethanol and 
dissolved in nuclease-free water. DNase treatment was applied by using DNase-free 
kit (Ambion) and the absorbance of RNA at 260 nm and 280 nm was measured. 
The ratio of A260/A280 was between 1.8-2.1 and the concentration of sample RNA 
was calculated by A260. RNA 2 µg was converted into cDNA by reverse-
transcription PCR as template for the downstream real-time PCR.  
 
Real-time RT-PCR quantitative detection of target mRNA transcripts was carried 
out using an ABI PRISM 7500 (Applied Biosystems, Foster City, CA). PCR 
reactions were performed in a total volume of 20 µl. SYBR green PCR master mix 
(10 µl; Applied Biosystems), 0.5 µl (final concentration 0.125 µM) of primers 
(forward and reverse), and 1.5 µl first-strand cDNA were mixed into 96-well PCR 
plates (Applied Biosystems). Primer sequences are as follows: cyclophilin A fwd, 
5'-TATCTGCAC TGCCAAGACTGA-3'; cyclophilin A rev, 5'-
CCACAATGCTCATGCCTTCTTT CA-3'; glucagon fwd, 5'-
GATCATTCCCAGCTT CCCAG-3'; glucagon rev, 5'-
CTGGTAAAGGTCCCTTCAGC-3' 217. Data were analyzed using ABR PRIM SDS 
v1.3.1 (Applied Biosystems software). All samples were assayed in triplicate, and 
each real-time PCR experiment was repeated three times on three different 
occasions.  
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2.2.2 Cell and tissue work  
2.2.2.1 Immunocytochemistry  
INSrαβ cells were infected with viruses expressing wild-type or mutant forms of 
PDX-1 at 100 MOI and cultured in medium containing 11.2 mM glucose for 24 h 
prior to treatment for 16 h in medium captaining 3 mM glucose. Cells were then 
cultured at 3 or 20 mM glucose for 6 h. Cells were fixed and permeabilized with 4% 
(v/v) paraformaldehyde plus 0.2% Triton X-100 138. A monoclonal primary 
antibody against c-myc (Roche, 1:1000) was revealed with Alexa 568-conjugated 
goat-anti-mouse antibody (1:1000) in 0.2% (v/v) bovine serum albumin. Cells were 
washed with PBS between incubations. Cells were treated with 4', 6-diamidino-2-
phenylindole (DAPI) staining and mounted on coverslips with Mowiol before 
analysis 138. 
 
2.2.2.2 Confocal Imaging  
Confocal Images were captured using a Leica SP2 upright laser scanning confocal 
microscope (X 63/1.32 oil-immersion lens) equipped with a krypton/argon laser 
(488 and 568 nm excitation lines) and a UV light. Images were analyzed off-line 
using VolocityTM 4.0 software.   
2.2.2.3 Preparation of Nuclear Extracts  
HEK293 cells cultured in T75 flasks were infected with adenoviruses expressing 
wild-type or mutant forms of PDX-1 at 100 MOI for 24 h and collected. These were 
then washed once with ice-cold PBS. The cell pellet was resuspended in 1 ml cold 
buffer (10 mM HEPES pH 7.9; 10 mM KCl; 0.1 mM EDTA; 0.1 mM EGTA; 1 
mM DTT; 0.5 mM PMSF) 218 by gentle pipeting. The cells were allowed to swell 
on ice for 15 min. and 50 µl of 10% NP-40 was added and the resuspension was 
vortexed for 10 s. The homogenate was centrifuged for 30 s in a microcentrifuge at 
  
  66 
13,200 rpm at 4 °C. The supernatant containing cytoplasm and RNA was discarded 
and the pellet was resuspended in 100 ml buffer (20 mM HEPES pH 7.9; 0.4 M 
NaCl; 1 mM EDTA; 1 mM EGTA; 1 mM DTT; 1 mM PMSF) 218 and the tube was 
vigorously rocked at 4°C for 15 min. on a shaking platform. The nuclear extract 
was centrifuged for 5 min. in a microcentrifuge at 13,200 rpm at 4°C. Protein 
concentrations were determined using the Pierce BCA protein Assay (Thermo 
scientific). Nuclear extracts were then divided into 20 µl aliquots and stored at -80 
°C.  
 
2.2.2.4 Ca2+-phosphate transfection 
HEK293 cells were transfected using Ca2+-phosphate 219. HEK293 cells were grown 
to 70-90% confluency in 12-well plates or T25 flask. Total DNA (as indicated in 
different reaction) was mixed with 2.5 M CaCl2 was added drop by drop to same 
volume of 2 X Hepes buffer saline (HBS) in a sterile tube while vortexing. The 
mixture was applied on top of the cells. Cells were harvested after 24-48 h after 
transfection for further immunoprecipitation or luciferase assay.  
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2.2.3 Protein expression and purification   
2.2.3.1 Transformation of BL21 E.coli 
BL21 cells (Invitrogen, UK) transformed using the same protocol as for XL-1 Blue 
super-competent cells.   
2.2.3.2 Preparation of HisMBPPDX-1 mutants expressing DNA 
construct. 
The HisMBP-PDX-1 (T152A) was constructed by replacing the PDX-1 fragment 
between restriction sites BsrGI and XhoI in HisMBPPDX-1 (wild-type) with the 
same fragment containing T152A mutation site from pcDNA3-PDX-1 (T152A). A 
detailed plasmid map is shown in Fig. 2.1 with restriction sites in bold.  
The HisMBPPDX-1 (S269A and S269E) was generated using site-directed 
mutagenesis kit (Stratagene, UK). The primers used and the method was as 
described in the previous section.  
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Figure 2.1. Illustration of HisMBPPDX-1 (WT) (A) and pcDNA3.1-
PDX-1 (T152A) (B) DNA plasmid and restriction sites (BsrG I and 
Xho I) used in restriction digestion. 
 
2.2.3.3 HisMBPPDX-1 protein production and purification 
One colony was grown in 5 ml of LB broth containing 50 µg/ml ampicillin at 37°C for 16 h, which was then further inoculated into 500 ml LB containing 50 µg/ml ampicillin  at  37°C until an O.D. of 0.4-0.6 at 600 nm was reached. 0.2 mM 
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Isopropyl-β-D-thiogaltopyranoside (IPTG) was added for induction and cells were 
cultured for another 16 h at 25°C. The induction process was illustrated in Fig. 
2.2A. Cells were harvested at 5000 rpm for 10 min. at 4°C in a Sorvall centrifuge 
using an SLA-3000 rotor. The pellet was resuspended in ice-cold PBS and 
harvested at 5500 rpm for 10 min. at 4°C. The pellet was vortexed and resuspended 
in ice-cold lysis buffer (50 mM Tris pH 7.5; 150 mM NaCl; 5 mM MgCl2; 1 mM β-
mercaptoethanol (BME); 1 mg/ml lysosyme; 1X protease inhibitors (Roche)) and 
then kept on ice for 30 min. Tween was added to a final concentration of 0.2% and 
the sample was sonicated for 30 s and allowed to rest for 1 min. This procedure was 
repeated three times. The sonicate was then transferred to pre-chilled tubes and 
centrifuged at 100,000 X g for 1 h at 4°C. Ni2+-NTA beads (Qiagen) were washed 
once with 50 ml cold PBS and equilibrated with 50 ml ice-cold wash buffer (50 mM 
Tris pH 7.9; 500 mM NaCl ; 5 mM MgCl2; 1 mM BME; 0.2% Tween) twice and 
sedimented by centrifugation at 800 g for 5 min. at 4°C. Supernatant (100 µl) after 
ultracentrifugation was kept as S100 whilst the rest was adjusted to 500 mM NaCl 
and added to the beads and incubated with rotation at 4°C for 1 h. The beads were 
sedimented by centrifugation at 3,000 rpm for 5 min. at 4°C. Flow through (FT; 100 
µl) was kept and the beads were washed twice with wash buffer and 100 µl of the 
first wash was kept. The beads were then resuspended in 10 ml wash buffer and 
poured into a column (Biorad) and wash buffer allowed to run through.  
Protein was eluted with increasing concentrations of imidazole (10, 50, 100, 150, 
200, 250 mM imidazole, pH 8) in wash buffer. Each eluate (10 µl), the S100, FT 
and column wash were separated on 12% SDS-PAGE and analyzed by coomassie 
blue staining. Eluate containing the protein product were dialysed for 16 h at 4°C in 
2 L of dialysis buffer (50 mM Tris pH 7.9; 150 mM NaCl; 5 mM MgCl2; 1 mM 
BME).  
A representative SDS-PAGE gel with fractions of HisMBP-PDX-1 (wild-type) 
protein was shown in Fig. 2.2B. The band around 90 kD is HisMBP-PDX-1 protein. 
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Fig.2.2. (A) Scheme illustrating the preparation HisMBP-PDX-1 
recombinant protein. (B) Preparation of recombinant mouse 
MBP-PDX-1 (wild-type).  Purification of HisMBP-PDX-1 (wild-
type) recombinant protein. Protein was eluted with increasing 
concentrations of imidazole (as indicated) in wash buffer. 10 µl of 
each eluate, the supernatant (S100), flow through (FT) and column 
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wash (W1) were separated on SDS-PAGE and analyzed by coomassie 
blue. 
2.2.3.4 AcTEV protease cleavage time course 
AcTEV Protease is an enhanced form of Tobacco Etch Virus (TEV) protease which 
recognizes the seven-amino-acid sequence: Glu-Asn-Leu-Tyr-Phe-Gln-Gly, present 
between the histidine tag and maltose-binding protein, and also between PDX-1 and 
maltose-binding protein (Fig. 2.3A).  AcTEV protease cleaves between Gln and Gly 
with high specificity. In order to check the efficiency of the protease, a time course 
for protease digestion was carried out and samples of wild-type protein digestion 
product at 1, 2, 4, 6 h were collected and migrated on SDS-PAGE before coomassie 
analysis. Fusion protein (20 µg) was mixed with 20X Tobacco Etch Virus protease 
(TEV) Buffer (50 mM Tris-HCl, pH 8.0, 0.5 mM EDTA), 1 mM dithiothreitol 
(DTT), and 1.0 μl AcTEV Protease (10 units) in a 150 μl reaction and incubated at 
30°C for 6 h. Aliquots (30 μl) were collected at 1, 2, 4, and 6 h.  These were mixed 
with 30 μl 2X SDS sample buffer (125 mM Tris-HCl, pH 6.8; 4% SDS; 1.4 M β-
mercaptoethanol; 20% (v/v) glycerol; 0.01% bromophenol blue) and kept at -20°C 
until required. 40 μl of each sample was analyzed by SDS-PAGE and coomassie 
blue staining. A representative SDS-PAGE with wild-type PDX-1 protein is shown 
in Fig. 2.3B.    
2.2.3.5 AcTEV protease cleavage and protein purification 
Fusion protein was incubated with AcTEV Protease at 30°C for 6 h as described. 
Amylose beads (New England BioLab) and Ni beads were equilibrated with 1X 
cleavage buffer and poured onto columns. Cleaved recombinant protein was added 
to amylase beads column to remove maltose-binding protein, and Ni beads column 
to remove histidine tag and histidine-tagged AcTEV protease. The final eluate 
containing purified protein was collected. A representative SDS-PAGE with wild-
type PDX-1 protein is shown in Fig. 2.3C. 
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Figure 2.3. (A) The AcTEV cleavage sites (ENLYFQG) in 
recombinant HisMBPPDX-1 protein. (B) and (C) Cleavage and 
purification of PDX-1 recombinant protein (wild-type). (B) AcTEV 
Protease cleavage time course at 1, 2, 4, and 6 h. (C) AcTEV Protease 
cleavage for 6 h. Cleaved recombinant protein was added to amylase 
beads column to remove maltose-binding protein, and Ni beads column 
to remove histidine tag and histidine-tagged AcTEV protease. 5 ml of 
both HisMBPPDX-1 (wild-type) and cleaved PDX-1 (wild-type) 
protein were separated on SDS-PAGE and analyzed by coomassie blue 
staining.    
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2.2.3.6 Recombinant protein concentration 
Recombinant protein was concentrated using vivaspin concentrators (Sartorius-
stedim, UK) with a molecular weight cut off of 30,000 Da. Protein elutions were 
pooled and concentrated by centrifugation at 4,000 g, at 4°C, for the time required 
to reduce the pooled volume to approximately 0.5 ml. The protein concentration 
was measured with BCA assay kit (Pierce, Thermal Scientific, UK).  
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2.2.4 Adenovirus preparation  
 
Fig.2.4. Schematic outline of the AdEasy system. The Pdx-1 gene is first cloned into a 
shuttle vector, pAdTrack-CMV. The resultant plasmid is linearized by digesting with 
restriction endonuclease PmeI, and subsequently transformed into E. coli BJ5183 cells 
containing an adenoviral backbone plasmid, pAdEasy-1. Recombinants are selected for 
kanamycin resistance, and recombination was confirmed by multiple restriction endonuclease 
analyses. Finally, the linearized recombinant plasmid is transfected into adenovirus packaging 
cell lines, HEK 293 cells. Recombinant adenoviruses typically are generated within 7–10 
days. The ‘‘left arm’’ and ‘‘right arm’’ represent the regions mediating homologous 
recombination between the shuttle vector and the adenoviral backbone vector.  The same 
strategy was applied to obtain mutant pAdEasy-CMV-PDX-1-c-myc plasmids. 
  
  75 
2.2.4.1 Construction of pAdEasy-CMV-PDX-1-c-myc via homologous 
recombination in bacteria 
A cDNA fragment encoding PDX-1 (wild-type or mutants) was excised from 
pcDNA3.1-PDX-1-c-myc using restriction enzymes HindIII and EcoRV as 
described in Table 2.1. The fragment was ligated into linearized vector pAdTrack-
CMV under cytomegalovirus immediate-early gene promoter control with the same 
restriction enzymes. Restriction digest was as described above. pAdTrack-CMV-
PDX-1 (wild-type or mutants)-c-myc (1 µg) were linearised with PmeI. The 
linearised plasmids were purified using Qiagen’s PCR purification kit and 
resuspended in 60 µl of dH2O. PmeI-digested shuttle plasmid (6 µl; 500 ng/µl) was 
transformed into 20 µl AdEasy-electrocompetent E.coli BJ5183 cells for 
homologous recombination with the pAdEasy-1 vector. Candidate clones were 
digested with PacI to verify proper recombination. With PacI digestion, two 
fragments (4.5 kb and 32 kb) were produced (Fig. 2.5C). 
Plasmids miniprep was performed and the sizes of supercoiled plasmids were 
checked by running one-fifth of a miniprep on a 0.8% (w/v) agarose gel. The aim 
was to obtain bands of DNA similar to the pAdEasy vector. A pair of bands of 25 
and ~40 kb were obtained. To further check the recombination, a restriction digest 
of the DNA from clones was performed with PacI. Candidate clones yielded a large 
fragment (near 30 kb), and a smaller fragment of 4.5 kb. Correct recombinant 
miniprep DNA 5 µl was re-transformed into Top 10 electrocompetent cells 
(Invitrogen). The plasmid was purified by Qiagen maxi-prep kit. 
The representative agarose gels showing the wild-type and T152 mutants viral 
constructs were shown in Fig. 2.5.  
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Fig.2.5. (A) Excision of PDX-1 cDNA and linearization of the viral vector. Restriction 
digest products by enzymes HindIII and EcoRV of wild-type and mutant forms of pcDNA3-
PDX-1-c-myc. (lane 1: wild-type; lane 2: T152A mutant; lane 3: T152E mutant; lane 4: 
T152D mutant) and the viral vector pAdTrack-CMV (lane 5) were run alongside 1kb DNA 
marker. The lower band in lane 1-4 is corresponding to the size of PDX-1 cDNA (~880bp), 
and the band shown in lane 5 corresponds to linearised pAdTrack-CMV (9.2kb). (B) 
Insertion of PDX-1 cDNA into viral vector pAdTrack-CMV. Restriction analysis of 
pAdTrack-PDX-1-c-myc ligation products following HindIII and EcoRV restriction digest. 
The digestion products were run alongside 1kb DNA marker. The lower bands in lane 2-5 
(lane 2: wild-type; lane 3: T152A mutant; lane 4: T152E mutant; lane 5: T152D mutant) 
corresponds to PDX-1 cDNA (~880bp) (Lane 1: pcDNA3-PDX-1-myc digestion); whilst the 
higher band in lane 2-5 corresponds to the viral vector (~9.2kb) which is the same as the 
linearised pAdTrack-CMV shown in lane 6. (C) Recombinant adenoviral vector 
containing wild-type and mutant PDX-1 gene. Restriction analysis of pAdEasy-CMV-
PDX-1-c-myc following PacI digestion. Wild-type and mutant PDX-1 recombinant digestion 
products (lane 1: wild-type; lane 2: T152A mutant; lane 3: T152E mutant; lane 4: T152D 
mutant) were run alongside the lambda DNA/HindIII marker (Sigma). The top band in lane 
1-4 corresponds to ~ 30kb and the lower band corresponds to ~4.3kb, which suggesting the 
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recombinant viral plasmids containing wild-type and mutant forms of Pdx-1 gene were 
successfully obtained. 
2.2.4.2 Viral production in HEK293 cells 
Recombinant adenoviral plasmid pAdEasy-CMV-PDX-1-c-myc (10 µg) was 
digested with PacI, purified with Qiagen’s PCR purification kit and resuspended in 
sterile H2O. 8 µg of digested pAdEasy-CMV-PDX-1-c-myc was transfected into a 
T-25 flask of HEK 293 cells by using standard Lipofectamine (Invitrogen) 
transfection according to the Manufacturer’s instructions. Transfection and viral 
production were monitored by Green Fluorescent Protein (GFP) expression by 
excitation with light at 488 nm microscope. Cells were extracted when 2-3 comets 
were formed (~7 days post-transfection), and the contents of the flask were 
transferred to a 70% confluent T-75 flask of HEK293 cells. Virus expression was 
evident at three days post infection.   
HEK293 cells were harvested at 7–10 days post-transfection, then subjected to three 
cycles of freeze-thawing in liquid nitrogen and a 37 °C water bath, respectively. 
The extract was subjected to centrifugation at 13,000 rpm for 10 min. and the viral 
supernatant was either stored at -80 °C or used to infect more HEK293 cells to 
create viral stocks. The recombinant virus particles were purified by 
ultracentrifugation in a caesium chloride gradient. The same strategies were applied 
to mutant pAdEasy-CMV-PDX-1-c-myc plasmids to make viruses expressing 
mutant PDX-1-c-myc.  
All the purified adenoviruses were then titrated by measuring green fluorescent 
protein (GFP) expression, as described below. 
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Fig.2.6. Adenovirus-mediated PDX-1-c-myc expression in mammalian 
cells  (A) GFP expression in HEK 293 cells 24 h after transfection with 
pAdEasy-CMV-PDX-1-c-myc, and five days after infection with adenovirus 
at 100 MOI. (B) MIN6 cells were infected by indicated adenoviruses at 100 
MOI for 24 h and 30 µg whole cells lysate was separated on SDS-PAGE 
and analyzed with anti-c-myc antibody to recognize the viral PDX-1 
expression. (C.) MIN6 cells were infected with wild-type PDX-1 at 
indicated MOI for 24 h and 30 µg whole cell lysate was separated on SDS-
PAGE and analyzed with anti-c-myc antibody to recognize the viral PDX-1 
expression. 
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2.2.4.3 Titration of Adenoviruses 
HEK293 cells were cultured in 24-well plates to 70% confluency. Then a serial 
dilution of the virus from the CsCl preparation was set up. Virus (2 µl) was added to 
1ml of culture medium. This dilution (1.1 µl) was taken and added to 1ml of 
medium. Then, 100 µl of this dilution was taken and added into 900 µl of HEK 
medium. The mixture was well mixed and was taken 100 µl and added into 900 µl 
of HEK medium. This dilution was repeated three more times to give six separate 
concentrations. The medium from all the wells of the 24-well plates was removed 
and the first pair was added in 0.5 ml each of the most concentrated virus solution 
(2 µl in 1 ml medium). The next pair was added in 450 µl of the next most 
concentrated dilution and so on for the other wells. The first pair of well thus 
received 1 ml each and the next get 1x10-3 µl, then 1x10-4 µl, 1x10-5 µl, 1x10-6 µl, 
and finally 1x10-7 µl. 
Cells were cultured overnight end then the next day GFP expression was monitored 
by fluorescence microscopy. Nearly all the cells from the first pair of wells were 
green. The next pair had quite a few (>50%) but there were successively fewer 
green cells with each dilution. The number of green cells was counted in the pair of 
wells that gives of the order of 10-100 green cells and was averaged. This is used to 
work out viral concentration (an average of 30 green cells in the 1X10-5 µl well is 
equivalent to 3 X 109 virus/ml). 
The volume of virus required to infect cells could then be calculated using the 
following formula: 
   Volume of Virus required (ml) =           Number of cells X MOI 
                                                              Viral concentration (pfu/ml) 
MOI: Multiplicity of Infection 
pfu : Plaque forming units 
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All the adenoviral plasmids used throughout this Thesis are detailed in Table 2.1 
and all viruses were prepared using the same methods.                    
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2.2.5 Protein Biochemistry 
 
2.2.5.1 SDS-PAGE 
Protein samples were denatured by the addition of Laemmli buffer 220 and boiling 
for 10 min. Protein were separated on SDS-PAGE gles comprising of a stacking gel 
(40% acrylamide 0.75 ml, 0.25 M Tris-HCl pH6.8 2.5 ml, 10% SDS 0.1 ml, dH2O 
6.55 ml, 10 ml TEMED and 10% APS 100 µl) and typically a 12% separating gel 
(40% acrylamide 3 ml, 1.5 M Tris-HCl pH8.8 2.5 ml, 10% SDS 0.1 ml, dH2O 4.4 
ml, 6.7 µl TEMED and 10% APS 33 µl). The protein was separated at 100 V. 
Proteins were then transferred onto PVDF membranes (GE Healthcare) using a 
BIO-RAD trans blot cell apparatus at 100 V for 1 h, or stained with Coomassie 
blue.   
2.2.5.2 Western immuno-blotting 
Proteins were analyzed immunologically after electrotransfer onto PVDF 
membranes which were blocked in 5% (M/V) nonfat dry milk in Tris-buffer saline 
with Tween 20 (TBST) for 1 h at 25 °C. Membranes were incubated with the 
indicated primary antibodies in TBST for 16 h at 4 °C followed by treatment with 
horseradish peroxidase-conjugated secondary antibodies. Blots were visualized with 
ECLTM western blotting system (GE Healthcare).   
2.2.5.3 Stripping for reprobing western blots 
Stripping buffer (20 ml SDS 10%, 12.5 ml Tris HCl pH 6.8 0.5 M, 67.5 ml ultra 
pure water, And 0.8 ml β-mercaptoethanol) was warmed to 50°C and added to a 
plastic bag together with the membrane. The bag was sealed and incubated at at 
50°C for up to 45 minutes with some agitation.  The solution was disposed under 
fumehood and the membrane was rinsed under running water tap for 1 h. The 
PVDF membrane was rehydrated in methanol for 1 min. and washed in TBST for 5 
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min. and restart the blocking stage.  
 
2.2.5.4 Densitometry  
Coomassie blue stained gels or Western immuno-blots were analyzed and the band 
densities were determined using Quantity One software (Bio-Rad). All calculated 
densities were corrected for background using a blank region close to each defined 
band.  
 
2.2.5.5 Electrophoretic Mobility Shift Assays  
Single-stranded oligonucleotide probes were 5’ end-labeled with [γ-32P] ATP using 
T4 polynucleotide kinase (Invitrogen). Labeled oligonucleotides were column-
purified (Pharmacia) and annealed to an excess of complementary strand. Nuclear 
extracts (2 µg protein) were incubated with 32P labeled probe for 30 min. at room 
temperature in electrophoretic mobility shift assay (EMSA) binding reaction buffer 
comprising 10 mM Hepes pH7.9, 60 mM KCl, 5 mM MgCl2, 5 mM DTT, 4 mM 
Spermidine, 1 mM EDTA, 1 µg of poly (dIdC)/poly (dI-dC) and 5% glycerol. 1 µl 
of PDX-1 antiserum (kindly provided by Dr. Chris Wright, Vanderbilt University) 
was added in supershift assays. Gel loading buffer was added and the mixtures were 
loaded on to a 20 X 20 cm non-denaturing 5% (w/v) polyacrylamide gel 
(acrylamide/bisacrylamide, 29:1), which was migrated in 0.5 X TBE (50 mM Tris, 
50 mM boric acid and 1 mM EDTA) at 120-150 V for 3 to 4 h. The gel was dried 
and subjected to autoradiography. The oligonucleotide fragments were derived from 
the A3/A4 98 element of the mouse insulin gene promoter which is important in 
insulin gene transcriptional regulation and also contains a PDX-1 binding motif 
(TAAT). The following oligonucleotide probes were used (top strands shown): 
mouse I insulin promoter (A3/A4 element) 98, 103, 5’ 
CTTATTAAGACTATAATAACCCTAAGACT A-3’ 221.    
  
  83 
2.2.5.6 Immunoprecipitation  
Cells were washed twice with ice-cold PBS. Lysis buffer (750 µl; 1% NP40; 50 
mM NaCl; 1% sodium deoxycholate; 0.1% sodium monododecyl sulfate (SDS); 50 
mM Tris-HCl pH7.5; 2 mM EDTA; 10 mM sodium phosphate; 50 mM NaF; 1 mM 
phenylmethylsulfonyl fluoride; 200 µM sodium orthovanadate; 1x protease 
inhibitor cocktail solution and phosphatase inhibitor cocktail 1 & 2, Sigma) was 
added and the cells were collected by scraping. The mixture was transferred into a 
1.5 ml centrifuge tube and was then placed on a rotating wheel at 4 °C for 30 min. 
to lyse the cells fully. The mixture was then centrifuged at 14,000 rpm for 5 min. to 
harvest the lysate (supernatant). Anti-c-myc antibody-conjugated beads (Santa-Cruz; 
40 µl) were added to the supernatant and lysis buffer was added to give a final 
volume of 1 ml in a 1.5 ml centrifuge tube, which was then rotated at 4 °C 
overnight. IP beads were then collected by centrifugation at 3,000 rpm at 4 °C for 
30 s, and washed 5 X with lysis buffer. The immunoprecipitated protein was either 
used for further in vitro phosphorylation or separated on SDS-PAGE.    
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2.2.6 Statistical analysis  
Data are given as means ± SEM for the number of experiments indicated in relative 
experiments. Comparisons were performed by two-tailed Student’s t-test by using 
Microsoft ExcelTM. Two-tailed t-tests were used to determine whether the 
differences in indicated parameters between the two compared conditions were 
statistically significant. Bonferroni adjustment technique was used for multiple 
comparisons, and a p-value of 0.05 was considered as statistically significant.                 
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3.  Chapter 3    
Phosphorylation of PDX-1 in vitro 
and in cloned β-cells 
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3.1 Introduction  
In an earlier study investigating the role of IUF-1 (PDX-1) in mediating glucose-
stimulated insulin gene expression, Macfarlane et al 63 reported that in isolated rat 
islets, low glucose (3 mM) incubation decreased the PDX-1 activity to 
‘undetectable levels’ in 6 h by measuring PDX-1 DNA-binding activity, whereas at 
high glucose (20 mM) PDX-1 activity remain stable for 24 h. These findings also 
suggested that the changes of PDX-1 activity were phosphorylation-dependent 63.  
Subsequent studies by several groups had examined the role of different kinases 
including the stress-activated protein kinase 2 (SAPK2) 135, PI3K 135, 137, glycogen 
synthase kinase 3 (GSK3) 142 and the homeodomain‐interacting  protein kinase 
(Hipk) 2 148 to investigate potential regulatory effect of these kinases involved in 
PDX-1 regulation. Although it is controversial whether SAPK2 is involved in the 
pathway regulating PDX-1 DNA-binding activity 135, 137, independent studies 
demonstrated that PI3K may play an important role in PDX-1 transactivational 
activity regulation 135, 137. In 2006, Boucher et al 142 demonstrated that a minor 
portion of PDX-1 is phosphorylated on serine 61 and/ or serine 66 in β-cells 
detected using a phospho-specific antibody technique. The phosphorylation is 
increased following proteasome inhibition, and it is also modulated by GSK3-
dependent mechanisms142. In a later study it is reported that the C-terminal PDX-1 
may also be regulated by phosphorylation as evidence showed that HIPK2 directly 
phosphorylates PDX-1 in vitro and increased the PDX-1 transcriptional activity 148.   
PAS (Per-Arnt-Sim) domains regulate many intracellular signalling pathways in 
response to both extrinsic and intrinsic stimuli 202. First described as a nutrient-
sensitive regulator in yeast 202, PAS domain regulated histidine kinase PASK (also 
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called PASKIN) was shown to be an important mediator of the effects of glucose on 
insulin and PDX-1 gene expression 209. Mice homozygous for the inactivation of 
PASK display normoglycemia on a normal chow diet, but become glucose 
intolerant on a high fat diet 210 and islets isolated from these animals display 
defective glucose-stimulated insulin secretion. 
 
In vitro phosphorylation studies performed in collaboration with Prof. Jared Rutter 
at University of Utah using recombinant PDX-1 and purified human PASK, showed 
that PDX-1 is efficiently phosphorylated in vitro at Thr-152 in the homeodomain by 
the nutrient-regulated kinase, PASK (Fig. 3.1). By applying phospho-site screening 
on the phosphorylated PDX-1 by PASK using mass spectrometry, a single site Thr-
152 was detected to be phosphorylated. Not only does this make future experiment 
simpler and more promising, it may also suggest a potential interaction between 
PASK and PDX-1. 
In this chapter, we sought to explore firstly whether Thr-152 is a specific 
phosphorylation site for PASK in vitro; additionally, we sought to study the 
phosphorylation of PDX-1 in living cells under physiological condition and 
moreover whether Thr-152, which was phosphorylated by PASK in vitro is a major 
phosphorylation site for PDX-1 in intact cells.  
By applying in vitro phosphorylation screening of wild-type and T152A mutant 
PDX-1 by a series of Ser/Thr kinases, Thr-152 appeared to be a specific in vitro 
target only for PASK. We also showed for the first time that wild-type PDX-1 is 
phosphorylated under physiological condition using 32Pi metabolic labeling in intact 
cells.  However, T152A mutant PDX-1 was not able to abolish the phosphorylation 
in 32Pi metabolic labeled living cells, indicating Thr-152 is probably not a major 
phosphorylation site for PDX-1 in living cells. Hence, whether Thr-152 is also 
phosphorylated in living cells by PASK need to be further studied using mass 
spectrometry.   
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3.2 Methods 
 
3.2.1 In vitro phosphorylation of recombinant PDX-1 by 
PASK   
HEK293 cells grown to 70% confluence in T-25 flasks were transfected overnight 
with 6 µg of plasmid encoding c-myc tagged-hPASK based in pcDNA3.1. DNA 
(6µg) in 225 µl ddH2O was mixed with 25 µl 2.5 M CaCl2. This mixture was then 
added drop by drop to 250 µl 2 X HBS in a sterile tube while vortexing. Empty 
expression plasmid (pcDNA3.1) was used to maintain a constant total amount of 
DNA among wells.   
Cells were washed twice with ice-cold PBS. Lysis buffer (750 µl; 1% NP40; 50 
mM NaCl; 1% sodium deoxycholate; 0.1% Sodium monododecyl sulfate (SDS); 50 
mM Tris-HCl pH7.5; 2 mM EDTA; 10 mM Sodium Phosphate; 50 mM NaF; 1 mM 
Phenylmethylsulfonyl fluoride; 200 µM Sodium orthovanadate; 1X protease 
inhibitor cocktail solution and phosphatase inhibitor cocktail 1 & 2; Sigma) was 
added and the cells were collected by scraping. The mixture was transferred into a 
1.5 ml centrifuge tube and was then placed on a rotating wheel at 4 °C for 30 min. 
to lyse the cells fully. The mixture was then centrifuged at 14,000 rpm for 5 min. to 
harvest the supernatant. C-myc antibody-conjugated beads (Santa-Cruz; 40 µl) were 
added to the surpernatant and lysis buffer was added to give a final volume of 1ml. 
The supernatant was rotated at 4 °C overnight and the beads were collected by 
centrifugation at 3,000 rpm at 4 °C for 30 s, and washed 5 times with lysis buffer.  
Immunoprecipitated PASK was washed twice in pre-kinase assay wash buffer (50 
mM Tris-HCl; 100 mM NaCl and 10 mM MgCl2, pH 7.4). The pellet was then 
resuspended in 60 µl kinase assay buffer (50 mM Tris-HCl pH 7.4; 10 mM MgCl2; 
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0.2 mM ATP and 1mM DTT). The reaction mixture was preincubated at 30 °C for 
1 h to autoactivate the kinase. [32P] ATP (0.1 mM) and recombinant wild-type or 
T152A mutant PDX-1 protein (2 µg) were added and mixed with the kinase and 
incubated at 30 °C for 1 h.   
3.2.2 In vitro phosphorylation of recombinant PDX-1 by 
various kinases   
Wild-type PDX-1 protein (1 µg) or the mutant PDX-1 protein (2 µg) were used in 
the assays. All kinases were active recombinant enzymes, either from commercial 
suppliers or from the University of Dundee. Each kinase was used at 50 ng per 
reaction, with the exception of the very active CaMKII (25 ng) and the less active 
Ark5 (100 ng) and SAPK2 (200 ng). The kinase buffer for PKCa was 10 mM 
HEPES pH 7.4, 10 mM 2-ME, 0.5 mM CaCl2, 0.25 mg/ml phosphatidyl serine, 0.05 
mg/ml diacylglycerol, 0.01% Triton X-100.  CamKI was used in 20 mM Tris pH 
7.5, 10 mM 2-ME, 1 mM CaCl2, and 40 µg/ml Calmodulin. CaMKII was activated 
by autophosphorylation in the presence of Ca2+/CaM and then used in 20 mM Tris 
pH 7.5, 10 mM 2-ME. All other kinases were used in 20 mM Tris pH 7.5, 10 mM 
2-ME.  
The kinase assays were carried out in duplicate at 30oC in the presence of 10 mM 
Mg-acetate and 0.1mM [γ32P]ATP. The [γ32P]ATP was freshly prepared for every 
set of experiments. The reactions were stopped by adding SDS-loading buffer and 
then analysed by SDS-PAGE, colloidal Coomassie staining and autoradiography. 
The reaction buffers for the kinetic study were supplemented with BSA in order to 
stabilize the kinases. The only exception was PKCα, because BSA inactivates 
PKCα. 1 µg of recombinant wildtype (WT) PDX-1 was mixed with 0, 3, 10, 30, 
100, 300, 1000 ng of SAPK2 (as indicated) and the kinase reactions were carried 
out at 30 °C. Time course was as indicated in the figures.  
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Recombinant wild-type (WT) PDX-1 (1µg) was mixed with 0, 3, 10, 30, 100, 300, 
1000 ng of JNK1 (as indicated) and the kinase reactions were carried out at 30 °C. 
Initial rates were taken at different time points (as shown).  
Recombinant wildtype (WT) PDX-1 (0 µg or 1 µg) was mixed with/ without 100 ng 
of JNK1 (as indicated) and the kinase reactions were carried out at 30 °C for 10 min 
or 60 min.  
Time course of reactions for phosphorylation of substrates by other kinases were 
measured as described in the Figure legends.  
I provided the recombinant wild-type (WT) and T152A PDX-1 and the in vitro 
phosphorylation kinase screening experiments and the following mass spectrometry 
phosphorylation site screening of JNK phosphorylated PDX-1 were done by 
Kinasource Ltd. Dundee, UK.  
 
3.2.3 Mass spectrometry to identify sites on PDX-1 
phosphorylated by JNK in vitro.  
PDX-1 (5 µg) was incubated for 45 min. with 0.2 µg JNK as described above. The 
reaction was stopped with SDS and proteins were separated by SDS-PAGE. The 
PDX-1 band (~46 kD) was excised, destained, digested with trypsin. 
Phosphorylated peptides were analyzed by electrospray ionization mass 
spectrometry in both the positive and negative ion mode. Fragmentation of the 
phosphorylated species in the negative ion mode provides a “unique” daughter ion 
(m/z 79) which is characteristic of a phosphate group. A Pre79 precursor ion scan 
identifies those parent masses that yield the daughter ion with a m/z of 79 Da (PO3-
). Given the known protein sequence, the peptide molecular weights obtained are 
sufficient to identify the phosphopeptides.  
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The PDX-1 sequence was inspected and some tryptic peptides, which may contain 
JNK sites, were predicted to be too large to be compatible with Pre79 parent ion 
scanning. In order to fragment PDX-1 further and generate peptides of compatible 
size, subsequent digestion was undertaken with chymotrypsin and the procedure 
was repeated. 
I provided the recombinant wild-type (WT) and T152A PDX-1 and the in vitro 
phosphorylation kinase screening experiments and the mass spectrometry 
phosphorylation site screening of JNK phosphorylated PDX-1 were done by 
Kinasource Ltd. Dundee, UK.  
 
3.2.4 Metabolic labeling with 32P   
INS-1(832/13) cells were grown to 70% confluence in T-75 flasks and infected for 
24 h with viruses expressing wild-type or T152A mutant PDX-1 at an MOI of 100. 
After recovery for 24 h, cells were washed twice with phosphate-free DMEM 
medium (GIBCO) and then pre-incubated in the same medium for 1 h at 37 °C.   
Cells were metabolically labeled for 4 h in phosphate-free medium containing 0.5 
mCi/ml [32P]-orthophosphate (Amersham, GE Healthcare) at 37 °C. Labeled cells 
were washed twice with ice-cold PBS and lyzed for further immunoprecipitation. 
Lysis buffer and immunoprecipitation were as described above (Chapter 2, P81).  
 
The IP beads were then collected by centrifugation at 3000 rpm at 4 °C for 30 s, and 
then washed 5 times with lysis buffer. The IP product was eluted with 30 µl sample 
buffer and boiled for 5 min. IP product was then migrated on a SDS-PAGE gel at 
100V for 5 h and the gel was then silver stained and dried using a Bio-Rad Model 
483 Slab Dryer at 80 °C for 1 h. Radioautography was then performed with Kodak 
BioMax MS Radioautography Film.  
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3.3 Results 
 
3.3.1 In vitro phosphorylation of PDX-1 by PASK.  
In preliminary studies, the in vitro phosphorylation of PDX-1 by PASK was 
examined in collaboration with Prof. Jared Rutter in University of Utah. PASK 
efficiently phosphorylated recombinant PDX-1 (Fig. 3.1) and a major 
phosphorylation site, Thr-152, was identified using mass spectrometry (Fig.3.5).  
 
Fig. 3.1 PASK efficiently phosphorylates PDX-1 in vitro.  
Purified human PASK, purified mouse PDX-1, or a combination were 
incubated with [γ-32P] ATP for 1 hour at 25°C.  Proteins were then 
separated by SDS-PAGE and the gel visualized by Coomassie staining 
(left panel) or by autoradiography (right panel). Note: hPASK 
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autophosphorylation; PDX-1* is a C-terminal fragment of PDX-1. This 
experiment was done by Dr. Huai-xiang Hao, University of Utah.  
 
3.3.2 Kinase screen for PDX-1 phosphorylation in vitro  
We next determined whether PDX-1 may be a substrate for phosphorylation on 
Thr-152, or other sites, by other kinases. Thus, AMPK, AKT1, AKT2, AKT3, 
Ark5, Aur A, CaMKI, CaMKII, Erk2, SAPK2, JNK1, MSK1, PKA, PKCα, 
ROCK1, and Rsk1 were tested in in vitro phosphorylation assays in order to 
determine the potential involvement of other potential signaling pathways which 
may regulate PDX-1 function. As shown in Fig. 3.2A and 3.2B, JNK1, PKCα and 
Rsk1 phosphorylated PDX-1 efficiently and JNK1 and Rsk1 phosphorylated PDX-1 
at more than one site. Moreover, PKCα also phosphorylated PDX-1 at one site. 
Aurora A and SAPK2 phosphorylated PDX-1, but only poorly. Additionally, there 
were very weak signals with AMPK, Ark5 and Erk2, which were not followed up.  
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Fig. 3. 2. Kinase screen for PDX-1 phosphorylation in vitro 
AMPK, AKT1, AKT2, AKT3, Ark5, Aur A, CaMKI, CaMKII, Erk2, 
SAPK2, JNK1, MSK1, PKA, PKCα, ROCK1, and Rsk1 were tested in in 
vitro phosphorylation assay in order to identify other potential pathways 
involved in PDX-1 regulation. Recombinant wildtype (WT) PDX-1 were 
provided by Rong AN and the in vitro phosphorylation kinase screening 
experiments were done by Kinasource Ltd. Dundee, UK. 
However despite of all the phosphorylation events detected for wild-type PDX-1 
above, PDX-1 was not phosphorylated on Thr-152 in vitro by these kinases 
including Aurora, Rsk1, PKCα, c-Jun kinase (JNK). Nevertheless, these kinases 
phosphorylated PDX-1 in vitro at other, presently undefined, sites.  In the cases of 
several of these kinases, including Rsk 1 and PKCα but not Aur A, a clear bandshift 
suggested multiple phosphorylation events (Fig. 3.3A-3.3D). 
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The phosphorylation with JNK1 was repeated by setting up the reactions 
with/without wild-type PDX-1 protein (Fig. 3.3E, 3.3F) and autoradiography 
demonstrated the existence of a labeled band in the reactions in the presence of 
PDX-1, while the signal increased as the incubation time was increased. These 
experiments confirmed that the phosphorylated protein was indeed PDX-1, and not 
autophosphorylated JNK1.  
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Fig. 3.3 In vitro phosphorylation of PDX-1 by Aurora A, PKCα , Rsk1, SAPK2 
and JNK. Wild-type (WT) and the de-phosphorylation form mutant PDX-1 in 
vitro phosphorylation by (A) Auro A, (B) PKCα, (C) Rsk1, (D) SAPK2 and (E) 
JNK. (F) 0 µg or 1 µg of recombinant wild-type (WT) PDX-1 was mixed with/ 
without 100 ng of JNK1. Reaction time course was indicated in figures. 
Recombinant wildtype (WT) and T152A PDX-1 were provided by Rong AN and 
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the in vitro phosphorylation kinase screening experiments were done by 
Kinasource Ltd. Dundee, UK. 
3.3.3 Mass spectrometry phosphorylation site screening on 
recombinant PDX-1 phosphorylated by JNK in vitro 
 
It was reported by Kawamori et al 78 that PDX-1 translocates from the nuclei to the 
cytoplasm of pancreatic β-cells in response to oxidative stress in hamster β-cell-
derived HIT-T15 cells and this oxidative stress-stimulated translocation is through 
the activation of the JNK pathway. However, the precise phosphorylation site(s) 
involved in the phosphorylation by JNK still remain unknown.  In this chapter we 
showed that JNK phosphorylates PDX-1 in vitro, and we then applied phospho-site 
screening using mass spectrometry to identify the PDX-1 in vitro phosphorylation 
sites which could provide potential target(s) for further study in living cells. 
Two major JNK1 sites on PDX-1 were mapped (Fig. 3.4). Ser66 was indicated to be 
phosphorylated from the Pre79 ion scan results of two peptides. One peak with m/z 
value of 602.3 represents L.EQGSPPDISPYEVPPL.A + Phospho (ST) and the 
other m/z 956.5 peak, which shows m/z 958.0 when searched using Mascot (the 
software search engine that uses mass spectrometry data to identify proteins from 
primary sequence databases; http://www.matrixscience.com/) represents 
F.TSSLGSLEQGSPPDISPY.E + Phospho (ST). Pre79 ion scan m/z 1286.7 peak 
(1287.67 in Mascot) represents R.SSGTPSGGGGGEEPEQDCAVTSGEEL.L + 
Phospho (ST) indicated that Thr-214 was phosphorylated.  
Although the Pre79 ion scan results at 857.5 (858.7 in Mascot) represents 
R.SSGTPSGGGGGEEPEQDCAVTSGEEL.L + Phospho (ST) demonstrated 
phosphorylation on Ser-212, it is much more likely that Thr-214 is the 
phosphorylated site in this peptide as the tandem mass spectrometry (MS/MS) data 
could not separate the two. The Mascot also detected the Ser-269 site (m/z 868.1 
and 651.3), but the peaks were almost invisible, indicating a very low level of 
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phosphorylation. Some tyrosine phosphorylation was also picked up by Mascot, but 
there were no corresponding peaks in the Pre79 ion scan spectrum. 
Another major peak with m/z 802.4 represents -.MNSEEQYYAATQL.Y + Acetyl 
(N-term); Oxidation (M). The other major Pre79 ion scan peaks with m/z of 630.3, 
635.5, 644.4, 762.4, 773.4 (Na-adduct of 762.4), 802.4 and 1028.6 and the adducts 
were not identified (Fig.3.4).  
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Figure 3.4. Mass spectrometry analysis of phosphorylation sites on 
recombinant PDX-1 generated by phosphorylation by JNK in vitro.  
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Pre79 ion spectrum of PDX-1 following phosphorylation by JNK1, and 
digestion with trypsin & chymotrypsin. PDX-1 (5 µg) was incubated for 45 
min with 0.2 µg JNK. The reaction was stopped with SDS and separated by 
SDS-PAGE. The PDX-1 band was excised, destained, and digested with 
trypsin and chymotrypsin. Recombinant wildtype (WT) PDX-1 was 
provided by Rong AN and the in vitro phosphorylation kinase screening 
experiments and the mass spectrometry phosphorylation site screening of 
JNK phosphorylated PDX-1 were done by Kinasource Ltd. Dundee, UK. 
 
3.3.4 In vitro phosphorylation of PDX-1 by PASK and 
generation of a phospho-Thr-152-specific antibody.  
Human PASK was immuno-purified from HEK293 cells transfected with cDNA 
expressing human PASK. Recombinant wild-type or T152A PDX-1 protein was 
generated and purified as described in Chapter 2. PASK efficiently phosphorylated 
recombinant PDX-1 at one major phosphorylation site, Thr-152. Mutation of Thr-
152 to Ala caused > 90 % suppression of 32Pi incorporation from [γ32-P] ATP (Fig. 
3.5). This experiment was conducted to verify the newly generated anti-phospho-
T152 PDX-1 antibody. Parallel western blotting using phospho-specific antibody 
against T152 phosphorylation was carried out and the result clearly showed that 
PASK phosphorylated PDX-1 on Thr-152 in vitro and the anti-phospho-T152 PDX-
1 antibody recognized the site with high specificity (Fig. 3.5).   
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Fig. 3.5. PDX-1 is efficiently phosphorylated by PASK in vitro. Immunoprecipitated 
human PASK (both wild-type (WT) and kinase inactive forms (KD)) overexpressed in one 
T-25 flask HEK 293 cells, and 2 µg of purified c-myc tagged mouse PDX-1 (both wild-type 
and T152A mutant forms), were incubated with [γ-32P] ATP or non-radioactive ATP for 1 h 
at 30°C. Proteins were then migrated on SDS-PAGE gels and visualized by 
autoradiography. Western immuno-blot analyses were performed using the anti-phospho-
T152-PDX-1 antibody on the parallel non-radioactive samples. The 175 kD band represents 
the autophosphorylated PASK. Wild-type (WT) and kinase inactive forms (KD) PASK 
were provided by Prof. Jared Rutter, University of Utah, USA (Chapter 2, Section 2.1.2).  
3.3.5 Phosphorylation of PDX-1 at Thr-152 in intact INS-
1(832/13) β-cells.   
To determine whether Thr-152 represented a major phosphorylation site in living 
pancreatic β-cells, we next labeled INS-1(832/13) cells over-expressing wild-type 
or (de)phospho mimetic mutants mediated by adenoviral vectors (Chapter 2) with 
radio-labeled inorganic phosphate (32Pi; Fig. 3.6). Incorporation of 32P was clearly 
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evident in both the wild-type (Fig. 3.6A) and the Thr-152 Ala-mutated protein (Fig. 
3.6B), while in the parallel experiment without 32Pi labeling the protein level of 
PDX-1 or GFP empty vector control was verified by western blotting. These data 
argue that the Thr-152 was unlikely to represent a major site of phosphorylation in 
intact cells, at least at 11.2 mM glucose.  
 
Fig. 3.6. Phosphorylation of PDX-1 in intact INS-1(832/13) cells.  
 INS-1(832/13) cells infected with wild-type (A) or T152A mutant (B) PDX-1-
expressing viruses were then metabolically labeled and lysed. Immunoprecipitated 
samples were analysed by SDS-PAGE gel and radioautography was then 
performed Parallel experiment without radiolabeling was also applied. PDX-1 or 
GFP expressing levels were examined using an anti-c-myc antibody (Roche) or 
anti-GFP antibody (Sigma) respectively. WCL: whole cell lysate. 
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3.4 Discussion  
We show here that recombinant PDX-1 is efficiently phosphorylated in vitro at Thr-
152 in the homeodomain by the nutrient-regulated kinase, PASK. Given the 
relatively low promiscuity of PASK towards a variety of substrates- PASK did not 
phosphorylate several other substrates tested, including the β-cell enriched 
transcription factors neuroD and MafA (personal communication, Prof. Jared 
Rutter, University of Utah), we speculated that this event may be of physiological 
significance in transducing intracellular signals generated by glucose to the β-cell 
nucleus. 
 
Moreover, the site appeared to be specific for PASK as the T152A mutant PDX-1 
recombinant protein showed no difference with wild-type PDX-1 in the in vitro 
phosphorylation by a series of kinases. This finding prompted us to investigate the 
phoshorylation of PDX-1 in living cells and, moreover, the role of Thr-152 
phosphorylation on PDX-1 transactivational activity in living cells. 
 
In order to study the physiological roles of Thr-152 phosphorylation in cells, 
adenoviruses expressing wild-type or Thr-152 (de) phospho- and phospho-mimetic 
forms of mutant were generated (as described in chapter 2) to ove-rexpress wild-
type or mutant PDX-1 in living cells. Our novel finding obtained by metabolic 
labeling experiments with immuno-purified wild-type PDX-1, was of a direct 
phosphorylation signal, indicating that PDX-1 is phosphorylated under 
physiological conditions in living β-cells. This result suggests that reversible 
phosphorylation may regulate PDX-1 function as suggested in previous reports 63, 
135, 137, 142, 148, 154. Our hypothesis, based on the unique Thr-152 phosphorylation site 
of PDX-1 specifically by PASK, was that the dephosho-form mutant on the site 
might very likely affect the phosphorylation status of PDX-1 in living cells if this 
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site represents the only, or one of a very few, phosphroylation sites. However, 
compared with the substantially decreased phospho-signal in recombinant T152A 
PDX-1 protein phosphorylated in vitro, the phosphorylation status of over-
expressed T152A PDX-1 in β-cells (Fig. 3.6A) did not display a dramatic 
difference verses wild-type PDX-1 (Fig. 3.6B).  
 
It has previously been reported that PDX-1 is phosphorylated at its N-terminus at 
S61 and S66 via a GSK-3-dependent pathway 142. This finding suggests the 
possibility that additional kinases may phosphorylate PDX-1 at other sites. Here, we 
performed a series of in vitro phosphorylation reactions using recombinant PDX-1 
and purified kinases in an effort to identify such kinases. Aurora, Rsk1, PKCα, JNK 
were all found to phosphorylate PDX-1 in vitro. Interestingly, it has been reported 
that induction of oxidative stress causes PDX-1 nuclear-cytoplasmic translocation 
via activation of JNK 78, although the phosphorylation site(s) have not been 
identified. Mass spectrometry was undertaken on recombinant PDX-1 
phosphorylated by JNK in vitro, aiming to map the potential phosphorylation site(s) 
(Fig. 3.4). Although Thr-152 did not appear to be phosphorylated, the sequencing 
did pick up a few other novel phosphorylation sites (i.e. Thr-214 and, interestingly, 
Ser-66, as previously reported by Boucher et al 142, though no evidence of 
phosphorylation at Ser-61 142 by this kinase was obtained), which again, indicated 
that the phosphorylation by PASK or on Thr-152 may not be a major regulation for 
PDX-1 function in β-cells. Hence, in order to investigate the potential physiological 
role(s) for this phosphorylation event, more direct functional approaches are likely 
to be needed. 
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4.  Chapter 4 
 
Phosphorylation of pancreatic 
duodenum homeobox-1 (PDX-1) at 
Threonine-152 is unlikely to mediate 
nuclear uptake and DNA binding in 
living β-cells. 
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4.1 Introduction 
 
In mature β-cells, PDX-1 is involved in the regulation of several key β-cell-specific 
genes which are critical for glucose-sensing and insulin synthesis (Chapter 1). Thus, 
PDX-1 was reported to bind to rat insulin I promoter A3/4 region and, by 
interacting with bHLH protein E47/Pan 1, binds to the E2 site to activate insulin 
gene transcription. In addition, PDX-1 has also been implicated in the regulation of 
the expression of the somatostatin, islet amyloid polypeptide (IAPP)90, 91, 
glucokinase (GK) 88and GLUT-2 87 genes. In mature β-cells, elevated glucose 
concentrations lead to the cytoplasmic nuclear-shuttling of PDX-1 which is 
accompanied by increased insulin promoter activity 137, 138, 216, 222, 223. This process 
may involve interaction of the homeodomain with the nuclear import protein, β-
importin 224. It has also been reported that changes in PDX-1 homeodomain DNA-
binding activity may be involved in regulation of insulin promoter activity during 
nutrient-dependent regulation 155, 222, 225. Moreover, the homeodomain of PDX-1 
plays a pivotal role in the recruitment of other transcription factors such as 
BETA2/Neuro D1, the E2A family proteins and coactivators including p300 and 
Bridge-1103, 104, 226, 227.   
 
Compared with the well-studied role for PDX-1 in pancreas development and β-cell 
function, less is known about its regulation, particularly at the post-translational 
level 142. For many other transcription factors, including the steroid receptor 
superfamily 228 and cytokine-activated ‘STAT’ (signal transducer and activator of 
transcription) 229, a shift from the cytosol to the nucleoplasm is a major means of 
activation. Whether post-translational modifications of PDX-1, including 
phosphorylation, are involved in the nuclear uptake and activation of PDX-1 
activity remains unclear. 
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In Chapter 3 we demonstrated that PDX-1 is phosphorylated under physiological 
condition in INS-1(832/13) cells. Moreover, we also have demonstrated that 
recombinant PDX-1 could be efficiently phosphorylated at a single residue, Thr-
152, by purified PASK. Given the relatively low promiscuity of PASK towards a 
variety of substrates, the question we ask here is whether this phosphorylation event 
regulates the nuclear uptake of PDX-1 and may therefore contribute to changes in 
the transactivational capacity of PDX-1 in native β-cells exposed to high 
extracellular glucose concentrations 138.  
 
Here, we have generated phospho- and dephospho- mimetic PDX-1 mutants at Thr-
152 to explore the likely effects of phosphorylation at this site on PDX-1 function, 
and examined the possible role(s) played by PASK in two β-cell systems, INS--
1(832/13) cells and INSrαβ cells 216. The latter cells are INS-1-derived stable cell 
lines expressing PDX-1 under the control of the reverse tetracycline-dependent 
transactivator (rtTA). In INSrαβ cells (though not in other α-cells and 
enteroendocrine cell lines) 230, PDX-1 potentially inhibites preproglucagon gene 
expression, allowing a switch from α-to β cell lineage.  
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4.2 Methods 
 
4.2.1 Dispersed human islets preparation.   
Human islets (produced by Prof. P. Johnsson, Department of Surgery, University of 
Oxford) were cultured in RPMI-1640 medium containing 11.2 mM glucose, 10% 
FCS, streptomycin and penicillin.  
 
Human islets were washed twice with PBS and treated trypsin for 10 min at 37°C 
with shaking. The islets were sedimented by centrifugation at 1,000 rpm and 
homogenized in minimal volume of trypsin by pipeting. 15 ml islet medium was 
added to the homogenized cells to wash out the trypsin. Cells were then collected 
by centrifugation, resuspended and distributed onto coverslips treated with poly-
lysine and covered with medium. 
 
4.2.2 Transfection and Immunoprecipitation   
MIN6 cells grown to 70% confluence in 6-well plate were transfected with c-myc-
tagged pcDNA3.1-PDX-1 (wild-type or mutants) following standard lipofectamine 
transfection method. The transfected cells were prepared for immunocytochemistry 
and confocal imaging as described below. This was done by Dr. Gabriela da Silva 
Xavier. 
HEK293 cells grown to 70% confluence in T-25 flasks were transfected by c-myc-
tagged pcDNA3.1-hPASK plasmid (6 µg) for 16 h using Ca2+-phosphate 
transfection. Immunoprecipitation follows the method described in Chapter 2. 
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4.2.3 Immunocytochemistry and Confocal Imaging  
cDNA encoding c-myc tagged wild-type or T152 mutant forms of PDX-1 in 
plasmid pcDNA3.1 was transfected in MIN6 β-cells. Cells were cultured in medium 
containing 25 mM glucose for 24 h prior to treatment for 16 h in medium 
containing 3 mM glucose, and then medium containing 3 or 25 mM glucose for a 
further 6 h. Immunocytochemistry was performed as previously described in 
chapter 2.  
 
INSrαβ cells were infected with viruses encoding wild type or mutant forms of 
PDX-1, or virus overexpressing human PASK at an MOI of 100. Cells were 
cultured in medium containing 11.2 mM glucose for 24 h prior to treatment for 16 h 
in medium containing 3 mM glucose, and then medium containing 3 or 20 mM 
glucose for a further 6 h. Dispersed human islets on coverslips were cultured in 
medium containing 11.2 mM glucose for 24 h prior to treatment for 16 h in medium 
containing 3 mM glucose, and then medium containing 3 or 17 mM glucose for a 
further 6 h.  Immunocytochemistry was performed as previously described in 
chapter 2.  
 
Monoclonal primary antibody for PDX-1 against c-myc (Roche) was used at 
1:1000, fluorophore-conjugated Alexa 568 goat-anti-mouse antibody was used at 
1:1000. Monoclonal primary antibody against human PASK (provided by Prof. 
Jared Rutter, Univeriy of Utah) was used at 1:100, fluorophore-conjugated Alexa 
568 anti-mouse antibody was used at 1:1000.  
 
For double-primary antibody staining in dispersed human islets, primary antibody 
against PASK was used at 1:100 and mixed with either anti-insulin generated from 
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guinea pig (Invitrogen; 1:1000) or anti-PDX-1 generated from guinea pig (kindly 
provided by Prof. Chris Wright, Vanderbilt; 1:1000). Fluorophore-conjugated Alexa 
488 anti-mouse antibody was used at 1:1000, Alexa 568 anti-guinea pig antibody 
was used at 1:1000.  
Cells were stained with 4', 6-diamidino-2-phenylindole (DAPI) to allow 
visualization of nuclei 138. Confocal Images were captured using a Leica SP2 
upright laser scanning confocal microscope (X63/1.32 oil-immersion lens) equipped 
with a krypton/argon laser (488 and 568 nm excitation lines) and a UV light. 
Images were analyzed off-line using VolocityTM4.0 software. 
Quantification of PDX-1 localization in MIN6 cells was performed by Dr. Gabriela 
da Silva Xavier using Image J software.  Quantification of PDX-1 localization in 
INSrαβ cells was analyzed using VolocityTM offline software. >= 30 cells per 
coverslip were randomly selected, and PDX-1 nuclear to cytosol distribution ratio 
was analyzed (cytosol distribution = [whole cell distribution]- [nuclear 
distribution]). Experiments were carried out three times in triplicates. 
Representative pictures were shown.  
 
4.2.4 Preparation of recombinant adenoviruses and viral 
infection   
Recombinant adenoviruses expressing the wild-type (WT) and mutant forms of 
PDX-1 (T152A, T152E, T152D) were prepared using the AdEasy system with the 
WT and mutant forms of PDX-1 plasmids. The generation of adenoviruses was as 
described in 231 and in Chapter 2. INSrαβ cells were infected with various 
adenoviruses at 100 multiplicity of infection (MOI) for 5 h and maintained at 11.2 
mM glucose for 24 h before subsequent experiments. The efficiency of adenovirus-
mediated gene transfer was typically ~85%.  
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4.2.5 Molecular modeling  
The crystal structure of the PDX-1 dimer bound to two double-stranded DNA 
duplexes (2H1K) was prepared for calculation in the following way: missing side-
chains were remodelled as required; hydrogen atoms were added consistent with pH 
7; the complex was soaked in a 10 Å layer of water which required 3829 water 
molecules. The complex was relaxed by 2000 cycles of conjugate gradient 
minimization. A phosphate group was built onto each Thr152 (residues A6 and B6 
in 2H1K) and the phospho-PDX-1 complex relaxed with a further 2000 steps of 
conjugate gradient minimization. Graphics manipulations and energy minimizations 
were performed with InsightII (2005) and Discover (2.98) from Accelrys. The 
molecular modeling experiment was done by Dr. Richard Session, University of 
Bristol.  
 
4.2.6 Sequencing and Mass Spectrometric Analysis of 
Phosphorylation sites mapping.   
T-75 flasks (30) of INS-1(832/13) cells were infected at an MOI of 50 with 
adenoviruses expressing both wild-type PDX-1 and/or PASK for 48 h. Cells were 
then collected and lyzed for immunoprecipitation as described above. The IP 
product was migrated on 10% (w/v) SDS-PAGE gels and stained with colloidal 
commassie blue (SimplyBlue SafeStain, Invitrogen).  
In each case, an obtained 1D band with good intensity, by colloidal commassie 
staining, and migrating at 46 kD, was processed by in-gel digestion with Lys-C. 
The digested sample was then extracted and were taken through three stages of 
analysis using a 4000 QTRAP (Applied Biosystems) mass spectrometer. The stages 
are as follows: Identification of protein(s) by nLC-MS-MS; parents of -79 (PO3-) 
analyses to detect phosphorylated peptides; data interpretation including de novo 
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assignment of phosphorylation sites) and final reporting. Thr-152 phosphorylation 
was further detected using OrbiTrap by targeting site-of-interest-containing 
peptides 232.  
 
The mass spectrometry experiments were done by Dr. Douglas Lamont in 
Fingerprint Ltd. University of Dundee.  
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4.3 RESULTS 
 
4.3.1 DNA-binding activity of PDX-1 phospho- and 
dephospho-mimetic mutants.   
To explore the possible impact of Thr-152 phosphorylation on PDX-1 DNA binding, 
electrophoretic mobility shift assays were performed. These indicated that over-
expressed wild-type or Thr-152 PDX-1 efficiently bound the oligonucleotide 
derived from the mouse preproinsulin promoter A3 element in a complex which 
was supershifted by anti- (myc or PDX-1) antibody, whereas PDX-1T152D or PDX-
1T152E largely failed to demonstrate the formation of a complex which could be 
super-shifted (Fig. 4.1 A1).  
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Fig. 4.1. Dephospho- and phospho-mimetic mutants at Thr152 affect PDX-1 
homeodomain DNA-binding capacity.  
A1. Nuclear extracts from HEK293 cells transduced with adenoviruses to over-
express wild-type or mutant forms of PDX-1 were incubated with a 32P-labeled 
oligonucleotide corresponding to the mouse I insulin promoter (A3/A4 element), with 
or without 1 ml rabbit anti-PDX-1 serum for supershift assay. A2. 30 µg of nuclear 
lysates from HEK293 cells infected by indicated viruses were migrated on SDS-
PAGE. The expression level of overexpressed PDX-1 was shown by immuno-blotting 
using anti-c-myc antibody. B.  Structural mimicking of PDX-1 on DNA binding. The 
circled upper structure shows PDX-1 protein and the lower structure represents the 
bound DNA. Hydrogen bonds between Thr-152 and the DNA phosphate group are 
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shown as black dashed lines. C. The structure of PDX-1 DNA binding with the 
amplified Thr-152 residue circled in the middle. Hydrogen bonds between Thr-152 
and the DNA phosphate group are shown as black dashed lines with the length of 
bonds.  D. The circled free Thr-152, when minimized shows how the Thr-152-OH 
hydrogen bonds tightly to the lower DNA phosphate in purple with a bond length of 
2.6 Å. E. The structure of Thr152-phosphate and DNA phosphate binding complex. 
When the Thr-152-phosphate is energy minimized, the structure of Thr-152 and DNA 
phosphate turn to repulsion with an increased bond length of 7.2 Å, given the 
constraints of the rest of the system (Molecular modeling was done by Dr. Richard 
Session, University of Bristol).  
To explore the underlying molecular changes responsible for the loss of DNA 
binding in the phospho-T152-mimetic mutants, we also deployed molecular 
modeling of the Thr152-preproinsulin promoter A3 element DNA bound to the 
PDX-1 homeodomain protein. Incorporation of a phosphate group at Thr-152 was 
predicted by this approach to interfere with an interaction with the DNA phosphate 
backbone, likely to be important for the tight binding shown in Fig. 4.1B. 
Correspondingly, when the T152-phosphate was energy minimized (Fig. 4.1C), the 
structure of the T152-phosphate and DNA phosphate-binding complex changed 
from tight binding (Fig. 4.1D) to repulsion.  
 
4.3.2 Subcellular localization of phospho- and dephospho-
mimetic PDX-1 mutants.   
cDNA encoding c-myc tagged wild-type or T152 mutant forms of PDX-1 in 
plasmid pcDNA3.1 was transfected to MIN6 β-cells. At low glucose concentrations 
(3 mM), both wild-type and T152A mutant PDX-1 remained very close to nuclear 
periphery and in the cytoplasm. At elevated glucose concentrations (30 mM) a 
translocation into the nucleoplasm was observed (Fig. 4.2). In contrast, T152D- and 
T152E-PDX-1 displayed a predominant cytosolic distribution at both low and high 
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glucose concentrations (Fig. 4.2) 
 
 
Fig. 4.2.  Subcellular distribution of wild-type or mutant forms of PDX-1 
examined by immunocytochemistry in MIN6 cells.  
Wild-type or mutant forms of PDX-1 were induced in MIN6 cells by transfection 
with lipofectamine. Cells were cultured at 3mM glucose for 16 h and then treated 
with 3mM or 30mM glucose for 6 h. c-Myc-tagged PDX-1 was detected using anti-
c-myc antibody (Roche) and Alexa 568 (Molecular Probe), and nuclear staining was 
achieved using DAPI (Immunocytochemistry were done by Dr. Gabriela da Silva 
Xavier; two-tailed students' t-test with bon-ferroni correction was used in statistical 
analysis).  
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We next expressed wild-type or mutant forms of PDX-1 in the INSrαβ cell line, a 
convenient model of a neuroendocrine precursor with properties of both α- and β 
cells 216. As previously described in MIN6 cells, elevated glucose concentrations led 
to a partial redistribution of c-myc-tagged PDX-1 from the cytosol to the nuclear 
compartment, an effect preserved in the T152A mutant (Fig. 4.3). By contrast, the 
acidic mutants of PDX-1 displayed lowered nuclear immunoreactivity at 3 mM 
glucose and a further decrease in the ratio of nuclear/cytosolic immuno-reactivity 
when the glucose concentration was raised to 20 mM.  
 
 
Fig. 4.3. Dephospho- and phospho-mimetic mutation of Thr-152 affects 
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PDX-1 nuclear-cytoplasmic distribution.  
A. Immunocytochemical analysis of the subcellular distribution of PDX-1-c-
myc. Wild-type, alanine, aspartic acid and glutamic acid mutant forms of 
PDX-1 were introduced into INSrαβ cells by infection with the 
corresponding adenoviruses. B. The ratio of nuclear PDX-1 protein to 
cytosolic PDX-1 distributed in the cells was taken under different condition 
using Volocity TM 4.0 quantification software. (Mean ± SEM, n =3; two-
tailed student’s t-test, Microsoft ExcelTM.)  
 
 
4.3.3 Transcriptional activity of wild-type PDX-1 and of 
phospho- and dephospho-mimetic mutants.   
To determine whether phosphorylation of PDX-1 at Thr-152 may affect the 
transcriptional activity of PDX-1 in intact cells, we over-expressed wild-type or 
mutant PDX-1 in INSrαβ cells. Previous study demonstrated no obvious effect of 
over-expressed PDX-1 on insulin gene expression 216, whereas preproglucagon gene 
expression level was suppressed indicating an α- to β- cell linage switch 216. We 
monitored the expression of preproglucagon (PPG) mRNA in INSrαβ 216. In the 
presence of doxycyclin and adenoviruses overexpressing wild-type or mutant PDX-
1, these cells displayed an induction of mouse PDX-1 mRNA (Fig. 4.4A), whereas 
PDX-1 level in cells infected by adenoviruses overexpressing PASK or GFP 
remains the same with cells without any induction (Fig. 4.4A). Meanwhile, cells 
with overexpressed wild-type or T152A PDX-1 as well as doxycyclin-induced 
PDX-1 displayed decreased level of endogenous preproglucagon mRNA 216 (Fig. 
4.4B, 4.4C); whereas cells with overexpressed PASK or GFP displayed no 
difference in preproglucagon mRNA expression compared with the control cells 
without any induction (Fig. 4.4B, 4.4C).  Adenoviral transduction of the cells with 
wild-type or T152A mutant PDX-1 led to equally efficient suppression of PPG 
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mRNA. By contrast, PDX-1T152D or PDX-1T152E failed to alter PPG mRNA levels 
compared to infection with null adenovirus. Likewise, co-infection with both 
PASK-expressing viruses and PDX-1-expressing viruses failed to further affect the 
transcriptional activity (Fig. 4.5B, 4.5C). 
 
 
Fig. 4.4. Dephospho- and phospho-mimetic mutation of Thr-152 affects 
PDX-1 transcriptional activity.  
A. INSrαβ cells were cultured in the presence of 500 ng/ml doxycyclin for 24 
h or infected with wild-type or mutant forms of PDX-1 at 100 MOI for 24 h 
leading to increased levels of PDX-1 mRNA expression. B. INSrαβ cells 
were cultured in the presence of 500 ng/ml doxycyclin for 24 h leading to 
decreased levels of preproglucagon mRNA expression. C. RNA was 
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extracted from cells infected with wild-type or mutant forms of PDX-1 at 100 
MOI for 24 h. Cyclophilin A, PDX-1 and glucagon gene expression were 
monitored by real time RT-PCR. (Mean ± SEM, n =3; two-tailed student’s t-
test, Microsoft ExcelTM.)  
 
 
 
 
Fig. 4.5. Dephospho- and phospho-mimetic mutation of Thr-152 
affects PDX-1 transcriptional activity.  
 PASK or GFP viruses were added to the cells at MOI 100 treated under 
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the same conditions as Fig. 4.4A, for 24 h. RNA was extracted and 
relative PDX-1 (A) and glucagon (B) gene expression was determined by 
real time RT-PCR for the effect of the indicated mutant versus null (GFP) 
virus control. (Mean ± SEM, n =3; two-tailed student’s t-test, Microsoft 
ExcelTM.)  
 
4.3.4 Phosphorylation of PDX-1 at Thr-152 in intact INS-
1(832/13) cells.  
 
In order to determine whether Thr-152 represented a major phosphorylation site for 
PDX-1 in living b-cells, we deployed in studies described in Chapter 3, metabolic 
labeling (Chapter 3, Fig. 3.6, P92). However, the incorporation of [32Pi] in 
immunoprecipitated wild-type or T152A mutant PDX-1 was not different, 
indicating that Thr-152 is not likely to be a major phosphorylation site for PDX-1 in 
living β-cells or is one of many. To be able to look at the phosphorylation status of 
PDX-1 on Thr-152 in living cells, a phospho-specific antibody was raised (by 
Pacific Immunology) against the region 145EENKRTRpTAYTRAQ158. The 
phospho-Thr-152 antibody specifically recognized the recombinant wild-type PDX-
1 protein phosphorylated by active PASK in vitro (Chapter 3, Fig. 3.5, P92). 
However, this antibody failed to recognize a specific band in either whole cell 
lysate (Fig. 4.6B), or cytoplasmic and nuclear extracts (Fig. 4.6A), despite detecting 
PDX-1 phosphorylated in vitro at Thr152 using purified PASK.  
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Fig. 4.6. Thr-152 phosphorylation in living β-cells (A) MIN6 infected 
with wild-type PDX-1 or PASK were cultured with 3 mM or 20 mM 
glucose for 6 h after 3 mM glucose for 16 h. Cytoplasmic (C)/ nucleic (N) 
extract were obtained; recombinant PDX-1 protein (Ctrl), phosphorylated in 
vitro by wild-type PASK (WT),was used as control. (B) MIN6 cells 
with/without overexpressed PASK/GFP as well as normal MIN6 cells were 
cultured with 3 mM or 20 mM glucose for 6 h after 3 mM glucose for 16 h.  
Whole cell lysates were obtained. In both cases, anti-phosphoT152-PDX-1 
antibody and polyclonal rabbit anti-PDX-1 antibody were used in western 
blotting (representative blots were shown, n =3).  
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Given that unphosphorylated Thr-152 was shown to be important for maintaining 
normal PDX-1 function and DNA binding (Fig.s 4.1-4.5), we next explored the 
possibility of a phosphorylation event at this site under patho-physiological 
conditions, notably including the presence of the proinflammatory cytokines, tumor 
necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-1β (IL-1β) 233. 
However, no obvious sign of phosphorylation on Thr-152 was detected using anti-
phospho-Thr-152 with the presence of cytokines (Fig. 4.7A and 4.7C). Likewise, 
co-infection with adenovirus expressing PASK also failed to affect phosphorylation 
of PDX-1 at Thr-152 (Fig. 4.7B). 
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Fig. 4.7. PDX-1 is not phosphorylated at Thr-152 in intact INS-
1(832/13) cells under a variety of conditions.  
INS-1(832/13) cells infected with wild-type PDX-1 (A) or PASK/GFP (B) 
expressing viruses, cells without viruses (C) as controls. After 24 h, cells 
were treated with/without a cytokine mix containing TNF-α, IFN-γ and 
IL-1β (PreproTech EC) for 6 h (51). Cytoplasmic (C)/nucleic (N) extracts 
were obtained; recombinant PDX-1 protein (Ctrl) phosphorylated in vitro 
by kinase inactive form PASK (DN) (lane 1, A) or wild-type PASK (WT) 
(lane 2, B and Ctrl in B, C) as control. Anti-phospho-PDX-1 antibody, 
anti c-myc antibody or polyclonal rabbit anti-PDX-1 antibody were used 
in western blotting respectively (representative blots were shown, n =3). 
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4.3.5 Mass spectrometry and phosphorylation site mapping   
In an effort to confirm our findings concerning phosphorylation on Thr-152 in 
intact cells, we next performed mass spectrometry analysis of immunopurified 
PDX-1 from INS-1(832/13) cells cultured at 20 mM glucose co-overexpressed with 
both wild-type PDX-1 and PASK (Fig. 4.8). We used OrbiTrap, which traps ions 
with a specific mass to charge ratio and analyses mass with a high mass accuracy, 
high resolving power and a high dynamic range 232.  
 
Fig. 4.8. Illustration of sample preparation for mass spectrometry 
sequencing.  
T-75 flasks (30) of INS-1(832/13) cells were infected at an MOI of 50 with 
adenoviruses expressing wild-type PDX-1and PASK for 48 h. Cells were 
then collected and lyzed for immunoprecipitation using anti-c-myc antibody-
conjugated beads (Santa Cruz). The IP product was migrated on 10% (w/v) 
SDS-PAGE gels and stained with colloidal commassie blue (SimplyBlue 
SafeStain, Invitrogen). Immuno-purified PDX-1 on SDS-PAGE was 
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provided by Rong AN. In-gel digestion and phosphorylation site mapping 
by mass spectrometry was done by Dr. Douglas Lamont in Fingerprint Ltd. 
University of Dundee.  
 
 
The results of the OrbiTrap analysis of sample PDX-1 after Lys-C digestion (Fig. 
4.9) showed that the peptide sequence 149RTR152TAYTRAQLLELEK164, predicted 
to be released by Lys-C digestion which cleaves at K residues, was used with and 
without phosphate in order to generate an inclusion list of ions for the MS system. 
Both data sets, one with an inclusion list and one with no inclusion list used, were 
run against the PDX-1 sequence supplied for PDX-1 (Mascot Search provided by 
MATRIX SCIENCE). Orbi-Trap analysis of immuno-precipitated PDX-1 after Lys-
C digestion indicated that the peptide 149RTR152TAYTRAQLLELEK164
 
was present 
in an un-phosphorylated form, but there was no evidence for the presence of the 
phosphorylated form.  
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Fig. 4.9. PDX-1 peptide fragments sequenced from LysC digestion  
Peptide fragments sequence from mouse PDX-1 protein were predicted after LysC 
digestion which cleaves at the Lysine (K) residue. Fourteen peptides were expected 
among which Thr-152 is located in the middle of the L6 peptide as shown in the 
graph.   
The data generated for PDX-1 for identity (ID) and phosphorylation site mapping 
analysis using precursor ion scanning of mass to charge ratio (m/z) 79 ([PO3]-) at 
80 eV (Pre79; Fig. 4.10) - was also searched against the sequence supplied for 
PDX-1 (Mascot Search) and against the NCBInr (all species). The ID analysis 
confirmed that PDX-1 was present. However the Pre79 analysis did not indicate any 
phosphorylated fragments (within detection limit of technique) from PDX-1 
generated by Lys-C digestion (Fig. 4.10).  
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Fig. 4.10.  Phosphorylation site mapping of PDX-1 by mass 
spectrometry.  
Immuo-purified PDX-1 was migrated by SDS-PAGE and the 1D band with 
good intensity by colloidal coomassie staining was processed by in-gel 
digestion with Lys-C (as described in Material and Methods). The Pre79 
(phosphorylation site mapping analysis) mass spectrum of PDX-1 peptides. 
m/z, mass-to-charge ratio. The data generated for PDX-1 for identity (ID) 
and phosphorylation site mapping analysis-using precursor ion scanning of 
mass to charge ratio (m/z) 79 ([PO3]-) at 80 eV (Pre79)- was also searched 
against the sequence supplied for PDX-1 (Mascot Search) and against the 
NCBInr (all species). Immuno-purified PDX-1 on SDS-PAGE was provided 
by Rong AN. In-gel digestion and phosphorylation site mapping by mass 
spectrometry was done by Dr. Douglas Lamont in Fingerprint Ltd. 
University of Dundee.  
 
Samples from cells cultured under the same condition as above were also digested 
with trypsin, predicted to release a fragment 152TAYTR156. However, this approach 
also failed to reveal evidence for the presence of phosphate at Thr-152 (data not 
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shown).  
The mass spectrometry experiments were done in collaboration with Dr. Douglas 
Lamont in Fingerprint Ltd. University of Dundee.  
 
4.3.6 Subcellular localization of overexpressed PASK in 
INSrαβ  cells.  
PASK was previously reported in cloned β-cells 202 to display a cytosolic 
distribution, whereas PDX-1 mainly shuttles between nuclear periphery and 
nucleoplasm in normal β-cells under physiological conditions in response to 
elevated glucose concentrations 138. We therefore studied the effect of PASK on 
PDX-1 transcriptional activity and on preproglucagon mRNA level by over-
expressing PASK and PDX-1 in INSrαβ cells (Fig. 4.4-4.5). The localization of 
over-expressed human PASK was also studied by immunocytochemistry using anti-
human PASK antibody. In INSrαβ cells, as reported before in cloned β-cells 202, 
overexpressed PASK displayed a predominant cytosolic distribution without any 
shift into nuclear area at elevated glucose concentrations (Fig. 4.11) 
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Fig. 4.11. Immunocytochemical analysis of the subcellular distribution 
of PASK.  
INSrαβ cells were infected with hPASK-over-expressing-adenoviruse at 
100 MOI for 24 h. Cells were cultured at 3 mM glucose for 16 h and then 
treated with 3 mM or 20 mM glucose for 6 h. c-Myc-tagged hPASK was 
detected using anti-PASK antibody and Alexa-568 (Molecular Probes). 
Nuclear staining was achieved using DAPI. 
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4.3.7 PASK is present in pancreatic β-cells from dispersed 
human islets.   
A recent report by Borter et al 213 suggests that PASK (referred to as PASKIN) 
mRNA levels were high in testes. However these authors were unable to detect 
PASK mRNA in pancreas or in islet β-cells.  However, in the research by Da Silva 
Xavier et al 209, PASK was shown to be involved in regulating glucose-stimulated 
insulin gene expression in pancreatic β-cells and in a later study by Hao 210 using 
the same PASK knock-out mice as Borter et al 213, the mice exhibited impaired 
glucose-stimulated insulin secretion from isolated pancreatic islets, altered 
triglyceride storage in liver, and increased metabolic rate in skeletal muscle. A very 
important question for the present study was to explore whether or not PASK is 
expressed in pancreatic β-cells and whether the expression is regulated by glucose.  
Due to the unavailability of commercial anti-PASK antibody for rodent species, we 
chose to study the subcellular localization of PASK in dispersed human islets by 
immunocytochemistry using anti-human PASK antibody. By probing the dispersed 
pancreatic islets with an anti-insulin antibody, insulin-secreting β-cells were 
identified and PASK immunoreactivity was found in both the nuclear and 
cytoplasmic areas (Fig. 4.12A). To further confirm the localization of both PDX-1 
and PASK in pancreatic β-cells, anti-PASK and anti-PDX-1 antibodies were used 
simultaneously. PASK and PDX-1 are both present in the nuclear area of β-cells 
(Fig. 4.12B). Taken together, these data provided evidence that PASK expression 
overlaps with PDX-1 expression in human pancreatic β-cells. However, no sign of 
translocation of PASK was observed in response to elevated glucose concentrations.   
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Fig. 4.12. PASK and PDX-1 co-localize in human pancreatic β-cells.  
Dispersed human islets were cultured in RPMI-1640 medium containing 3 
mM glucose for 16 h before subsequent incubation in media containing 3 or 
17 mM glucose for 6 h. PASK in (A) and (B), was detected using anti-human 
(h) PASK antibody and revealed with Alexa 488-conjugated secondary 
antibody (Molecular Probes). In (A), insulin was detected to label b-cells and 
was probed with anti-insulin antibody (Roche) and Alexa 568-conjugated 
secondary antibody (Molecular Probes). In (B), PDX-1 was labeld using anti-
PDX-1 antibody and Alexa 568-conjugated secondary antibody (Molecular 
Probes). In both (A) and (B), nuclear staining was achieved with DAPI.  
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4.4 DISCUSSION  
We have shown in Chapter 3 that recombinant PDX-1 is efficiently phosphorylated 
in vitro at Thr-152 in the homeodomain by the nutrient-regulated kinase, PASK. Given the relatively low promiscuity of PASK towards a variety of substrates‐ 
PASK did not phosphorylate several other substrates tested, including the β-cell 
enriched transcription factors neuroD and MafA (personal communication with 
Prof. Jared Rutter, University of Utah), we  speculated  that  this  event  may  be physiological.  In this Chapter we therefore deployed multiple approaches to 
explore the possibilities that Thr-152 may be phosphorylated in living β-cells, and 
that PASK may be the responsible PDX-1 kinase. This issue appeared particularly 
important given the profound effects, demonstrated here (Fig.s 4.1-4.5), of 
mimicking the phosphorylation at Thr-152 on the DNA binding and transactivation 
capacity of PDX-1, and on the ability of this factor to determine the lineage of a 
common α/β-cell precursor cell line. 
 
In this Chapter, it was observed that mimicking phosphorylation on the potential 
site identified in vitro resulted in a potent inactivation of PDX-1 reflected in a near 
total loss of DNA-binding capacity and in the abilities of the factor to induce a cell 
lineage switch in INSrαβ cells. Arguing against the view that PASK phosphorylates 
PDX-1 in situ, nuclear localization of the kinase in MIN6 β-cells was not previously 
been noted for over-expressed PASK 209 (though studies of the endogenous protein 
in rodent cell lines were not possible due to the absence of an antibody with 
adequate specificity for immunocytochemical analyses). We now show, using direct 
and complementary approaches, that Thr-152 is unlikely to be significantly 
phosphorylated in situ under a variety of conditions, including those in which 
endogenous PASK is activated (elevated glucose concentrations) or after over-
expression of the exogenous kinase. The present data thus indicate that Thr-152 is 
not a major site of phosphorylation of PDX-1 in living β-cells under most 
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conditions, and that phosphorylation at this site is not altered under conditions in 
which the nuclear accumulation of PDX-1 is clearly affected (i.e high versus low 
glucose concentrations). 
 
What may underlie the apparent difference in the ability of PASK to phosphorylate 
PDX-1 at Thr-152 efficiently in vitro, but not in intact cells? The PDX-1 
homeodomain is important for PDX-1 DNA binding ability and may play an even 
more pivotal role in protein-protein interaction between PDX-1 and other co-
activators. One possibility, therefore, is that DNA-bound PDX-1 may provide a 
poor substrate for PASK at this site, owing to a direct competition/steric blockage 
by bound DNA or an associated protein-binding partner for PDX-1. On the other 
hand, as studies of the endogenous protein in rodent cell lines were not possible due 
to the absence of an antibody with adequate specificity for immunocytochemical 
analyses, alternatively, this difference might due to the fact that overexpressed, 
exogenous PASK and PDX-1 are differently localized in the cells. Indeed, as shown 
in Fig. 4.11, overexpressed human PASK exhibited a predominantly cytosolic 
distribution in INSrαβ cells irrespective of the glucose concentration. Nonetheless, 
since PDX-1 shuttles dynamically from the cytosol to the nucleus 138, 224, it remains 
conceivable that the factor may interact with PASK in the cytosol. Overall, 
therefore, it seems most likely that PDX-1 is protected from phosphorylation by 
overexpressed PASK at Thr-152 by a combination of nuclear segregation, DNA 
binding and perhaps interactions with other binding partners. 
 
However, since PDX-1 shuttles dynamically from the cytosol to the nucleus 138, 224, 
we also provided evidence that PASK is detected in both the cytosol and nuclear 
areas in dispersed human islets especially in pancreatic β-cells where PDX-1 was 
also detected in the nuclear area (Fig.12), suggesting possibilities that in primary 
human pancreatic β-cells, PDX-1 could indeed potentially interact with endogenous 
PASK.  
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We have evidence that PASK over-expression in MIN6 cells can increase 
preproinsulin and PDX-1 promoter activity 209. In our study, we looked at the 
regulation by PASK of PDX-1 transcriptional activity in INSrαβ cells in which the 
PDX-1 over-expression had undetectable effects on insulin gene expression. 
Instead, wild-type PDX-1 over-expression was shown to substaintially decrease 
preproglucagon gene expression. However, co-overexpression of PASK and PDX-1 
did not lead to any change in preproglucagon gene expression in these cells. Hence, 
regulation by PASK may act through more complicated pathways requiring 
engagement of other intracellular factors bridging between PASK and PDX-1 rather 
than a direct protein-protein interaction.  
 
We conclude that the regulation by glucose of preproinsulin promoter activity, 
previously shown to require PASK activity 209, is unlikely to be achieved through 
direct phosphorylation of PDX-1 by this kinase. Future studies will be required to 
elucidate the mechanisms through which PASK acts in this signaling pathway. 
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5.  Chapter 5   
Glucose-dependent phosphorylation of 
PDX-1 at serine-269 in clonal pancreatic β-
cells: identification of potential protein 
kinases, and impact on PDX-1 function 
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5.1 Introduction  
In contrast to the relatively well-studied functions of the N-terminus and the 
homeodomain of PDX-1, the role of the conserved C-terminus is less known. 
Human mutations in the C-terminus of PDX-1 are associated with the development 
of type 2 diabetes 158-160, and previous findings indicate that the C-terminal domain 
may serve as both a repressor and an activator of PDX-1 function. The C-terminus 
may thus inhibit the synergy between PDX-1 and a second transcription factor, E47 
on the preproinsulin promoter, whilst also containing a cryptic transactivation 
domain involved in regulating the somatostatin gene TAAT1 enhancer 70, 101. 
Stoffers et al 160 identified the first PDX-1 C-terminus interacting protein-PCIF1 
(PDX-1 C-terminal interacting factor) in the pancreas and suggested that PCIF1 
may modulate PDX-1 function during normal pancreas development and/or 
differentiation.  
 
Homeodomain-interacting protein kinase 2 (HIPK2) is an evolutionary conserved 
serine/threonine nuclear kinase belonging to the family of homeodomain-interacting 
protein kinases (HIPK) which includes HIPK1, HIPK2 and HIPK3 and also the 
more distantly related protein HIPK4.234 
 The HIPK family was initially discovered as a novel family of HIPKs that localize 
to nuclear speckles, and act as binding partners 234 and transcriptional co-repressors 
for NK homeodomain transcription factors 234. The NK homeodomain transcription 
factors were found to be important for embryonic development and organogenesis 
including development of the heart.  
The kinase domains of HIPK1, 2 and 3 share >90% homology 234, 235. Mice 
deficient for either Hipk2 or Hipk1 alone are grossly normal, while doubly deficient 
mice die prenatally and show various abnormalities including defects in 
hematopoiesis and blood vessel formation 235, 236.   
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HIPK2 is the most highly characterized family member in the HIPKs family. It 
localizes mainly to subcellular nuclear area 235. HIPK2 contains an N-terminal 
kinase domain with a small ubiquitin-related modifier (SUMO) attachment site at 
lysine 25 237-239. It also contains an interaction domain for the homeodomain 
transcription factors, and two PEST motifs (rich in Proline, Glutamic acid, Serine 
and Threonine) that overlap with a region allowing SUMO binding. These regions 
are flanked by an autoinhibitory domain and a C-terminal region that is rich in short 
repeats of S, Q or A. The entire sequence of the protein is well conserved among 
vertebrates, while the kinase domain is even found in Drosophila melanogaster and 
Caenorhabditis elegans. 
 
HIPK2 is one of the kinases that simultaneously exert diverse biological functions 
240. HIPK2 can be activated by DNA-damaging agents or morphogenic signals and 
consequently HIPK2-regulated gene expression programs trigger differentiation and 
development or alternatively, apoptosis 240. Biochemical and genetic studies have 
revealed an important role of HIPK2 for development 241-244 and the regulation of 
cell death 240, 245-248. HIPK2 regulates gene expression by phosphorylation of 
transcription factors and accessory components of the transcription machinery. As 
such, it interacts with, and modulates by phosphorylation, the function of 
homeodomain proteins including p53, Myb and CtBP1 242, 247, 249-251. The function 
of HIPK2 phosphorylation is dependent on the cell type and promoter context 240.  
 
HIPK2 is regulated by a post-translational modification of an ubiquitin-like protein, 
SUMO-1, via covalent bonding to lysine 25 on HIPK2 237-239. This is similar to the 
binding of SUMO-1 to PML and Sp100 252. The conjugation of SUMO-1 is thought 
to direct each of these proteins to nuclear bodies (NBs), which appear to play a role 
in autoimmunity and viral protection. HIPK2 is the first protein kinase found to be 
directed to nuclear bodies in response to ubiquitin-like modification 253. 
 
A recent study reported that HIPK2 is expressed in the developing pancreatic 
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epithelium from embryonic day (e) 12 to e15 but that the expression becomes 
preferentially confined to pancreatic endocrine cells at later developmental stages. 
Moreover, HIPK2 was reportedly able to modulate positively the transcriptional 
activity of PDX-1, and HIPK2 directly phosphorylates the C-terminal portion of 
PDX-1 161. These data not only provided evidence of a new mechanism by which 
IPF1/PDX1 transcriptional activity is regulated, but also lead to a novel potential 
pathway that could contribute to the study on the regulatory effect of PDX-1 C-
terminus. 
 
In this Chapter, we have identified a novel phosphorylation site in the C-terminal 
domain of PDX-1, Ser-269 via mass spectrometry analysis and an anti-phospho-
Serine-specific antibody. This site is phosphorylated by HIPK2 in vitro, and the 
phosphorylation on S269 is regulated by glucose in MIN6 cells.  
It has been reported in a previous study by Edlund, a minor proportion of PDX-1 is 
phosphorylated on S61 and S66, and that phosphorylation marks PDX-1 for 
degradation by a GSK3-dependent mechanism. In vitro phosphorylation studies 
undertaken here also provided evidence for a relationship between S269 
phosphorylation and GSK3 phosphorylation at other sites in the regulation of PDX-
1. However, mutation studies of indicated that S269 phosphorylation does not affect 
the localization, DNA-binding ability or transcriptional activity of PDX-1. Thus, 
our data provided the first in vivo phosphorylation site on PDX-1 that has been 
identified by mass spectrometry Phospho-site screening then provided evidence of 
the potential regulatory network in which S269 may be involved. This may shed 
light on signaling pathways by which the function of the PDX-1 C-terminus is 
regulated. 
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5.2 Methods   
5.2.1 Sequencing and Mass Spectrometric Analysis of 
Phosphorylation sites  
T-75 flasks (30) of INS-1(832/13) cells were infected at 50 MOI with adenovirus 
expressing wild-type PDX-1 for 48 h. Cells were then collected and lyzed for 
immunoprecipitation as described (Chapter 2; P74). IP product was migrated on 
10% (w/v) SDS-PAGE gels and stained with colloidal commassie blue (SimplyBlue 
SafeStain, Invitrogen). The 1D band with good intensity by colloidal commassie 
staining was processed by in-gel digestion with trypsin. The digested samples were 
then extracted and were taken through three stages of analysis using a 4000 QTRAP 
(Applied Biosystems) mass spectrometer. The stages were as follows: Identification 
of protein(s) by nLC-MS-MS; Parents of -79 (PO3-) analyses to detect 
phosphorylated peptides; data interpretation including de novo assignment of 
phosphorylation sites) and final reporting. Ser-152 phosphorylation was further 
detected using OrbiTrap by targeting site-of-interest containing peptide 232.  
The mass spectrometry experiments were done by Dr. Douglas Lamont in 
Fingerprint Ltd. University of Dundee.   
5.2.2 Peptide competition assay for anti-phospho-S269-PDX-
1 antibody. 
 
INS-1(832/13) cells were infected at 50 MOI with adenoviruses expressing wild-
type PDX-1 and PASK for 48 h. Cells were then collected and nuclear lysate was 
obtained as described in Chapter 2 (P58). Three identical lanes of the SDS-PAGE 
gel were loaded 30 µg each of the nuclear extract. Proteins were separated and 
transferred onto a PVDF membrane which was then blocked with 5% skimmed 
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milk in TBST as described for PCA assay. Anti-phospho-S269-PDX-1 antibody 
was slowly thawed on ice and diluted 1:100 in 5% BSA. The lyophilized phospho-
/non-phospho peptides were slowly warmed to room temperature under desiccation. 
Each peptide was reconstituted to a concentration of 100 µM using molecular 
biology-grade ultrapure water at room temperature. Peptide stock solution (2.66 
µM) and water control were prepared (sample (a): no peptide control; sample (b): 
non-phosphorylated peptide 2X stock; sample (c): phosphorylated peptide 2X 
stock) and 1 ml of the 2X antibody stock was added into each of the samples above. 
The mixture was incubated at 4°C for 24 h with gentle rocking. Samples were then 
centrifuged for 15 min. at 4°C in a microcentrifuge at 13,000 rpm to pellet any 
immune complexes. The supernatant was removed carefully. The pre-incubated 
antibody in each of the three samples was used onto the three identical strips for 
normal immunoblotting as described before in Chapter 2.  
After the phospho-specific antibody blotting, the blots were stripped and re-blotted 
with anti-c-myc antibody.  
5.2.3 Transient Transfections and Luciferase Assay 
 
For immunocytochemistry, plasmids pAdTrack-PDX-1 wild-type, -S269A or -
S269E were transfected into INSrαβ cells with Lipofectamine 2000 according to 
the Manufacturer’s instructions. Plasmids pcDNA3.1-PDX-1 wild-type and 
p260Ins.LucFF  138, S269A, S269E expression vectors were made using a site-
directed mutagenesis kit (Strategene) in pcDNA3.1 vector (Invitrogen). For 
luciferase assays, HEK293 cells were transfected using Ca2+-phosphate. HEK293 
cells were grown to 70-90% confluency in 12-well plates. Total DNA (as indicated) 
was mixed with 2.5M CaCl2 was added drop by drop to same volume of 2 X HBS 
in a sterile tube while vortexing. Empty expression plasmid was used to maintain a 
constant total amount of DNA among wells. Cells were harvested 48 h following 
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transfection and protein cells extraction for western blot analyses or for luciferase 
assays were carried out. For luciferase assays, the data are presented as firefly 
luciferase activity normalized to Renilla luciferase activity expressed from the 
cotransfected plasmid, pRL-TK (Promega).  
 
5.2.4 In vitro phosphorylation of PDX-1 by HIPK2, CK1 or 
GSK3β 
 
In vitro phosphorylation was carried out following the manufacturer’s instruction 
for active HIPK2 (Upstate). Purified wild-type or S269A PDX-1 (2 µg) was mixed 
with the indicated amount of HIPK2 in kinase buffer (8 mM MOPS pH 7.0, 200 µM 
EDTA, 10 µM MgCl2, 100 µM ATP) with or without 2 µCi [γ-32P] ATP. The 
reaction mixtures were incubated at 30 °C for 30 min. Reactions were stopped by 
adding Laemmli buffer (62.5 mM Tris-HCl pH 6.8, 2.2% SDS, 10% glycerol, 1 
mM PMSF, 5% β-mercaptoethanol, 0.005% bromophenol blue). The samples were 
then separated on SDS-PAGE and analyzed by autoradiography (labeled samples) 
or western immuno-blotting (unlabeled samples) using the indicated antibodies.  
 
PDX-1 (3 µg, either wild type or S269A mutant) was firstly incubated at 37 °C in a 
medium (20 µl) containing 10 mM Tris buffered MOPS pH 7.5, 20 mM magnesium 
acetate, 1 mM DTT, and 0.25 mM ATP in the presence of the phosphorylating 
kinase (1.7, 1.5 and 2 pmol for CK1δ, GSK3β and HIPK2, respectively). After 45 
min., GSK3β (1.5 pmol) was added (water in the controls) together with a new 
mixture of [γ33-P] ATP (specific radioactivity 5000 cpm/pmol) and the incubation 
continued for 15 min. Samples were then blocked with Laemmli buffer and 
subjected to PAGE-SDS and western blotting. Nitrocellulose membranes were 
directly exposed to autoradiography and subsequently immunostained with 
antipSer269 antibodies. Recombinant wild-type PDX-1 and S269A PDX-1 were 
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provided by Rong AN and the in vitro phosphorylation experiments by CK1δ and 
GSK3β were performed by Dr. Flavio Meggio and Prof. Lorenzo Pinna (University 
of Padova, Italy).                    
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5.3 RESULTS  
5.3.1 Mass spectrometry and phosphorylation site mapping   
In an effort to identify the major phosphorylation sites on PDX-1 in intact β-cells, 
we scanned peptides released after trypsin digestion of the protein 
immunoprecipitated from MIN6 β-cells. Phosphorylation site mapping was then 
undertaken with a 4000 QTRAP LC/MS/MS system. The data generated for PDX-1 
for identity (ID) and phosphorylation site mapping analysis - using precursor ion 
scanning of mass to charge ratio (m/z) 79 ([PO3]-) at 80 eV (Pre79) - were also 
searched against the sequence supplied for PDX-1 (Mascot Search) and against the 
NCBInr (all species). Peptide 262LPSGLSVpSPQPSSIAPLRPQEPR284 was 
found to be phosphorylated on Ser269 (Fig. 5.1; bold; corresponding to Ser268 in 
the human sequence). Peptide 
211SSGTPSGGGGGEEPEQDCAVTSGEELLAVPPLPPPGGAVPPGVPAAVR25
8 (Fig. 5.1) was also found to bear at least one phosphate group. However, the 
precise site of phosphorylation of this peptide was not investigated further. 
Immuno-purified PDX-1 in SDS-PAGE was provided by Rong AN. In-gel 
digestion and the mass spectrometry experiments were done by Dr. Douglas 
Lamont in Fingerprint Ltd. University of Dundee.  
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5.3.2 Characterization of anti-phospho-S269-PDX-1 antibody 
using a peptide competition assay 
 
The peptide competition assay aimed to confirm the specific reactivity of anti-
peptide polyclonal phospho-specific antibodies. As the anti-phospho-S269-PDX-1 
antibody was observed to reveal more than one band when probing in cell lysates, 
this assay provides a means of determining which band is specific for the phospho-
specific antibody. Two experiments were run in parallel, one in which the 
phosphorylated form of the peptide immunogen was used and one with the non-
phosphorylated form of the immunizing peptide. The immunoblotting experiment 
was run in duplicate; in one set including antibody pre-incubated with peptide, and 
another with a control antibody not pre-incubated with peptide. The signals in Fig. 
5.2A (a) (water only, no peptide control) represent the maximum signal detected by 
the phospho-specific antibody. Signals obtained with sample (b) (non-
phosphorylated peptide) and sample (c) (phosphorylated peptide) was compared to 
the signal from sample (a) to determine if the peptides compete for antigen binding. 
There was very little binding to the 46 kD band for sample (c) in which the 
antibody had been pre-incubated with excess of phosphorylated peptide. This 
suggests that the 46 kD band is the specific band for the anti-phosphoS269-PDX-1 
antibody. Total protein level appear to be equal as indicated using anti-c-myc 
antibody in Fig. 5.2B.  
  
  149 
  
Fig. 5.2. Peptide competition assay for anti-phosphoS269-PDX-1 
antibody.  
Three identical strips a, b and c were immunoblotted by pre-incubated anti-
phosphoS269-PDX-1 antibody with water, non-phosphopeptide and 
phosphopeptide respectively. The indicated band represents phosphoS269-
PDX-1. Blots were then stripped and re-blotted by anti-c-myc antibody. The 
46 kD band shows the whole myc-tagged PDX-1 level.     
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5.3.3 PDX-1 is phosphorylated on Ser-269 in living β-cells 
and by HIPK2 in vitro. 
 
It has previously been reported 161 that homeodomain-interacting protein kinase 2 
(HIPK2) directly phosphorylates the C-terminal domain of PDX-1 at undefined 
site(s) lying between aa215 and aa283 161. Since HIPK2 is considered to be a 
proline-directed kinase 161, and S269 is adjacent to a proline residue (see above and 
Fig. 5.1), we investigated whether S269 may be phosphorylated by HIPK2 in vitro. 
This possibility was examined using active HIPK2 and recombinant c-myc-tagged 
wild-type or S269A PDX-1 as substrates. Wild-type PDX-1 incorporated increasing 
amount of 32P as the amount of active HIPK2 was increased, as expected (Fig. 
5.3A). In contrast, incorporation of 32P into recombinant S269A PDX-1 was hardly 
detectable at all levels of HIPK2 activity tested (Fig. 5.3A). In both cases, HIPK2 
was also present as an autophosphorylated band. This was accompanied, in 
experiments performed with non-radioactive ATP, with the appearance of an 
immunoreactive band at ~46 kDa as revealed using an antiphospho-S269 PDX-1 
antibody. As predicted, no immunoreactivity was apparent after treatment of the 
S269A mutant PDX-1 (Fig. 5.3B).  
 
Whilst the increased signal detected with the anti-phospho-S269-specific PDX-1 
antibody in the case of wild-type PDX-1 confirmed the above finding, residual 
incorporation of phosphate into S269A PDX-1 (Fig. 5.3A) suggested the existence 
of other sites for phosphorylation by this kinase. Indeed, and as revealed by mass 
spectrometry (Fig. 5.1), a long peptide, 
211SSG214TPSGGGGGEEPEQDCAVTSGEELLAVPPLPPPGGAVPPGVPAAVR 
was also detected as containing phosphate. Although the exact site of 
phosphorylation was not pursued further, we noted that Thr214, present in the 
above peptide, and followed by a proline residue, meets the criteria for 
phosphorylation by proline-directed kinases including HIPK2. 
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Fig. 5.3. PDX-1 is phosphorylated on Ser-269 in living  b-cells and by 
HIPK2 in vitro. (A) Recombinant PDX-1-myc (2 µg ; WT or S269A) were 
mixed with indicated amount of active HIPK2 in the presence of [γ‐32P]ATP 
for 30 min. Autoradiography shows the radiolabeled PDX-1 and HIPK2. 
Coomassie staining shows the PDX-1 protein level. (B) Parallel experiment 
with the absence of  [γ‐32P]ATP was analyzed by western blot using 
indicated antibodies. 
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5.3.4 Ser-269 may also be phosphorylated by GSK3β  
 
It has previously been reported 142 that a minor portion of PDX-1 is phosphorylated 
in the N-terminal domain at Ser61 and Ser66 and the phosphorylation is modulated 
by a GSK3-dependent mechanism. Hence, our data showing that Ser269 is 
phosphorylated by HIPK2 in vitro prompted us to explore the potential regulatory 
mechanisms controlling this phosphorylation event. We noted that Ser269 lies 
within the sequence 269SPQP273S, corresponding to the consensus sequence for 
GSK3 phosphorylation (S/T-X-X-X-pS/T; pS/T represents the priming residue) 254, 
255. We therefore conducted a series of in vitro phosphorylation trials to explore the 
phosphorylation of PDX-1 by GSK3. Since phosphorylation by GSK3 usually 
requires priming by phosphorylation of the downstream residue (Ser273 in the case 
of subsequent phosphorylation at Ser269) we studied phosphorylation in the 
presence of GSK3 alone, or in the additional presence of CK1δ ( often used to 
prime subsequent phosphorylation by GSK3 256, 257. CK1δ phosphorylated PDX-1 
on its own and the addition of GSK3 caused a highly reproducible increase (means 
± SEM, 71 ± 14 %; n = 3, p<0.01; two-tailed student’s t-test, Microsoft ExcelTM) of 
the overall incorporation of 33P (Fig. 5.4A). Moreover, when Ser269 was replaced 
by an alanine residue phosphorylation by CK1δ and the increase of 33P 
incorporation by addition of GSK3β were significantly reduced, compared to wild-
type (24 ± 15 %; n = 3; p<0.05; two-tailed student’s t-test, Microsoft ExcelTM; Fig. 
5.4A) implicating Ser269 as a potential target of either CK1δ or GSK3β. However, 
this conclusion could not be confirmed using the anti-pSer269 PDX-1 specific 
antibody: the antibody failed to detect any signal in either case (Fig. 5.4A and see 
the Discussion).  
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Fig. 5.4. Ser-269 may also be phosphorylated by GSK3. 
PDX-1 either wild type or S269A mutant was firstly incubated with the 
phosphorylating kinase (CK1, GSK3 and HIPK2) before further reaction with 
GSK3/water. Samples were then blocked with Laemli buffer and subjected to 
PAGE-SDS and western blotting. Nitrocellulose membranes were directly exposed 
to autoradiography and subsequently immunostained with anti-pSer269 antibodies. 
(A) PDX-1 wild-type and S269A mutant phosphorylation by CK1δ and GSK3 and 
corresponding model. (B) PDX-1 wild-type and S269A mutant phosphorylation by 
HIPK2 and GSK3 and corresponding model. Recombinant wild-type PDX-1 and 
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S269A PDX-1 were provided by Rong AN and the in vitro phosphorylation 
experiments by CK1δ and GSK3β were performed by Dr. Flavio Meggio and Prof. 
Lorenzo Pinna (University of Padova, Italy). Statistical analysis shown in the text 
was done with the results from three independent experients using two-tailed 
student’s t-test, Microsoft ExcelTM. 
 
As shown above (Fig. 5.3A) and in Fig. 4B, HIPK2 alone catalysed the 
incorporation of Pi into recombinant PDX-1, and this was accounted for by 
phosphorylation at Ser269 as revealed with the phospho-Ser269 specific PDX-1 
antibody (Fig. 5.4B). Intriguingly, addition of GSK3β besides HIPK2 also increased 
phospho-radiolabeling of PDX-1, while actually causing a decrease in the signal 
detected with the antiphosphoSer269-specific antibody (Fig. 5.4B, left panel). 
These data suggest that although HIPK2 and GSK3β play a synergistic role in the 
phosphorylation of PDX-1, this hierarchical mechanism does not involve S269. 
Consistent with this, the S269A PDX-1 mutant undergoes synergistic 
phosphorylation by the combination of HIPK2 and GSK3β similar to PDX-1 wild 
type (Fig. 5.4B). These results therefore indicate that there must be other residue(s) 
in PDX-1 which can be phosphorylated by HIPK2 in vitro besides S269, and that 
such a phosphorylation primes the subsequent intervention of GSK3β. 
 
5.3.5 Ser-269 phosphorylation is regulated by glucose in 
living β-cells (MIN6)   
We next explored the possibility that phosphorylation of PDX-1 at Ser-269 may be 
regulated by glucose in living β-cell lines and may, at least potentially, contribute to 
the regulation of PDX-1 function by glucose. After treatment at low glucose 
concentrations (3 mM) for 16 h, we cultured MIN6 cells in medium containing 30 
mM glucose for different times (Fig. 5.5A). Parallel control experiments, in which 
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the glucose concentration was maintained at 3 mM throughout, were also 
performed.  
 
 
 
Fig. 5.5. Phosphorylation on S269 is regulated by glucose concentration 
in MIN6 cells. 
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(A) MIN6 cells were cultured in medium containing 3 mM glucose for 16 h 
and incubated with 3 or 30 mM glucose for indicated time. The same amount 
of nuclear lysate was separated on SDS-PAGE and gels were analyzed by 
western blot using anti-phospho-S269 antibody and anti-PDX-1 antibody. 
The graph is the representative one of three independent experiments. (B) 
The relative phospho-S269 PDX-1 (B1), PDX-1 (B2) expression level and 
the ratio of phosphor-S269 PDX-1 to total PDX-1 level (B3) are shown in a 
graphic representation. Each condition was normalized to 3 mM for 0.5 h 
protein level. The results are the means±SEM of three independent 
experiments. **, p<0.01; *, p<0.05; ns: non-significant (two-tailed student’s 
t-test, Microsoft ExcelTM ). 
Both wild-type and mutant forms of PDX-1 at Ser-269 displayed a dominant 
nuclear area distribution at both low and high glucose concentration (Below; Fig. 
5.6). Thus nuclear extracts from all conditions were separated on SDS-PAGE and 
analysed by immunoblotting using the antiphospho-S269 PDX-1 antibody.  
At both low and high glucose concentrations, the phosphorylation of PDX-1 at 
Ser269 was increased with time (Fig. 5.5A and B1). However, as early as 30 min. 
after exposure to these glucose concentrations, cells maintained at 30 mM glucose 
displayed a markedly lower degree of phosphorylation at Ser269 in PDX-1 (Fig. 
5.5B1), and this difference increased, with enhanced phosphorylation at Ser269, 
during the subsequent 24 h. Meanwhile, total PDX-1 level was examined using 
anti-PDX-1 antibody (Fig. 5.5A and B2). It displayed a gradual decrease in total 
PDX-1 immunoreactivity with time in cells maintained at 3 mM glucose (Fig. 5.5A 
and B2). By contrast, in cells maintained at 30 mM glucose, total PDX-1 level 
increased with time (Fig. 5.5A and B2).  
In order to analyze the glucose regulation in the phosphorylation of PDX-1 at 
Ser269 independently from the changes of total PDX-1 level, ratio of 
phosphoSer269-PDX-1/total nuclear PDX-1 was taken and compared (Fig. 5.5B3). 
The normalized ratio (phosphoSer269-PDX-1/total nuclear PDX-1) increased 
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dramatically in cells maintained at 3 mM glucose during experimental time period 
(Fig. 5.5B3) whereas the ratio of phosphorylation at Ser269 levels to total nuclear 
PDX-1 was more stable at 30 mM glucose. 
 
5.3.6 Phosphorylation at Ser269 affects the subcellular 
distribution of PDX-1 in MIN6 cells. 
 
To explore the potential effect of PDX-1 of Ser269, MIN6 cells were infected with 
adenoviruses expressing c-myc-tagged wild-type, S269A or S269E mutant forms of 
PDX-1. Cells were then cultured for 6 h at either 3 mM or 30 mM glucose 138. 
Over-expressed PDX-1.c-myc was visualized in fixed and permeabilized cells, 
using anti-c-myc antibody. Both wild-type and S269A mutant PDX-1.c-myc were 
localized in the majority of cells to the nuclear periphery at low glucose 
concentration by co-labeling of the nucleoplasm with a DNA-binding stain 
(Fig.5.6A and Fig. 5.6B). In the remaining cells, the over-expressed protein was 
localized to both the nuclear periphery and the nucleoplasm. No appreciable PDX-
1.c-myc immunoreactivity was detectable in the cell cytosol. In MIN6 cells 
overexpressing wild-type or S269A mutant PDX-1, as previously reported in single 
MIN6 cells137, 138, 154, 224, cells incubated for the same period in the presence of 30 
mM glucose displayed largely nucleoplasmic localization indicating that high 
glucose causes a redistribution of PDX-1 towards the nucleoplasm 216 (Fig. 5.6A 
and Fig.5.6B quantification). However, the phosphomimetic S269E mutant PDX-1 
displayed a dramatically different localization pattern and response to high glucose, 
compared to wild-type or S269A mutant PDX-1. Thus, at low (3 mM) glucose 
concentrations, 15.6% of S269E mutant PDX-1 displayed a nuclear peripheral 
localization (Fig. 5.6B); whilst at 30 mM glucose, the percentage of nuclear 
peripheral localization of PDX-1-c-myc immunoreactivity was increased by around 
four times (64.2%; Fig. 5.6B). Thus, phosphorylation on Ser269 is likely to affect 
the subcellular localization of PDX-1 by hampering the PDX-1 translocation from 
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nuclear periphery to nucleoplasm induced by high glucose concentrations.  
 
 
 
        
Fig. 5.6. Ser-269 phosphorylation and PDX-1 subcellular localization.  
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(A) MIN6 cells were infected by adenoviruses expressing Wild-type, S269A 
or S269E mutant PDX-1 at an MOI of 100 for 24 h. Cells were cultured at 3 
mM glucose for 16 h and then treated with 3 mM or 30 mM glucose for 6 h. 
Anti-c-myc antibody (Roche) and Alexa-568 (Molecular Proves) were used 
to detect c-myc tagged PDX-1. Nuclear staining was achieved using DAPI. 
Confocal images were captured using a Leica SP2 upright laser scanning 
confocal microscope (x63/1.32 oil-immersion lens) equipped with a 
krypton/argon laser (488 and 568 nm excitation lines) and UV light. (B) 300-
500 cells were analysed under each condition for quantification. The 
percentage of nuclear-peripheral PDX-1 protein distributed in the cells under 
different condition was taken using Volosity TM 4.0 quantification software. 
A graphic representation depicting the percentage of nuclear-peripheral 
PDX-1 at 3/30 mM glucose is shown. The results are the means±SEM of 
three independent experiments. **, p<0.01; *, p<0.05 (two-tailed student’s t- 
test, Microsoft ExcelTM). 
 
5.3.7 Phosphorylation on Ser269 does not affect the DNA-
binding ability of PDX-1.   
To explore the impact of Ser269 phosphorylation on PDX-1 DNA binding, a 30 bp 
fragment of the mouse insulin I gene promoter, containing a PDX-1 binding motif 
(TAAT) 103, was used in electrophoretic mobility shift assays (EMSA). In 
agreement with previous findings 45, 61, 258, 259, nuclear lysate from cells over-
expressing wild-type PDX-1 showed strong binding to the oligonucleotide derived 
from this promoter element (Fig. 5.7). The binding was specific and was blocked 
efficiently with unlabeled probe (Fig.5.7). Binding was also super-shifted with anti-
PDX-1 antibody. In nuclear extracts from PDX-1 S269A or PDX-1 S269E-
expressing cells, the same binding band was evident and in each case this was 
susceptible to supershifting with anti-PDX-1 antibody. Thus, both phospho-mimetic 
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and dephospho-mimetic mutants of PDX-1 at Ser269 displayed similar DNA-
binding activities compared to wild-type PDX-1, suggesting that phosphorylation at 
this site is unlikely to affect this parameter directly. 
 
 
Fig. 5.7. Ser-269 phosphorylation and PDX-1 DNA-binding ability.  A. 
30 µg of nuclear lysates from HEK293 cells infected by indicated viruses 
were migrated on SDS-PAGE. The expression level of overexpressed PDX-
1 was shown by immuno-blotting using anti-c-myc antibody. B. The 
indicated amounts of nuclear extracts of HEK 293 cells with or without 
over-expressing wild-type or mutant forms of PDX-1 were incubated with 
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[γ-32P] labeled oligonucleotide corresponding to mouse I insulin promoter 
(A3/A4 element) as indicated with/without 1µl PDX-1 antibody for 
supershift assay, or with 5X, 10X or 20X un-labeled oligonucleotides as 
binding competitor (Representative blot was shown; the experiments were 
performed three times independently). 
 
5.3.8 Phosphorylation at Ser269 is unlikely to affect PDX-1 
transcriptional activity or stability. 
 
It has previously been reported that the C-terminal domain of PDX-1 may play an 
important role in controlling transcriptional activity 159. We therefore investigated 
whether the dephospho- or phosphomimetic mutant forms of PDX-1, S269A and 
S269E respectively, displayed different transcriptional activity with respect to wild-
type PDX-1. 
 
We began by studying the ability of PDX-1 to affect cell lineage definition by 
monitoring the expression of glucagon mRNA in the INSrαβ cell line 216. In these 
cells, doxycyclin induces mouse PDX-1 mRNA, and strongly decreases glucagon 
mRNA levels, reflecting a switch towards a β-cell lineage 216. Adenoviral 
transduction of INSrαβ cells with wildtype, S269A or S269E mutant PDX-1 all led 
to similarly efficient suppression of glucagon mRNA expression compared with the 
effect of doxycyclin (Fig. 5.8A). Thus, the ability of the over-expressed dephospho- 
or phospho-mimetic forms of PDX-1 to affect lineage definition was not altered 
compared to wild type PDX-1 in this cell system. 
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Fig. 5.8. Ser-269 phosphorylation and PDX-1 transcriptional activity.  
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Glucagons (A) gene expression in INSrαβ cells overexpression de- and phospho-
mimetic mutants on PDX-1. RNA was extracted from cells treated with 500 ng/ml 
doxycylin or infected with wild-type or mutant PDX-1. Cyclophilin A and glucagon 
gene expression were monitored by real time RT-PCR. The relative glucagon gene 
expression level to cyclophilin A was shown in (A). (B) HEK 293 cells were 
transfected using Ca2+-phosphate with pcDNA3 empty vector or pcDNA3-PDX-1-
c-myc WT or S269A/E mutant forms, PPI promoter-luciferase, and Renilla-
luciferase. The results are the means ± SEM of three independent experiments (*, 
P<0.5; **, P<0.01; two-tailed student’s t test, Microsoft ExcelTM). (C) Equal 
amount of whole cell lysates from the luciferase assay were analysed by western 
blot using anti-c-myc antibody. The relative mean value of PDX-1 expression level 
was shown in a graphic representation.  
We next explored the impact of mutations at Ser269 on the transactivation of the 
preproinsulin promoter using a luciferase promoter -reporter system in a 
heterologous cell line. Transfection of HEK293 cells with equivalent amounts 
plasmid encoding myc-tagged wild-type, S269A or S269E PDX-1 led to the same 
degree of induction of the human preproinsulin promoter, compared to cells 
transfected with empty vector only (Fig. 5.8B). Transfection efficiency in these 
experiments was verified by western (immuno-) blotting using anti-c-myc antibody; 
the levels of the three different forms of PDX-1 assessed in this way was similar.  
In a preliminary experiment, we also tested whether the phosphorylation of PDX1 
on Ser269 could affect PDX1 protein stability by pulse-chase analysis. MIN6 cells, 
infected either with PDX1 wild type or with the two Ser269 mutants, were pulse 
labeled for three hours with a mixture of [35S] methionine and cysteine and then 
chased for 0, 2, 4, 8, 16 h in fresh medium containing an excess of unlabeled 
methionine and cysteine. Neither the phosphomimetic S269E nor the non-
phosphorylatable S269A mutations displayed altered protein stability compared to 
the wild type (preliminary data by Dr. Francesca Simplici not shown). 
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5.4 DISCUSSION  
The principal aim of the work described in this Chapter was to further elucidate the 
molecular mechanisms involved in the regulation by glucose and other stimuli of 
the nuclear uptake, DNA binding and transactivation capacities of PDX-1. We 
demonstrate firstly that Ser269 in the C-terminal domain of PDX-1 is 
phosphorylated in living β-cells. As far as we are aware, this represents the first 
description of a phosphorylation event on PDX-1 in situ achieved through the use of 
mass spectrometry and subsequently verified with a phosphospecific antibody. 
Whilst evidence has previously been obtained by others 141, 142 and in chapter 3 that 
PDX-1 exists as a phosphoprotein in clonal β-cells, and that the incorporation of Pi 
may be modulated by glucose, the sites of phosphorylation were poorly defined. Of 
note, phosphorylation of PDX-1 at Ser61 and Ser66 was recently reported in MIN6 
cells 142 based on the abolition of a gel shift to a higher molecular weight species 
(43 kDa) presumed to represent a form phosphorylated at Ser66, and using 
phosphospecific antibodies. Oxidative stress in response to H2O2 was shown in the 
same study to increase phosphorylation at these sites, possibly via the activation of 
GSK3. However, the effects of glucose on the extent of phosphorylation at either 
site were not investigated in this earlier report, in which the action of glucose to 
promote nuclear uptake of PDX-1 138, 154, 216, 260 was not observed. However, it must 
be emphasized that the extent of the change in cytosplasmic-nuclear localization of 
PDX-1 in response to altered glucose concentrations is relatively modest and may 
not have been apparent in the study by Boucher et al 142 where the cytosplasmic 
versus nuclear distribution of the factor was not quantitated precisely at the level of 
individual cells. In the present studies, by contrast, we were unable to detect any 
direct evidence for significant phosphorylation of the corresponding peptide 
(bearing Ser61 and Ser66) under the conditions used. Likewise, whilst recombinant 
PDX-1 is avidly phosphorylated in vitro by the nutrient regulated kinase Per-Arnt-
Sim (PAS) kinase 260, we have been unable to demonstrate any occupancy at the site 
phosphorylated in vitro (Thr152) in intact cells (Chapter 4). 
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We also show here that the degree of phosphorylation of PDX-1 at Ser269 was 
decreased at elevated glucose concentrations and correlated inversely with PDX-1 
levels. In a preliminary experiment testing whether the phosphorylation of PDX1 on 
Ser269 could affect PDX1 protein stability by pulse-chase analysis with MIN6 cells 
infected either with PDX1 wild type or with the two Ser269 mutants, neither the 
phosphomimetic S269E nor the non-phosphorylatable S269A mutations displayed 
altered protein stability compared to the wild type. 
 
Wild type c-myc-tagged PDX1-expressing adenovirus was mutagenized to replace 
Ser269 either with an alanine, to produce a dephosphomimetic S269A mutant, or 
with a glutamic acid, producing a phosphomimetic S269E mutant. MIN6 cells were 
infected with either PDX1 wild type or the mutants and immunostained with anti-c-
myc antibody. Whereas in response to an increase (3-30mM) in glucose 
concentration both the wild-type and the S269A mutant translocated from the 
nuclear periphery to the nucleoplasm, the phosphomimetic S269E mutant localized 
preferentially to the nuclear periphery at high glucose concentration. However, 
other functional analysis of the possible effects of phosphorylation at the site using 
(de) phosphomimetic mutants on transactivation of preproinsulin promoter activity 
or PDX-1 DNA-binding ability failed to reveal further differences between the 
transactivation capacity of the wild-type protein compared to mutants bearing A or 
E in place of S269. As the effect of PDX-1 mutants on preproinsulin promoter 
activity was studied in the non-beta-cell environment-HEK293 cells by plasmids-
transfection, in order to obtain a definite conclusion, similar experiments in MIN6 
β-cells will be a future direction.  
 
What may be the role, if any, of GSK3β in regulating PDX-1 function or stability? 
Whilst GSKβ alone was unable to lead to the phosphorylation of PDX-1 (not 
shown), both wild-type and S269A PDX-1 were phosphorylated in vitro by CK1δ. 
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Importantly, the apparent phosphorylation of wild-type PDX-1 was increased by the 
addition of GSK3, implying that the latter enzyme phosphorylates PDX-1 at a site 
“primed” by CK1δ. As proposed in Fig. 5.9B, CK1δ-catalysed phosphorylation of 
PDX-1 at Ser273 may render the sequence 269SPQP273S susceptible to subsequent 
phosphorylation by GSK3 at Ser269, now lying in a consensus site for GSK3 
phosphorylation site. What is the evidence that CK1δ may, in fact, phosphorylate 
PDX-1 at Ser273? Although the sequence around Ser273 does not fit any known 
CK1δ consensus, it might be noted that CK1δ is often able to phosphorylate 
“atypical” targets, as reported by Marin et al for NF-AT4 261 and β-catenin 262. 
Although direct confirmation of the above hypothesis was not provided by the use 
of an anti -phosphoSer269-specific antibody, it is possible that the close proximity 
of another phosphate residue on Ser273 would block the recognition of phospho-
Ser269 by the anti-pSer269 phosphospecific antibody (Fig. 5.4A, and see Fig. 
5.9B). This in fact was raised against the 
phosphopeptide…SVpSPQPS273SI…including S273 in its non-phosphorylated form 
(see Methods) and it is quite conceivable that the bis-phosphorylated sequence will 
escape recognition by a mono-phosphospecific antibody. 
 
On the other hand, a priming effect of HIPK2 for phosphorylation by GSK3 (Fig. 
5.4B) can be more easily reconciled with the observed data. Thus, if we assume that 
HIPK2 is a proline-directed kinase, then both Thr214 and Ser269 in the C-terminal 
domain of PDX-1 represent potential phosphorylation sites. Indeed we demonstrate 
directly (Fig. 5.3) that wild-type PDX-1 is phosphorylated by HIPK2 on Ser269, as 
well as at least one other site(s) (Fig. 5.3). However, Ser269 cannot prime 
phosphorylation by GSK3 as it lacks a Ser/Thr residue upstream, at the canonical n-
4 position. Likewise Thr214, representing another appealing candidate as a 
potential HIPK2 site found by MS analysis in a phosphorylated peptide (see Fig. 
5.1), lacks a S/T residue at position n-4. 
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Fig. 5.9. Model of GSK3 regulation on Ser269 phosphorylation.  
(A) Schematic diagram of PDX-1 structure and the potential 
phosphorylation sites involved in GSK3 phosphorylation. The black region 
represents PDX-1 C-terminus. (B) Model of synergistic phosphorylation by 
casein kinase I δ and GSK-3 on both wild-type PDX-1 and S269A mutant. 
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(C) Model of synergistic phosphorylation by HIPK2 and GSK-3 on both 
wild-type PDX-1 and S269A mutant. WT represents wild-type. 
 
Moreover no S/T-x-x-x-S/T-P motif suitable for sequential phosphorylation by 
HIPK2 at the downstream residue, and then by GSK3 at the upstream can be found 
in the entire sequence of mouse PDX-1. We have to assume, therefore, that either 
phosphorylation by HIPK2 in this case is not specified by the S/T-P motif, or that 
the residue phosphorylated by HIPK2 primes the intervention of GSK3 at a position 
other than the usual one, i.e. n-4. Pertinent to this may be on the one hand the 
observation that the crucial dependence of HIPK2 targeting on a prolyl residue at 
position n+1 is only based on the observation that its phosphosites identified to date 
fulfill this feature 263 and we know that some Pro-directed protein kinases do 
tolerate the replacement of the crucial proline by a different residue; on the other 
hand, priming of GSK3 is sometimes determined by phosphoresidue(s) which are 
located far away in the primary structure from the target residue, as typically 
exemplified by Inhibitor-2 of protein phosphatase 1, whose crucially functional 
phosphorylation by GSK3 at T72 needs to be primed by CK2 which phosphorylates 
I-2 at several residues, mostly S86 and others even further away from T72 264. It has 
been postulated that in these cases the consensus is “three-dimensionally” 
determined. 
 
In summary, our data provide the first report of a phosphorylation event in PDX-1 
in living β cells, as revealed through the use of mass spectrometry and confirmed by 
the generation of a phosphoserine-specific antibody. Moreover, we provide 
evidence that phosphorylation of the identified residue, Ser269, is dynamically 
regulated by glucose. Moreover, the phosphomimetic mutant S269E PDX-1 
appeared to alter the reported PDX-1 translocation from nuclear periphery to 
nucleoplasm at elevated glucose. As it was mentioned in the introduction, Boucher 
et al reported that HIPK2 is expressed in the developing pancreatic epithelium from 
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embryonic day (e) 12 to e15 but that the expression becomes preferentially confined 
to pancreatic endocrine cells at later developmental stages. Moreover, HIPK2 was 
reportedly able to modulate positively the transcriptional activity of PDX-1, and 
HIPK2 directly phosphorylates the C-terminal portion of PDX-1 161.  The 
phosphorylation site(s) are not known, however, identification of phosphorylation 
sites on the few known HIPK2 targets suggest that HIPK2 may be a proline-
directed serine/threonine kinase 249, 265. Analysis of PDX-1 sequence showed that 
Serine269-proline (Ser269), together with threonine214-proline (Thr214) were both 
potential phosphorylation sites on the C-terminus. In this Chapter, we reported that 
PDX-1 can be phosphorylated by HIPK2 on Ser269 in vitro. This finding indicated 
that that Ser269 is a strong candidate for HIPK2 phosphorylation and can help the 
future study on the phosphorylation of PDX-1 by HIPK2 in living cells.   
We also provide evidence that phosphorylation of PDX-1 by HIPK2 and/or CK1δ 
may influence the upstream phosphorylation of PDX-1 by GSK3 in response to 
glucose, insulin or other factors, to mediate the stability of PDX-1. Future studies 
will be required to determine the roles, if any, of changes in the activity of these 
potential upstream kinases in regulating PDX-1 phosphorylation at Ser269 in living 
β-cells. Moreover, the extent to which phosphorylation of PDX-1 at Ser269 may 
influence the DNA binding or transactivation capacity of PDX-1 remains unclear, 
given our present findings using (de)phosphomimetic forms of the protein; 
experiments using more physiological levels of PDX-1 variants, which were not 
technically feasible in this study, will be necessary to address these questions in the 
future.   
  
  
  170 
 
 
 
6.  Chapter 6 
 
 
 
General Discussion 
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6.1 Review of experimental findings   
Pancreatic Duodenum Homeobox (PDX-1) is a homeodomain transcription factor 
and a key regulator of β-cell development and differentiation and plays a crucial 
role in β-cell specific gene expression.  It is therefore critical to understand the 
regulation of PDX-1, especially the post-translational regulatory network. The work 
in this thesis investigated the phosphorylation of PDX-1 under physiological 
condition and directly demonstrated that PDX-1 is phosphorylated in living β-cells 
(Chapter 3). It also further explored the in vivo phosphorylation sites of PDX-1 and 
the regulatory effects of the phosphorylation on these sites on PDX-1 transcriptional 
activity (Chapter 4 and 5).  
 
Additional kinases which may phosphorylate PDX-1 at various sites have been 
proposed by different groups 63, 78, 137, 142, 148, 154. We also performed a series of in 
vitro phosphorylation reactions using recombinant PDX-1 and purified kinases. 
Aurora, Rsk1, PKCα, JNK were all found to phosphorylate PDX-1 in vitro (Chapter 
3). In vitro phosphorylation sites of PDX-1 by JNK were revealed (Thr-214 and 
Ser-66) using mass spectrometry sequencing (Chapter 3). 
 
In an effort to investigate the signaling pathway involved in PDX-1 post-
translational regulation, in vitro phosphorylation using recombinant PDX-1 and 
purified human PASK showed that PDX-1 is efficiently phosphorylated in vitro at 
Thr-152 in the homeodomain by the nutrient-regulated kinase, PASK (Chapter 3). 
Moreover, the site appeared to be specific for PASK as the T152A mutant PDX-1 
recombinant protein showed no difference with wild-type PDX-1 in the in vitro 
phosphorylation by a series of kinases including Aurora, Rsk1, PKCα, JNK etc. 
(Chapter 3). This finding prompted us to investigate the phosphorylation of PDX-1 
in living cells and the role of Thr-152 phosphorylation on the transactivational 
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capacity of PDX-1 in native β-cells exposed to high extracellular glucose 
concentrations (Chapter 4). 
We demonstrated the first time that PDX-1 is phosphorylated under physiological 
condition in INS-1(832/13) cells (Section 3.3.5). The problem we tackled is what 
role does Thr-152 phosphorylation by PASK play in the post-translational 
regulation of PDX-1? We generated phospho- and dephospho- mimetic PDX-1 
mutants to explore the likely effects of Thr-152 phosphorylation on PDX-1 
function, and examined the possible role(s) played by PASK in two β-cell systems, 
INS-1(832/13) cells and INSrαβ cells 216. In the latter cell-type (though not in other 
α-cells and enteroendocrine cell lines) 230, PDX-1 potentially inhibits 
preproglucagon gene expression, allowing a switch from α-to β-cell lineage.  
 
It was observed that mimicking phosphorylation on Thr-152 resulted in a potent 
inactivation of PDX-1 reflected in a near total loss of DNA-binding capacity and in 
the ability of the factor to induce a cell lineage switch in INSrαβ cells. Arguing 
against the view that PASK phosphorylates PDX-1 in situ, nuclear localization of 
the kinase in MIN6 β-cells was not previously noted for over-expressed PASK 209. 
We now show, using direct and complementary approaches, that Thr-152 is 
unlikely to be significantly phosphorylated in situ under a variety of conditions, 
including those in which endogenous PASK is activated (elevated glucose 
concentrations) or after over-expression of the exogenous kinase (Chapter 4). The 
present data thus indicate that Thr-152 is not a major site of phosphorylation of 
PDX-1 in living β-cells under most conditions, and that phosphorylation at this site 
is not altered under conditions in which the nuclear accumulation of PDX-1 is 
affected (ie high versus low glucose concentrations). 
 
Additionally, we identified a novel phosphorylation site in the C-terminal domain 
of PDX-1, Ser-269, via mass spectrometry analysis and by using an anti-
phosphoSerine-specific antibody (Chapter 5). This site is phosphorylated by HIPK2 
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in vitro, and the phosphorylation on S269 is regulated by glucose concentration in 
MIN6 cells. Moreover, the phosphomimetic mutant PDX-1 (S269E) appeared to 
alter the PDX-1 translocation from nuclear periphery to nucleoplasm at elevated 
glucose concentration. As reported in a previous study by Edlund a minor portion of 
PDX-1 is phosphorylated on S61 and S66, and the phosphorylation is modulated by 
a GSK3-dependent mechanism and marks the degradation of PDX-1. In this Thesis, 
the in vitro phosphorylation studies also provided potential possibilities of the 
relationship between the S269 phosphorylation, GSK3 phosphorylation and 
regulation of PDX-1 (Chapter 5). However, mutation of S269 phosphorylation did 
not affect the DNA-binding ability and transcriptional activity of PDX-1 (Chapter 
5). Thus, we present the first in vivo phosphorylation site of PDX-1, identified from 
mass spectrometry phospho-site screening, and provide evidence of the potential 
regulation network the site could be involved in. This may shed light on the 
discovery of the signaling pathway which regulates the C-terminus of PDX-1. 
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6.2 Updated PDX-1 phosphorylation network   
That PDX-1 transcriptional activity is regulated by glucose-dependent 
phosphorylation of the protein was first proposed by Macfarlane et al 63. Potential 
kinases triggering this event were investigated in this early study 63, and it was 
reported that neither cyclic AMP-dependent protein kinase A nor protein kinase C 
were involved. 
 
Further study indicated that glucose-stimulated PDX-1 DNA-binding activity to the 
regulatory region of the human insulin gene134, and PDX-1-activated gene 
transcription, were shown inhibited by a specific inhibitor of the stress-activated 
protein kinase 2 (SAPK2), SB203580 135, which also inhibited the glucose triggered 
activation of MAPKAP-K2, an immediate downstream target of SAPK2. As 
discussed on page 37 Elrick and Docherty 154 observed that PDX-1 shuttles between 
the nuclear periphery and the nucleoplasm in a phosphorylation dependent manner 
in response to changes in extracellular glucose and insulin concentrations and the 
translocation of PDX-1 is inhibited by the PI3K inhibitor wortmannin and the 
p38/SAPK2 inhibitor SB 203580, suggesting that the PI3K and p38/SAPK2 
pathways are involved 154.  
 
However, as reported by Rafiq et al 137, in MIN6 β-cells, neither the inhibition of 
SAPK2 by SB 203580 nor overexpressing wild-type SAPK2 or its upstream kinase 
MKK6 ( MAP kinase kinase-6) affected the preproinsulin promoter activity, PDX-1 
transcriptional activity and PDX-1 subcellular translocation. Moreover, they failed 
to detect any regulation on extracted p38/SAPK2 activity by elevated glucose 
concentration. Meanwhile, this study did confirm that PI3K is ‘necessary and 
sufficient’ for the glucose-activated PPI gene transcription, however, whether or not 
the downstream signaling pathway involve p38/SAPK2 remains unknown.  
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P38/SAPK2, together with the extracellular signal-regulated kinases (ERK1, 
ERK2)266-268 and the c-Jun N-terminal kinases (JNKs), all belong to the 
serine/theronine-specific protein kinases, mitogen-activated protein (MAP) kinases. 
The JNKs are responsive to stress such as cytokines, ultraviolet irradiation, heat 
shock, and osmotic shock and are involved in cell differentiation and apoptosis 269. 
Kawamori et al 78 reported that PDX-1 translocates from the nuclei to the cytoplasm 
of pancreatic β-cells in response to oxidative stress in hamster β-cell-derived HIT-
T15 cells and this oxidative stress-stimulated translocation is through the activation 
of the JNK pathway but the precise phosphorylation site(s) remain unknown.   
 
In this Thesis, a series of kinases including ERK2, SAPK2 and JNK were tested by 
in vitro phosphorylation of PDX-1 (Chapter 3). The results suggested that both 
SAPK2 and ERK2 phosphorylate PDX-1 very poorly. However, JNK 
phosphorylated PDX-1 well in vitro and the phosphorylation sites, as revealed by 
mass spectrometry phosphorylation site screening on recombinant PDX-1 protein 
(Chapter 3), included Ser-66 and Thr-214. These findings provide direct evidence 
for JNK phophorylation of PDX-1 in vitro and could account for the oxidative 
stress-induced PDX-1 translocation observed by Kawamori and colleagues 78, and 
are also potential candidate phosphorylation sites for JNK phosphorylation of PDX-
1 in living cells.   
Interestingly, Boucher et al 142 demonstrated in 2006 using phospho-specific 
antibodies that a minor proportion of PDX-1 is phosphorylated on serine 61 and/ or 
serine 66 in β-cells. Phosphorylation was increased following proteasome 
inhibition, and it is also modulated by a GSK3-dependent mechanism.  GSK3 
activity has been found to be increased in insulin target tissues from diabetic mice 
143, 144 and inhibiting GSK3 using specific inhibitors or lithium chloride improved 
glucose metabolism in insulin resistant Zucker rats 145, 146. Boucher et al also found 
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that oxidative stress increased PDX-1 phosphorylation on either site, and further 
increased the degradation of the protein, while the half-life of the protein is 
decreased. The phosphorylation was found to be modulated by oxidative stress in a 
GSK3-dependent manner. It has also been reported that active canonical Wnt 
signaling decreased GSK3 activity 147 and β-cells are sensitive to the oxidative 
stress which increases with age. Thus a new mechanism was proposed for the 
declined levels of PDX-1 and resultant β-cell dysfunction during diabetes 
progression in which the canonical Wnt signaling counteracts age-related increase 
in oxidative stress by inhibiting GSK3 activity to rescue PDX-1 from protein 
degradation and in turn maintain normal β-cell function 142. It was discussed in 
Chapter 5 that a priming process is necessary for GSK3 phosphorylation, moreover 
the Kawamori et al 78 study together with our finding that Ser-66 is phosphorylated 
by JNK in vitro could indicate an intermediate role of the JNK pathway as a 
priming process for further GSK3 function during the oxidative stress-induced 
regulation of PDX-1.  
In an attempt to identify potential upstream kinases for PDX-1 in pancreatic β-cells, 
we also studied the in vitro phosphorylation of PDX-1 by AMP-activated protein 
kinase (AMPK), and also Akt/PKB. However, neither of these candidates 
phosphorylated PDX-1 in vitro. Interestingly the nutrient-sensing kinase PASK 
efficiently phosphorylated PDX-1 on Thr-152, while not being able to 
phosphorylate other β-cell enriched transcription factors including NeuroD and 
MafA. However, studies using site-mutagenesis of Thr-152 in living β-cells 
indicated that the site is important for the DNA-binding, transcriptional activity and 
subcellular localization of PDX-1. Whether it is a physiological phosphorylation 
site of PDX-1 in normal β-cells remains unclear (Chapter 4). 
Additionally, phosphorylation site screening by mass spectrometry helped us to 
identify a novel phosphorylation site on PDX-1 in living β-cells, S269. 
Interestingly, this was found to be a phosphorylation site for the homeodomain-
interacting protein kinase-2 (HIPK2)  in vitro (Chapter 5). The phosphorylation of 
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PDX-1 by HIPK2 on C-terminus was reported by Boucher et al recently 148 but the 
exact phosphorylation sites were not identified. Our finding thus opens up a new 
avenue of investigation of mechanisms which regulate PDX-1’s transcriptional 
activity, and also possibly pancreas development and/or β-cell function 148.  
In summary, as shown in Fig. 6.1, phosphorylation of PDX-1 involves a complex 
network which may involve several kinases and signalling pathways. We tackled 
the phosphorylation of PDX-1 based on previous results from others and from our 
group, involving PASK, p38/SAPK2, c-Jun N-terminal kinase, GSK3 and HIPK2. 
The findings in this Thesis substantially update our understanding of PDX-1 
phosphorylation and the kinases involved, and lead us a further step on the way to 
unveiling the final regulatory signaling pathway(s) controlling PDX-1 
phosphorylation.  
 
Fig. 6.1 Schematic summary of PDX-1 phosphorylation by kinases discussed in 
this Thesis. 
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6.3 Future perspectives   
Despite the advances made in understanding PDX-1 phosphorylation in this Thesis, 
a number of questions still remain to be answered.  
 
1. Is PDX-1 a downstream target of PASK regulation in β-cells? In the study 
of PDX-1 phosphorylation by PASK, Thr-152 was shown to be an in vitro 
phosphorylation site but with no physiological relevance in living β-cells. It 
has been reported by Da Silva Xavier et al 209 that silencing of PASK 
expression markedly decreased the accumulation of preproinsulin and PDX-
1 mRNAs in response to high glucose. Additionally, regulation by PASK or 
glucose of both the preproinsulin and PDX-1 promoters was completely 
abrogated by deletion of PDX-1-binding sites, implicating PDX-1 and 
possibly MafA as targets of PASK action 209. Therefore, this could indicate 
other phosphorylation site(s) on PDX-1 by PASK if there is a direct 
interaction between PASK and PDX-1 in living cells or otherwise, as is 
proposed in 209, the downstream target of PASK could be MafA instead. 
However, the study by Hao et al in 2007 210 again made hypothesis more 
complicated as they found that the expression levels of several genes 
involved in insulin transcription and glucose-stimulated insulin secretion 
(GSIS), including PDX-1, MafA, GLUT2, and glucokinase, were also 
unchanged in PASK −/− islets 210.  
 
2. Is phospho-Thr-152 less stable in vivo? The results in Chapter 4 show that 
Thr-152 phosphorylation was not detected in living β-cells using either 
phospho-specific antibody against phosphorylation on Thr-152 or mass 
spectrometry phospho-site screening. Howeover, the phosphorylation may 
bring about nuclear export and rapid degradation and thus it may be very 
difficult to detect phospho-Thr-152 using any approach.   
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Hence alternative mass spectrometry approach could be applied in the 
future. For example, the phosphoprotein peptides could be selected and 
concentrated using a phosphospecific surface (Surface-enhanced laser 
desorption ionization (SELDI)) or by immobilized metal ion affinity 
chromatography (IMAC) as well as by purifying the radioactive peptides 
and then using mass spectrometry to investigate the phospho-site. For 
sample preparation, protein lysate from cells cultured at low glucose 
conditions when the PDX-1-DNA binding is weaker could be used to obtain 
more efficient sequencing results.   
3. What is the subcellular localization of endogenous PASK in rodents? 
Overexpressed human PASK in rodent cloned β-cell lines was localized 
predominantly in the cytoplasm, as revealed by the anti-PASK antibody 
against human PASK due to the inavailability of anti-PASK antibody 
against rodent PASK. However, in dispersed human islets the endogenous 
PASK displayed universal distribution both in the cytosol and the nuclear 
area in β-cells. One explanation could be that endogenous PASK 
distribution between dispersed cells and intact islets is different; it has 
previously been reported by Pérez-Armendariz et al 270 that the behavior of 
cells in intact islets differs significantly from the behavior of dispersed cells 
when they were studying the electrical activity of pancreatic islets was 
studied using patch clamp. Therefore, more primary tissue work on human 
islets will be needed e.g. immunohistochemistry on intact human islets. 
Another explanation could be that overexpressed human PASK distributes 
differently in rodent cell lines in which case specific antibodies against 
rodent PASK for immunocytochemistry need to be generated.   
4. Is PDX-1 phosphorylated by HIPK2 or JNK at identified potential sites in 
living cells? Potential phosphorylation sites of PDX-1 by HIPK2 and JNK 
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In vitro phosphorylations were identified, Ser-269 by HIPK2 and Ser-66, 
Thr-214 by JNK, respectively. In the study by Boucher et al 148, transfection 
of Hipk2 siRNA reduced by approximately 50% the activity of the insulin 
promoter in MIN6 cells already 36 h post-transfection and HIPK2 was 
found positively modulate PDX-1 target genes in a PDX-1-dependent 
manner. What is the in vivo relevance of HIPK2 in related to PDX-1 
phosphroylation on Ser269? In order to give a clearer answer, RNA 
interference approaches could be introduced to reduce HIPK2 expression 
and to examine the impact of siRNA mediated silencing of HIPK2 on PDX-
1 phosphorylation on Ser269 in MIN6 cells.  
 
The identification of the potential phosphorylation sites could lead to more 
specific phosphorylation study in living cells and the physiological 
relevance of the sites need to be investigated.  
 
5. What is the relationship between GSK-3 and phosphorylation of PDX-1 at 
Ser-269 in living cells? In chapter 5, both wild-type and S269A PDX-1 were 
phosphorylated in vitro by CK1δ. Importantly, the apparent phosphorylation 
of wild-type PDX-1 was increased by the addition of GSK3, implying that 
the latter enzyme phosphorylates PDX-1 at a site “primed” by CK1δ. As 
discussed in Chapter 5, CK1δ-catalysed phosphorylation of PDX-1 at 
Ser273 may render the sequence 269SPQP273S susceptible to subsequent 
phosphorylation by GSK3 at Ser269, now lying in a consensus site for 
GSK3 phosphorylation site. However, anti-phosphoSer-269 PDX-1 
antibody failed to detect the signal very likely because the close proximity 
of another phosphate residue on Ser273 would block the recognition of 
phospho-Ser269 by the anti-pSer269 phosphospecific antibody. Therefore, 
further study on the possible GSK3 phosphorylation on Ser-269 could be 
conducted with the help of phospho-specific antibody recognizing both 
phospho-Ser-269 and phospho-273. Additionally, the regulatory effect of 
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GSK3 on PDX-1 phosphorylation at Ser269 in living cells could be studied 
using GSK3 inhibitors and the anti-phospho-Ser-269-PDX-1 antibody. 
 
6. Studies in primary pancreatic islets. In order to enhance the physiologic 
relevance of the studies, it is essential and interesting to validate the findings 
in this thesis in primary pancreatic islets in future study. For example, one 
future direction could be to study the glucose regulation on the 
phosphorylation of PDX-1 at Ser-269 using the phospho-specific antibody 
against phospho-Ser-269 PDX-1 in isolated primary murine pancreatic 
islets.  
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6.4 Overall conclusions  
The findings in this Thesis bring new understanding on the role and regulation of 
PDX-1 phosphorylation. We have studied the phosphorylation sites of PDX-1 using 
mass spectrometry phospho-site mapping and by exploring the potential upstream 
kinases using in vitro phosphorylation. We focused initially on the novel in vitro 
phosphorylation site Thr-152 on PDX-1 by PASK and another phosphorylation site 
Ser-269 in living cells revealed by mass spectrometry.  We investigated the role of 
phosphorylation on Thr-152 and Ser-269 in the regulation of this critical 
transcription factor by examing the transcriptional activity, subcellular localization 
etc. of PDX-1 mutants on these sites. Studies in living cells confirmed that PASK is 
not likely to phosphorylate PDX-1 on Thr-152 site under physiological conditions 
although phospho-mimetic mutant PDX-1 on this site showed a substantial loss of 
DNA-binding ability, increased cytosolic distribution at elevated glucose 
concentration and was able to increase preproglucagon gene expression in INSrαβ 
cells. We also show that the phosphorylation of PDX-1 at Ser269 was decreased at 
elevated glucose concentrations and correlated inversely with PDX-1 levels. 
Meanwhile it also appeared to alter PDX-1 nuclear uptake at elevated glucose 
concentration. However, further analysis of the possible effects of phosphorylation 
at the site using (de) phosphomimetic mutants failed to detect any differences 
between the transactivation capacity of the wild-type protein compared to S269A or 
S269E mutants. We found this site is phosphorylated by HIPK2 in vitro and we also 
provide evidence that in vitro phosphorylation of PDX-1 by HIPK2 and/or CK1δ 
may influence the upstream phosphorylation of PDX-1 by GSK3 in response to 
glucose, insulin or other factors, to mediate the stability of PDX-1.  
Finally, in order to further complete the networks of PDX-1 phosphorylation and to 
better understand the post-translational regulation of PDX-1, future questions on 
PDX-1 regulation by PASK, phosphorylation of PDX-1 by other upstream 
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candidate kinases (ie. JNK, HIPK2 and GSK-3) on proposed potential sites in living 
cells need to be answered as mentioned in the Future Perspective section.  
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